,ID,lineage,string
0,doi:10.1016/s0168-1702(97)00081-6,A.1,"Two biological clones (A.1 and B.2) of the classical swine fever virus strain Alfort/187 and the recombinant virus vA187-1, derived from a cDNA clone of Alfort/187, were used to establish persistently infected cultures oft he swine kidney cell lines SK-6 and PK-41."
0,doi:10.1016/j.jinf.2021.04.005,B.1.1.7,"The emergence of novel SARS-CoV-2 variants is generating widespread concern, as they harbor a constellation of mutations that might lead to increased transmissibility3 and/or immune evasion from previous infection or vaccination.4 The lineage B.1.1.7 (variant of concern [VOC]−202012/01; also known as clade 20I/501Y.V1), firstly identified in the UK in December 2020,1
,
5 has rapidly spread worldwide (https://cov-lineages.org/global_report_B.1.1.7.html)."
1,doi:10.1016/j.jinf.2021.04.005,B.1.221,"Other lineages that were linked to the SGTF in this study were classified as B.1.258 (5), B.1.177 (3), B.1.221 (1), and B.1.1.222 (1).Fig."
2,doi:10.1016/j.jinf.2021.04.005,B.1.177,"Other lineages that were linked to the SGTF in this study were classified as B.1.258 (5), B.1.177 (3), B.1.221 (1), and B.1.1.222 (1).Fig."
3,doi:10.1016/j.jinf.2021.04.005,B.1.1.222,"Other lineages that were linked to the SGTF in this study were classified as B.1.258 (5), B.1.177 (3), B.1.221 (1), and B.1.1.222 (1).Fig."
4,doi:10.1016/j.jinf.2021.04.005,B.1.258,"Other lineages that were linked to the SGTF in this study were classified as B.1.258 (5), B.1.177 (3), B.1.221 (1), and B.1.1.222 (1).Fig."
0,doi:10.1016/s1473-3099(21)00262-0,B.1.1.7,"Genomic surveillance efforts have uncovered SARS-CoV-2 variants with mutations in the viral spike glycoprotein, which binds the human angiotensin-converting enzyme 2 (ACE2) receptor to facilitate viral entry.1 Such variants represent a public health challenge during the COVID-19 pandemic because they increase viral transmission and disease severity.2 The B.1.351 variant, first identified in South Africa, has three notable mutations in the spike receptor-binding domain (RBD)—namely, K417N, E484K, and N501Y3—whereas the B.1.1.7 variant, first identified in the UK, carries the N501Y mutation (appendix pp 2–4)."
1,doi:10.1016/s1473-3099(21)00262-0,B.1.351,"Genomic surveillance efforts have uncovered SARS-CoV-2 variants with mutations in the viral spike glycoprotein, which binds the human angiotensin-converting enzyme 2 (ACE2) receptor to facilitate viral entry.1 Such variants represent a public health challenge during the COVID-19 pandemic because they increase viral transmission and disease severity.2 The B.1.351 variant, first identified in South Africa, has three notable mutations in the spike receptor-binding domain (RBD)—namely, K417N, E484K, and N501Y3—whereas the B.1.1.7 variant, first identified in the UK, carries the N501Y mutation (appendix pp 2–4)."
0,doi:10.1371/journal.ppat.1010022,B.1.617.1,"Here, we examine the sensitivity of variants of concern (VOCs) representative of the B.1.617.1 and B.1.617.2 (first associated with infections in India) and B.1.351 (first associated with infection in South Africa) lineages of SARS-CoV-2 to neutralisation by sera from individuals vaccinated with the BNT162b2 (Pfizer/BioNTech) and ChAdOx1 (Oxford/AstraZeneca) vaccines."
1,doi:10.1371/journal.ppat.1010022,B.1.617.2,"Here, we examine the sensitivity of variants of concern (VOCs) representative of the B.1.617.1 and B.1.617.2 (first associated with infections in India) and B.1.351 (first associated with infection in South Africa) lineages of SARS-CoV-2 to neutralisation by sera from individuals vaccinated with the BNT162b2 (Pfizer/BioNTech) and ChAdOx1 (Oxford/AstraZeneca) vaccines."
2,doi:10.1371/journal.ppat.1010022,B.1.351,"Here, we examine the sensitivity of variants of concern (VOCs) representative of the B.1.617.1 and B.1.617.2 (first associated with infections in India) and B.1.351 (first associated with infection in South Africa) lineages of SARS-CoV-2 to neutralisation by sera from individuals vaccinated with the BNT162b2 (Pfizer/BioNTech) and ChAdOx1 (Oxford/AstraZeneca) vaccines."
3,doi:10.1371/journal.ppat.1010022,B.1.1.7,"The B.1.617.2 (Delta) variant that spread from India in March 2021 is now the dominant SARS-CoV-2 variant type in the United Kingdom [1], replacing the B.1.1.7 (Alpha; “Kent”) variant and spreading rapidly across the globe."
4,doi:10.1371/journal.ppat.1010022,B.1.617,"Accordingly, this resulted in the widespread usage of the “double mutant” misnomer, and initial designation as the B.1.617 Pango lineage."
5,doi:10.1371/journal.ppat.1010022,B.1.617.3,"Availability of further sequence data led to the assignment of sub-lineages: B.1.617.1, B.1.617.2 and B.1.617.3, of which B.1.617.2 is now the dominant variant in the UK."
6,doi:10.1371/journal.ppat.1010022,B.1.427,"L452R is one of the defining mutations of the lineage B.1.427/B.1.429, a variant of interest (VOI) first identified in California and associated with reduced neutralisation titres with plasma from vaccinated or convalescent individuals [7]."
7,doi:10.1371/journal.ppat.1010022,B.1.525,"In contrast, recent data from 20 sera collected from clinical trial participants vaccinated with BNT162b2 showed relatively similar levels of neutralising antibodies against B.1.617.1, B.1.617.2, B.1.618 (all first identified in India) and B.1.525 (first identified in Nigeria) using a live virus assay (plaque reduction assay) [21]."
8,doi:10.1371/journal.ppat.1010022,B.1.618,"In contrast, recent data from 20 sera collected from clinical trial participants vaccinated with BNT162b2 showed relatively similar levels of neutralising antibodies against B.1.617.1, B.1.617.2, B.1.618 (all first identified in India) and B.1.525 (first identified in Nigeria) using a live virus assay (plaque reduction assay) [21]."
0,doi:10.3346/jkms.2021.36.e346,B.1.1.529,"In November 2021, 14 international travel-related severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant of concern (VOC) patients were detected in South Korea."
0,doi:10.1016/s1473-3099(22)00132-3,B.1.617.2,"Furthermore, the T-cell responses to spike peptide pools of wild-type SARS-CoV-2 and delta (B.1.617.2) SARS-CoV-2 were only studied in a healthy vaccinated group."
0,doi:10.1016/s1473-3099(22)00120-7,B.1.617.2,"Furthermore, considering the large sample size, collecting samples and performing serological testing would have been prohibitively time consuming and would have defeated the purpose of generating estimates of vaccine effectiveness in a timely manner during the SARS-CoV-2 delta (B.1.617.2) variant surge in India.."
0,doi:10.1093/eurpub/ckab164.097,B.1.1.7,"This study aimed at evaluating the neutralizing activity against the viral variants emerged in the United Kingdom (B.1.1.7), Brazil (B.1.1.28.1), and South Africa (B.1.351) in human serum samples from hospitalized patients infected by SARS-CoV-2 during the first pandemic wave in Italy in 2020..

Serum samples of 42 COVID-19 patients hospitalized in Italy between March and May 2020, were included in the present study."
1,doi:10.1093/eurpub/ckab164.097,B.1.351,"This study aimed at evaluating the neutralizing activity against the viral variants emerged in the United Kingdom (B.1.1.7), Brazil (B.1.1.28.1), and South Africa (B.1.351) in human serum samples from hospitalized patients infected by SARS-CoV-2 during the first pandemic wave in Italy in 2020..

Serum samples of 42 COVID-19 patients hospitalized in Italy between March and May 2020, were included in the present study."
0,doi:10.1016/j.euroneuro.2021.10.447,B.1.1.7,New variants of coronavirus such as the 501.V2 and B.1.1.7 have emerged and obscurities in pathogenesis have increased even further with these variants.
0,doi:10.1007/s41324-021-00428-z,V.2,"This study quantitatively assessed and mapped the light extents and urban region in Kerala, one of the southwest Indian states from 2012 to 2020 with the help of low light imaging day/night band data collected from the VIIRS and utilised VIIRS night time Lights V.2 time series from the monthly averages with filtering to eliminate extraneous features such as aurora, biomass burning, and background."
1,doi:10.1007/s41324-021-00428-z,V.1,The V.1 monthly products are produced with and without stray light corrected data.
0,doi:10.5365/wpsar.2022.13.1.883,B.1.526,"These preliminary results, showing that the Theta variant did not seem to be associated with more severe disease, were similar to findings on the Iota variant (B.1.526) in New York, which also contained the E484K mutation."
0,doi:10.7189/jogh.12.05008,B.1.617.2,The emergence of the B.1.617.2 Delta variant of concern was associated with increasing numbers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and COVID-19 hospital admissions.
0,doi:10.3389/fmed.2022.828402,B.1.351,The clinical outcomes of the Beta (B.1.351) variant of concern (VOC) of the SARS-CoV-2 virus remain poorly understood.
1,doi:10.3389/fmed.2022.828402,B.1.1.7,This outbreak slightly preceded and then overlapped with a second outbreak of the better understood VOC Alpha (B.1.1.7) in the region.
2,doi:10.3389/fmed.2022.828402,P.1,"Alpha (PANGO lineage B.1.1.7) was first detected in the United Kingdom while Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) were originally from South Africa, Brazil, and India, respectively."
3,doi:10.3389/fmed.2022.828402,B.1.617.2,"Alpha (PANGO lineage B.1.1.7) was first detected in the United Kingdom while Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) were originally from South Africa, Brazil, and India, respectively."
4,doi:10.3389/fmed.2022.828402,B.1.1.529,"The fifth SARS-CoV-2 variant of concern, Omicron (B.1.1.529 lineage), was first publicly announced in South Africa on 25 November 2021 and swept Europe and other regions, becoming rapidly dominant (3)."
0,doi:10.1016/j.virol.2022.03.008,B.1.1.529,"Standard Gibbs energy of binding and binding constant for the Omicron (B.1.1.529) strain were found to be ΔBG⁰ = −45.96 kJ/mol and KB = 1.13 ∙ 10+8 M−1, respectively.."
1,doi:10.1016/j.virol.2022.03.008,P.1,"Very soon after the beginning of the pandemic, other strains appeared in various regions, labelled B.1.1.7 (Alpha), B.1.351 (Beta), B.1.36, P.1 (Gamma) and B.1.617 (Delta)."
2,doi:10.1016/j.virol.2022.03.008,B.1.36,"Very soon after the beginning of the pandemic, other strains appeared in various regions, labelled B.1.1.7 (Alpha), B.1.351 (Beta), B.1.36, P.1 (Gamma) and B.1.617 (Delta)."
3,doi:10.1016/j.virol.2022.03.008,B.1.1.7,"Very soon after the beginning of the pandemic, other strains appeared in various regions, labelled B.1.1.7 (Alpha), B.1.351 (Beta), B.1.36, P.1 (Gamma) and B.1.617 (Delta)."
4,doi:10.1016/j.virol.2022.03.008,B.1.617,"Very soon after the beginning of the pandemic, other strains appeared in various regions, labelled B.1.1.7 (Alpha), B.1.351 (Beta), B.1.36, P.1 (Gamma) and B.1.617 (Delta)."
5,doi:10.1016/j.virol.2022.03.008,B.1.351,"Very soon after the beginning of the pandemic, other strains appeared in various regions, labelled B.1.1.7 (Alpha), B.1.351 (Beta), B.1.36, P.1 (Gamma) and B.1.617 (Delta)."
0,doi:10.3389/fimmu.2022.820250,B.1.617.2,"Although virus-specific antibody response has been extensively investigated in blood samples of SARS-CoV-2-infected patients and vaccinees, local humoral immunity in the oral cavity and its relationship to systemic antibody levels needs to be further addressed..

We fine-tuned a virus neutralization assay (vNTA) to measure the neutralizing activity (NA) of plasma and saliva samples from 20 SARS-CoV-2-infected (SI), 40 SARS-CoV-2-vaccinated (SV), and 28 SARS-CoV-2-vaccinated subjects with a history of infection (SIV) using the “wild type” SARS-CoV-2 lineage B.1 (EU) and the Delta (B.1.617.2) strains."
1,doi:10.3389/fimmu.2022.820250,B.1,"Although virus-specific antibody response has been extensively investigated in blood samples of SARS-CoV-2-infected patients and vaccinees, local humoral immunity in the oral cavity and its relationship to systemic antibody levels needs to be further addressed..

We fine-tuned a virus neutralization assay (vNTA) to measure the neutralizing activity (NA) of plasma and saliva samples from 20 SARS-CoV-2-infected (SI), 40 SARS-CoV-2-vaccinated (SV), and 28 SARS-CoV-2-vaccinated subjects with a history of infection (SIV) using the “wild type” SARS-CoV-2 lineage B.1 (EU) and the Delta (B.1.617.2) strains."
0,pubmed:34873578,B.1.1.529,The latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron (B.1.1.529) has ushered panic responses around the world due to its contagious and vaccine escape mutations.
0,doi:10.3390/pathogens10050614,P.1,"On 17 March 2021, several VOCs were detected, including lineage B.1.1.7, first identified in the UK, B.1.351 in South Africa, Lineage P.1 (B.1.1.28.1) in Brazil, and novel Sub-Lineage A (A.23.1), reported in Uganda, and B.1.525, reported in Nigeria."
1,doi:10.3390/pathogens10050614,B.1.1.7,"On 17 March 2021, several VOCs were detected, including lineage B.1.1.7, first identified in the UK, B.1.351 in South Africa, Lineage P.1 (B.1.1.28.1) in Brazil, and novel Sub-Lineage A (A.23.1), reported in Uganda, and B.1.525, reported in Nigeria."
2,doi:10.3390/pathogens10050614,B.1.525,"On 17 March 2021, several VOCs were detected, including lineage B.1.1.7, first identified in the UK, B.1.351 in South Africa, Lineage P.1 (B.1.1.28.1) in Brazil, and novel Sub-Lineage A (A.23.1), reported in Uganda, and B.1.525, reported in Nigeria."
3,doi:10.3390/pathogens10050614,A.23.1,"On 17 March 2021, several VOCs were detected, including lineage B.1.1.7, first identified in the UK, B.1.351 in South Africa, Lineage P.1 (B.1.1.28.1) in Brazil, and novel Sub-Lineage A (A.23.1), reported in Uganda, and B.1.525, reported in Nigeria."
4,doi:10.3390/pathogens10050614,B.1.351,"On 17 March 2021, several VOCs were detected, including lineage B.1.1.7, first identified in the UK, B.1.351 in South Africa, Lineage P.1 (B.1.1.28.1) in Brazil, and novel Sub-Lineage A (A.23.1), reported in Uganda, and B.1.525, reported in Nigeria."
5,doi:10.3390/pathogens10050614,B.1.325,"The SARS-CoV-2 P.1 variant has a unique genetic profile of 17 amino acid changes, including three mutations (E484K, K417T, and N501Y) in the receptor-binding domain (RBD) region that are also present in the B.1.325 variant, a recent lineage that first emerged in South Africa [3]."
0,doi:10.1111/tbed.14104,B.4,"The corresponding analysis on origins, transmission dynamics and genetic diversity of SARS‐CoV‐2 virus, represented at least two introductions of the virus into the country, constructing two major clusters defined as B.4 and B.1*."
1,doi:10.1111/tbed.14104,B.1,"Therefore, our results confirm B.4 as the dominant lineage in Iranian outbreak during the February–June 2020 interval and introduce B, B.1, B.1."
0,doi:10.1186/s40249-021-00926-0,B.1.617.2,This relationship might differ for the recently emerged B.1.617.2 (delta) variant of SARS-CoV-2.
0,doi:10.1073/pnas.2106535118,P.1,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are of concern, with the P.1 variants dominating in Brazil."
0,doi:10.1016/j.tmaid.2021.102242,B.1.1.7,"Co-first authors..

Variants of SARS-CoV-2 lineages including the most recently circulated Omicron, and previous pandemic B.1.351, B.1.1.7, which have been public concerns, contain a N501Y mutation located in the spike receptor binding domain."
1,doi:10.1016/j.tmaid.2021.102242,B.1.351,"Co-first authors..

Variants of SARS-CoV-2 lineages including the most recently circulated Omicron, and previous pandemic B.1.351, B.1.1.7, which have been public concerns, contain a N501Y mutation located in the spike receptor binding domain."
2,doi:10.1016/j.tmaid.2021.102242,B.1.1.529,"Recently, Omicron (B.1.1.529) was reported or predicted to be associated with rapid increase of COVID-19 cases (https://www.who.int/news/item/28-11-2021-update-on-omicron)."
0,doi:10.3390/biology11030400,B.1.1.529,"Accurate assessments of the incidence of new-onset diabetes induced by COVID-19 and its pathogenicity are still unknown, especially in the context of the circulation of SARS-CoV-2 variants, such as Omicron (B.1.1.529), which is a major challenge for the future.."
0,doi:10.1084/jem.20202756,B.1.1.7,"Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen..

Development of multiple safe and effective vaccines to control the ongoing COVID-19 pandemic (Cucinotta and Vanelli, 2020; World Health Organization, 2020b) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; Wu et al., 2020; Zhu et al., 2020) is a global priority, and several vaccines have already been authorized or approved for use in humans to fight the pandemic (Voysey et al., 2021; Baden et al., 2021; Polack et al., 2020)."
1,doi:10.1084/jem.20202756,B.1.351,"Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen..

Development of multiple safe and effective vaccines to control the ongoing COVID-19 pandemic (Cucinotta and Vanelli, 2020; World Health Organization, 2020b) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; Wu et al., 2020; Zhu et al., 2020) is a global priority, and several vaccines have already been authorized or approved for use in humans to fight the pandemic (Voysey et al., 2021; Baden et al., 2021; Polack et al., 2020)."
2,doi:10.1084/jem.20202756,B.1,"(A) Correlation between Leiden-0008 strain (B.1 lineage; LUMC) and Wuhan-Hu-1 (A lineage, Nexelis)."
0,doi:10.46234/ccdcw2021.179,B.1.617.2,Guangdong CDC published in preprint a critically important study of the effectiveness of China’s inactivated vaccines against the B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) — a strain of the virus that causes coronavirus disease 2019 (COVID-19) and is circulating globally (1-2).
0,doi:10.1016/j.ymthe.2021.09.024,B.1.617.2,"The coronavirus disease 2019 (COVID-19) pandemic continues to pose a serious threat to people’s lives, owing to the variants, particularly the B.1.617.2 (delta) variant."
0,doi:10.1101/2021.05.03.21256506,B.1.1.7,"Compared with lineage B, we estimate a 1.5-fold (95% CI: 1.0–2.2) reduction in neutralization against the B.1.1.7, 8.7-fold (95% CI: 6.5–11.7) reduction against B.1.351 and 5.0-fold (95% CI: 4.0–6.2) reduction against P.1."
1,doi:10.1101/2021.05.03.21256506,B.1.351,"Compared with lineage B, we estimate a 1.5-fold (95% CI: 1.0–2.2) reduction in neutralization against the B.1.1.7, 8.7-fold (95% CI: 6.5–11.7) reduction against B.1.351 and 5.0-fold (95% CI: 4.0–6.2) reduction against P.1."
2,doi:10.1101/2021.05.03.21256506,P.1,"The neutralizing antibodies induced by administration of inactivated vaccines and mRNA vaccines against lineage P.1 were also remarkably reduced by an average of 5.9-fold (95% CI: 3.7–9.3) and 1.5-fold (95% CI: 1.2–1.9)..

Our findings indicate that the antibody response established by natural infection or vaccination might be able to effectively neutralize B.1.1.7, but neutralizing titers against B.1.351 and P.1 suffered large reductions."
3,doi:10.1101/2021.05.03.21256506,B.1.427,"Another variant of lineage B.1.427/B.1.429, which first emerged in California, was categorized as a Variant of Concern (VOC) in March 2021 according to classification developed by SARS-CoV-2 Interagency Group (SIG) in United States, containing a single L452R mutation in RBD in spike, whose ability of reduced sensitivity to neutralization has yet to be determined9.."
4,doi:10.1101/2021.05.03.21256506,B.1.1.29,"Specifically, lineage B.1.1.117, B.1.1.26, B.1.1.50, and B.1.1.29 served as the reference strains when comparing with SARS-CoV-2 variants in some studies11,16,21,22, and they were classified as lineage B.1 due to close phylogenetic distance and shared mutation site of 614G22,23."
5,doi:10.1101/2021.05.03.21256506,B.1,"Specifically, lineage B.1.1.117, B.1.1.26, B.1.1.50, and B.1.1.29 served as the reference strains when comparing with SARS-CoV-2 variants in some studies11,16,21,22, and they were classified as lineage B.1 due to close phylogenetic distance and shared mutation site of 614G22,23."
6,doi:10.1101/2021.05.03.21256506,B.1.1.50,"Specifically, lineage B.1.1.117, B.1.1.26, B.1.1.50, and B.1.1.29 served as the reference strains when comparing with SARS-CoV-2 variants in some studies11,16,21,22, and they were classified as lineage B.1 due to close phylogenetic distance and shared mutation site of 614G22,23."
7,doi:10.1101/2021.05.03.21256506,B.1.1.26,"Specifically, lineage B.1.1.117, B.1.1.26, B.1.1.50, and B.1.1.29 served as the reference strains when comparing with SARS-CoV-2 variants in some studies11,16,21,22, and they were classified as lineage B.1 due to close phylogenetic distance and shared mutation site of 614G22,23."
8,doi:10.1101/2021.05.03.21256506,B.1.1.117,"Specifically, lineage B.1.1.117, B.1.1.26, B.1.1.50, and B.1.1.29 served as the reference strains when comparing with SARS-CoV-2 variants in some studies11,16,21,22, and they were classified as lineage B.1 due to close phylogenetic distance and shared mutation site of 614G22,23."
9,doi:10.1101/2021.05.03.21256506,B.1.526,"VOIs include lineage B.1.526, B.1.525 and P.2, with increased transmissibility and disease severity, and VOCs include lineage B.1.1.7, B.1.351, P.1, B.1.427, and B.1.429, with significant reduction in neutralization and increased hospitalizations or deaths24."
10,doi:10.1101/2021.05.03.21256506,B.1.525,"VOIs include lineage B.1.526, B.1.525 and P.2, with increased transmissibility and disease severity, and VOCs include lineage B.1.1.7, B.1.351, P.1, B.1.427, and B.1.429, with significant reduction in neutralization and increased hospitalizations or deaths24."
11,doi:10.1101/2021.05.03.21256506,P.2,"VOIs include lineage B.1.526, B.1.525 and P.2, with increased transmissibility and disease severity, and VOCs include lineage B.1.1.7, B.1.351, P.1, B.1.427, and B.1.429, with significant reduction in neutralization and increased hospitalizations or deaths24."
12,doi:10.1101/2021.05.03.21256506,B.1.429,"VOIs include lineage B.1.526, B.1.525 and P.2, with increased transmissibility and disease severity, and VOCs include lineage B.1.1.7, B.1.351, P.1, B.1.427, and B.1.429, with significant reduction in neutralization and increased hospitalizations or deaths24."
0,doi:10.3390/microorganisms10020280,B.1.1.529,"Finally, we found substantial differences in the prion-like domain of the S1 region of the spike protein across emerging variants including Omicron (B.1.1.529)."
1,doi:10.3390/microorganisms10020280,P.1,"We also analyzed PrDs in the spike protein of the variants of concern (VOC) B.1.617.2 (Delta) and B.1.1.529 (Omicron), variants of interest (VOI) and variants being monitored (VBM), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.427 (Epsilon), B.1.617.1 (Kappa) and P.2 (Zeta), some of which are known for their ability to escape antibody neutralization [33,34,35,36]..

Further analyses of these PrD-containing proteins in SARS-CoV-2 may improve our understanding of the COVID-19 infection and provide new insights into its pathophysiology and novel targets for developing therapies, including antiprion compounds with binding properties to prion proteins..

To identify the PrDs present in viral proteomes, protein sequences were obtained from the UniProt Knowledge Base and National Center for Biotechnology Information (NCBI) database [37,38].."
2,doi:10.3390/microorganisms10020280,B.1.1.7,"We also analyzed PrDs in the spike protein of the variants of concern (VOC) B.1.617.2 (Delta) and B.1.1.529 (Omicron), variants of interest (VOI) and variants being monitored (VBM), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.427 (Epsilon), B.1.617.1 (Kappa) and P.2 (Zeta), some of which are known for their ability to escape antibody neutralization [33,34,35,36]..

Further analyses of these PrD-containing proteins in SARS-CoV-2 may improve our understanding of the COVID-19 infection and provide new insights into its pathophysiology and novel targets for developing therapies, including antiprion compounds with binding properties to prion proteins..

To identify the PrDs present in viral proteomes, protein sequences were obtained from the UniProt Knowledge Base and National Center for Biotechnology Information (NCBI) database [37,38].."
3,doi:10.3390/microorganisms10020280,B.1.617.2,"We also analyzed PrDs in the spike protein of the variants of concern (VOC) B.1.617.2 (Delta) and B.1.1.529 (Omicron), variants of interest (VOI) and variants being monitored (VBM), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.427 (Epsilon), B.1.617.1 (Kappa) and P.2 (Zeta), some of which are known for their ability to escape antibody neutralization [33,34,35,36]..

Further analyses of these PrD-containing proteins in SARS-CoV-2 may improve our understanding of the COVID-19 infection and provide new insights into its pathophysiology and novel targets for developing therapies, including antiprion compounds with binding properties to prion proteins..

To identify the PrDs present in viral proteomes, protein sequences were obtained from the UniProt Knowledge Base and National Center for Biotechnology Information (NCBI) database [37,38].."
4,doi:10.3390/microorganisms10020280,P.2,"We also analyzed PrDs in the spike protein of the variants of concern (VOC) B.1.617.2 (Delta) and B.1.1.529 (Omicron), variants of interest (VOI) and variants being monitored (VBM), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.427 (Epsilon), B.1.617.1 (Kappa) and P.2 (Zeta), some of which are known for their ability to escape antibody neutralization [33,34,35,36]..

Further analyses of these PrD-containing proteins in SARS-CoV-2 may improve our understanding of the COVID-19 infection and provide new insights into its pathophysiology and novel targets for developing therapies, including antiprion compounds with binding properties to prion proteins..

To identify the PrDs present in viral proteomes, protein sequences were obtained from the UniProt Knowledge Base and National Center for Biotechnology Information (NCBI) database [37,38].."
5,doi:10.3390/microorganisms10020280,B.1.617.1,"We also analyzed PrDs in the spike protein of the variants of concern (VOC) B.1.617.2 (Delta) and B.1.1.529 (Omicron), variants of interest (VOI) and variants being monitored (VBM), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.427 (Epsilon), B.1.617.1 (Kappa) and P.2 (Zeta), some of which are known for their ability to escape antibody neutralization [33,34,35,36]..

Further analyses of these PrD-containing proteins in SARS-CoV-2 may improve our understanding of the COVID-19 infection and provide new insights into its pathophysiology and novel targets for developing therapies, including antiprion compounds with binding properties to prion proteins..

To identify the PrDs present in viral proteomes, protein sequences were obtained from the UniProt Knowledge Base and National Center for Biotechnology Information (NCBI) database [37,38].."
6,doi:10.3390/microorganisms10020280,B.1.427,"We also analyzed PrDs in the spike protein of the variants of concern (VOC) B.1.617.2 (Delta) and B.1.1.529 (Omicron), variants of interest (VOI) and variants being monitored (VBM), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.427 (Epsilon), B.1.617.1 (Kappa) and P.2 (Zeta), some of which are known for their ability to escape antibody neutralization [33,34,35,36]..

Further analyses of these PrD-containing proteins in SARS-CoV-2 may improve our understanding of the COVID-19 infection and provide new insights into its pathophysiology and novel targets for developing therapies, including antiprion compounds with binding properties to prion proteins..

To identify the PrDs present in viral proteomes, protein sequences were obtained from the UniProt Knowledge Base and National Center for Biotechnology Information (NCBI) database [37,38].."
7,doi:10.3390/microorganisms10020280,B.1.351,"We also analyzed PrDs in the spike protein of the variants of concern (VOC) B.1.617.2 (Delta) and B.1.1.529 (Omicron), variants of interest (VOI) and variants being monitored (VBM), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.427 (Epsilon), B.1.617.1 (Kappa) and P.2 (Zeta), some of which are known for their ability to escape antibody neutralization [33,34,35,36]..

Further analyses of these PrD-containing proteins in SARS-CoV-2 may improve our understanding of the COVID-19 infection and provide new insights into its pathophysiology and novel targets for developing therapies, including antiprion compounds with binding properties to prion proteins..

To identify the PrDs present in viral proteomes, protein sequences were obtained from the UniProt Knowledge Base and National Center for Biotechnology Information (NCBI) database [37,38].."
0,doi:10.3390/microorganisms9040677,P.1,"The rapid spread of the SARS-CoV-2 lineages B.1.1.7 (N501Y.V1) throughout the UK, B.1.351 (N501Y.V2) in South Africa, and P.1 (B.1.1.28.1; N501Y.V3) in Brazil has led to the definition of variants of concern (VoCs) and recommendations for lineage specific surveillance."
1,doi:10.3390/microorganisms9040677,B.1.1.7,"The rapid spread of the SARS-CoV-2 lineages B.1.1.7 (N501Y.V1) throughout the UK, B.1.351 (N501Y.V2) in South Africa, and P.1 (B.1.1.28.1; N501Y.V3) in Brazil has led to the definition of variants of concern (VoCs) and recommendations for lineage specific surveillance."
2,doi:10.3390/microorganisms9040677,B.1.351,"The rapid spread of the SARS-CoV-2 lineages B.1.1.7 (N501Y.V1) throughout the UK, B.1.351 (N501Y.V2) in South Africa, and P.1 (B.1.1.28.1; N501Y.V3) in Brazil has led to the definition of variants of concern (VoCs) and recommendations for lineage specific surveillance."
3,doi:10.3390/microorganisms9040677,V.1,"SARS-CoV-2 genomes were generally amplified following the amplicon sequencing strategy of the ARTIC protocol (https://artic.network/ncov-2019, accessed on 3 March 2021) with V.1 or V.3 primers and 150 nucleotide paired-end sequenced, on an Illumina platform e.g., [32,33]."
4,doi:10.3390/microorganisms9040677,B.1.258,"Our WGS data of samples collected in December 2020 showed that most of the S gene dropout samples were due to the B.1.258 lineage, at least in eastern Switzerland."
0,doi:10.1016/j.meegid.2021.105088,P.1,"We identified 13 types of viral lineages including R.1, P.1, B.1.1.7 (Alpha) and B.1.617.2 (Delta)."
1,doi:10.1016/j.meegid.2021.105088,B.1.1.7,"We identified 13 types of viral lineages including R.1, P.1, B.1.1.7 (Alpha) and B.1.617.2 (Delta)."
2,doi:10.1016/j.meegid.2021.105088,R.1,"We identified 13 types of viral lineages including R.1, P.1, B.1.1.7 (Alpha) and B.1.617.2 (Delta)."
3,doi:10.1016/j.meegid.2021.105088,B.1.617.2,"We identified 13 types of viral lineages including R.1, P.1, B.1.1.7 (Alpha) and B.1.617.2 (Delta)."
4,doi:10.1016/j.meegid.2021.105088,B.1.1.214,"After the emerging of the R.1 lineage harboring E484K variant (designated VOI in Japan), the prevalent B.1.1.214 lineage were no longer identified."
5,doi:10.1016/j.meegid.2021.105088,C.37,"The several viral lineages have been designated as variant of concern (VOC) or variant of interest (VOI)..

On May 31, 2021, World Health Organization (WHO) proposed a new designation, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) as the four VOCs and Epsilon (B.1.427/B.1.429), Zeta (P.2), Eta (B.1.525), Theta (B.1.525) Lota (B.1.526), Kappa (B.1.617.1) and Lambda (C.37) as the seven VOIs (World Health Organization, 2021)."
6,doi:10.1016/j.meegid.2021.105088,B.1.526,"The several viral lineages have been designated as variant of concern (VOC) or variant of interest (VOI)..

On May 31, 2021, World Health Organization (WHO) proposed a new designation, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) as the four VOCs and Epsilon (B.1.427/B.1.429), Zeta (P.2), Eta (B.1.525), Theta (B.1.525) Lota (B.1.526), Kappa (B.1.617.1) and Lambda (C.37) as the seven VOIs (World Health Organization, 2021)."
7,doi:10.1016/j.meegid.2021.105088,B.1.427,"The several viral lineages have been designated as variant of concern (VOC) or variant of interest (VOI)..

On May 31, 2021, World Health Organization (WHO) proposed a new designation, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) as the four VOCs and Epsilon (B.1.427/B.1.429), Zeta (P.2), Eta (B.1.525), Theta (B.1.525) Lota (B.1.526), Kappa (B.1.617.1) and Lambda (C.37) as the seven VOIs (World Health Organization, 2021)."
8,doi:10.1016/j.meegid.2021.105088,B.1.351,"The several viral lineages have been designated as variant of concern (VOC) or variant of interest (VOI)..

On May 31, 2021, World Health Organization (WHO) proposed a new designation, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) as the four VOCs and Epsilon (B.1.427/B.1.429), Zeta (P.2), Eta (B.1.525), Theta (B.1.525) Lota (B.1.526), Kappa (B.1.617.1) and Lambda (C.37) as the seven VOIs (World Health Organization, 2021)."
9,doi:10.1016/j.meegid.2021.105088,B.1.525,"The several viral lineages have been designated as variant of concern (VOC) or variant of interest (VOI)..

On May 31, 2021, World Health Organization (WHO) proposed a new designation, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) as the four VOCs and Epsilon (B.1.427/B.1.429), Zeta (P.2), Eta (B.1.525), Theta (B.1.525) Lota (B.1.526), Kappa (B.1.617.1) and Lambda (C.37) as the seven VOIs (World Health Organization, 2021)."
10,doi:10.1016/j.meegid.2021.105088,B.1.617.1,"The several viral lineages have been designated as variant of concern (VOC) or variant of interest (VOI)..

On May 31, 2021, World Health Organization (WHO) proposed a new designation, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) as the four VOCs and Epsilon (B.1.427/B.1.429), Zeta (P.2), Eta (B.1.525), Theta (B.1.525) Lota (B.1.526), Kappa (B.1.617.1) and Lambda (C.37) as the seven VOIs (World Health Organization, 2021)."
11,doi:10.1016/j.meegid.2021.105088,P.2,"The several viral lineages have been designated as variant of concern (VOC) or variant of interest (VOI)..

On May 31, 2021, World Health Organization (WHO) proposed a new designation, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) as the four VOCs and Epsilon (B.1.427/B.1.429), Zeta (P.2), Eta (B.1.525), Theta (B.1.525) Lota (B.1.526), Kappa (B.1.617.1) and Lambda (C.37) as the seven VOIs (World Health Organization, 2021)."
12,doi:10.1016/j.meegid.2021.105088,B.1.149,"The result showed the 325 samples were classified into 13 types of lineage (B, B.1, B.1.1, B.1.149, B.1.1.284, B.1.1.214, B.1.411, B.1.346, R.1, P.1, B.1.1.220 B.1.1.7 and B.1.617.2) (Table 1
).Table 1Identified viral lineages in the community of Japan.Table 1LineageDesignation by WHODesignation by CDC (USA)Designation by ECDC (Europe)Designation by NIID (Japan)Number of samplesIdentified periodB––––1February 2020B.1––––2March 2020B.1.1––––8March to November 2020B.1.149––––1March 2020B.1.1.284––––20July 2020 to January 2021B.1.1.214––––96August 2020 to February 2021B.1.411––––4December 2020B.1.346––––3January 2021R.1–––VOI20January to May 2021P.1VOCVOCVOCVOC1February 2021B.1.1.220a––––3April 2021B.1.1.7VOCVOCVOCVOC165April to June 2021B.1.617.2VOCVOCVOCVOC1June 2021Total325VOI, variant of interest; VOC, variant of concern; WHO, World Health Organization; CDC, Centers for Disease Control and Prevention; ECDC, European Centre for Disease Prevention and Control; NIID, National Institute of Infectious Diseases.aHarboring E484K mutation.."
13,doi:10.1016/j.meegid.2021.105088,B.1,"The result showed the 325 samples were classified into 13 types of lineage (B, B.1, B.1.1, B.1.149, B.1.1.284, B.1.1.214, B.1.411, B.1.346, R.1, P.1, B.1.1.220 B.1.1.7 and B.1.617.2) (Table 1
).Table 1Identified viral lineages in the community of Japan.Table 1LineageDesignation by WHODesignation by CDC (USA)Designation by ECDC (Europe)Designation by NIID (Japan)Number of samplesIdentified periodB––––1February 2020B.1––––2March 2020B.1.1––––8March to November 2020B.1.149––––1March 2020B.1.1.284––––20July 2020 to January 2021B.1.1.214––––96August 2020 to February 2021B.1.411––––4December 2020B.1.346––––3January 2021R.1–––VOI20January to May 2021P.1VOCVOCVOCVOC1February 2021B.1.1.220a––––3April 2021B.1.1.7VOCVOCVOCVOC165April to June 2021B.1.617.2VOCVOCVOCVOC1June 2021Total325VOI, variant of interest; VOC, variant of concern; WHO, World Health Organization; CDC, Centers for Disease Control and Prevention; ECDC, European Centre for Disease Prevention and Control; NIID, National Institute of Infectious Diseases.aHarboring E484K mutation.."
14,doi:10.1016/j.meegid.2021.105088,B.1.1.220,"The result showed the 325 samples were classified into 13 types of lineage (B, B.1, B.1.1, B.1.149, B.1.1.284, B.1.1.214, B.1.411, B.1.346, R.1, P.1, B.1.1.220 B.1.1.7 and B.1.617.2) (Table 1
).Table 1Identified viral lineages in the community of Japan.Table 1LineageDesignation by WHODesignation by CDC (USA)Designation by ECDC (Europe)Designation by NIID (Japan)Number of samplesIdentified periodB––––1February 2020B.1––––2March 2020B.1.1––––8March to November 2020B.1.149––––1March 2020B.1.1.284––––20July 2020 to January 2021B.1.1.214––––96August 2020 to February 2021B.1.411––––4December 2020B.1.346––––3January 2021R.1–––VOI20January to May 2021P.1VOCVOCVOCVOC1February 2021B.1.1.220a––––3April 2021B.1.1.7VOCVOCVOCVOC165April to June 2021B.1.617.2VOCVOCVOCVOC1June 2021Total325VOI, variant of interest; VOC, variant of concern; WHO, World Health Organization; CDC, Centers for Disease Control and Prevention; ECDC, European Centre for Disease Prevention and Control; NIID, National Institute of Infectious Diseases.aHarboring E484K mutation.."
15,doi:10.1016/j.meegid.2021.105088,B.1.411,"The result showed the 325 samples were classified into 13 types of lineage (B, B.1, B.1.1, B.1.149, B.1.1.284, B.1.1.214, B.1.411, B.1.346, R.1, P.1, B.1.1.220 B.1.1.7 and B.1.617.2) (Table 1
).Table 1Identified viral lineages in the community of Japan.Table 1LineageDesignation by WHODesignation by CDC (USA)Designation by ECDC (Europe)Designation by NIID (Japan)Number of samplesIdentified periodB––––1February 2020B.1––––2March 2020B.1.1––––8March to November 2020B.1.149––––1March 2020B.1.1.284––––20July 2020 to January 2021B.1.1.214––––96August 2020 to February 2021B.1.411––––4December 2020B.1.346––––3January 2021R.1–––VOI20January to May 2021P.1VOCVOCVOCVOC1February 2021B.1.1.220a––––3April 2021B.1.1.7VOCVOCVOCVOC165April to June 2021B.1.617.2VOCVOCVOCVOC1June 2021Total325VOI, variant of interest; VOC, variant of concern; WHO, World Health Organization; CDC, Centers for Disease Control and Prevention; ECDC, European Centre for Disease Prevention and Control; NIID, National Institute of Infectious Diseases.aHarboring E484K mutation.."
16,doi:10.1016/j.meegid.2021.105088,B.1.346,"The result showed the 325 samples were classified into 13 types of lineage (B, B.1, B.1.1, B.1.149, B.1.1.284, B.1.1.214, B.1.411, B.1.346, R.1, P.1, B.1.1.220 B.1.1.7 and B.1.617.2) (Table 1
).Table 1Identified viral lineages in the community of Japan.Table 1LineageDesignation by WHODesignation by CDC (USA)Designation by ECDC (Europe)Designation by NIID (Japan)Number of samplesIdentified periodB––––1February 2020B.1––––2March 2020B.1.1––––8March to November 2020B.1.149––––1March 2020B.1.1.284––––20July 2020 to January 2021B.1.1.214––––96August 2020 to February 2021B.1.411––––4December 2020B.1.346––––3January 2021R.1–––VOI20January to May 2021P.1VOCVOCVOCVOC1February 2021B.1.1.220a––––3April 2021B.1.1.7VOCVOCVOCVOC165April to June 2021B.1.617.2VOCVOCVOCVOC1June 2021Total325VOI, variant of interest; VOC, variant of concern; WHO, World Health Organization; CDC, Centers for Disease Control and Prevention; ECDC, European Centre for Disease Prevention and Control; NIID, National Institute of Infectious Diseases.aHarboring E484K mutation.."
17,doi:10.1016/j.meegid.2021.105088,B.1.1,"The result showed the 325 samples were classified into 13 types of lineage (B, B.1, B.1.1, B.1.149, B.1.1.284, B.1.1.214, B.1.411, B.1.346, R.1, P.1, B.1.1.220 B.1.1.7 and B.1.617.2) (Table 1
).Table 1Identified viral lineages in the community of Japan.Table 1LineageDesignation by WHODesignation by CDC (USA)Designation by ECDC (Europe)Designation by NIID (Japan)Number of samplesIdentified periodB––––1February 2020B.1––––2March 2020B.1.1––––8March to November 2020B.1.149––––1March 2020B.1.1.284––––20July 2020 to January 2021B.1.1.214––––96August 2020 to February 2021B.1.411––––4December 2020B.1.346––––3January 2021R.1–––VOI20January to May 2021P.1VOCVOCVOCVOC1February 2021B.1.1.220a––––3April 2021B.1.1.7VOCVOCVOCVOC165April to June 2021B.1.617.2VOCVOCVOCVOC1June 2021Total325VOI, variant of interest; VOC, variant of concern; WHO, World Health Organization; CDC, Centers for Disease Control and Prevention; ECDC, European Centre for Disease Prevention and Control; NIID, National Institute of Infectious Diseases.aHarboring E484K mutation.."
18,doi:10.1016/j.meegid.2021.105088,B.1.1.284,"The result showed the 325 samples were classified into 13 types of lineage (B, B.1, B.1.1, B.1.149, B.1.1.284, B.1.1.214, B.1.411, B.1.346, R.1, P.1, B.1.1.220 B.1.1.7 and B.1.617.2) (Table 1
).Table 1Identified viral lineages in the community of Japan.Table 1LineageDesignation by WHODesignation by CDC (USA)Designation by ECDC (Europe)Designation by NIID (Japan)Number of samplesIdentified periodB––––1February 2020B.1––––2March 2020B.1.1––––8March to November 2020B.1.149––––1March 2020B.1.1.284––––20July 2020 to January 2021B.1.1.214––––96August 2020 to February 2021B.1.411––––4December 2020B.1.346––––3January 2021R.1–––VOI20January to May 2021P.1VOCVOCVOCVOC1February 2021B.1.1.220a––––3April 2021B.1.1.7VOCVOCVOCVOC165April to June 2021B.1.617.2VOCVOCVOCVOC1June 2021Total325VOI, variant of interest; VOC, variant of concern; WHO, World Health Organization; CDC, Centers for Disease Control and Prevention; ECDC, European Centre for Disease Prevention and Control; NIID, National Institute of Infectious Diseases.aHarboring E484K mutation.."
0,doi:10.1099/acmi.0.000252,B.1,"WGS revealed indistinguishable SARS-CoV-2 genomes recovered from the adults at the gathering, which were closely related genetically to B.1 lineage viruses circulating in the local community."
1,doi:10.1099/acmi.0.000252,A.2,"Interrogation of the GISAID database revealed an identical A-to-G mutation at the same nucleotide position resulting in S:N30S in just one other sequenced genome submitted to the platform to date (hCoV-19/Panama/335944/2020, GISAID accession: EPI_ISL_496830); however, this sequence belongs to the A.2 lineage implying independent acquisition of the N30S mutation in both lineages..

(a) Phylogeny of Irish community SARS-CoV-2 sequences (n=674), including the assigned viral lineages and notable spike variants observed."
2,doi:10.1099/acmi.0.000252,B.1.1.7,"For example, the B.1.1.7 ‘Variant of Concern’, which is defined by a set of 23 genomic variations including an S:N501Y substitution and deletions at positions 69–70, spread rapidly throughout the United Kingdom from late November 2020 [28] and received significant attention due to evidence supporting increased viral transmissibility and its association with the failure of S gene qPCR targets [28, 29]."
3,doi:10.1099/acmi.0.000252,B.1.177,"These include D614G, associated with the B.1 lineage observed in this family cluster, which is now ubiquitous and appears to have a moderate effect on SARS-CoV-2 transmissibility [30]; A222V, present in the 20A.EU1 (B.1.177) cluster which has spread quickly across Europe from Spain and become dominant in Irish sequences [31]; and N439K, a variant for which there is evidence to suggest increased ACE2 receptor binding affinity and immune-escape from neutralising antibodies [32].."
0,doi:10.15585/mmwr.mm7028e2,B.1.617.2,"The B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, was identified in India in late 2020 and has subsequently been detected in approximately 60 countries (1)."
1,doi:10.15585/mmwr.mm7028e2,B.1.1.7,"Emerging evidence suggests that attack rates for the B.1.617.2 variant are potentially higher than are those for other variants of concern, including the B.1.1.7 (Alpha) variant (2,4)."
0,doi:10.3390/v13081647,P.1,"We report here on the emergence of two variants of concern, B.1.1.7 (Alpha) and P.1 (Gamma), and their displacement of the D614G B.1 variant in a Missouri sewershed.."
1,doi:10.3390/v13081647,B.1.1.7,"We report here on the emergence of two variants of concern, B.1.1.7 (Alpha) and P.1 (Gamma), and their displacement of the D614G B.1 variant in a Missouri sewershed.."
2,doi:10.3390/v13081647,B.1,"We report here on the emergence of two variants of concern, B.1.1.7 (Alpha) and P.1 (Gamma), and their displacement of the D614G B.1 variant in a Missouri sewershed.."
0,doi:10.1128/mra.00657-21,B.1.466.2,"In addition, this study described the presence of lineage B.1.351 as a type of variant of concern (VOC) and lineages B.1.466.2 and B.1.524 as local variants.."
1,doi:10.1128/mra.00657-21,B.1.351,"In addition, this study described the presence of lineage B.1.351 as a type of variant of concern (VOC) and lineages B.1.466.2 and B.1.524 as local variants.."
2,doi:10.1128/mra.00657-21,B.1.524,"In addition, this study described the presence of lineage B.1.351 as a type of variant of concern (VOC) and lineages B.1.466.2 and B.1.524 as local variants.."
3,doi:10.1128/mra.00657-21,B.1.468,"In addition, this study also documented B.1.524 of Malaysian lineage and B.1.466.2 and B.1.468 of Indonesian lineages.."
0,doi:10.1126/sciadv.abj3627,B.1.1.7,SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 do not cause more severe disease in rhesus macaques..
1,doi:10.1126/sciadv.abj3627,B.1.351,SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 do not cause more severe disease in rhesus macaques..
2,doi:10.1126/sciadv.abj3627,B.1,"Here, we compared variants of concern (VOC) B.1.1.7 and B.1.351 to a recent B.1 SARS-CoV-2 isolate containing the D614G spike substitution in the rhesus macaque model."
0,doi:10.1038/s41598-022-08559-5,B.1,"Using a clinical strain of the Omicron variant, we analyzed the neutralizing power of eight currently used monoclonal antibodies compared to the ancestral B.1 BavPat1 D614G strain."
1,doi:10.1038/s41598-022-08559-5,B.1.1.529,"C. Drosten through EVA GLOBAL (https://www.european-virus-archive.com/) and contains the D614G mutation..

SARS-CoV-2 Omicron (B.1.1.529) was isolated from a nasopharyngeal swab of the 1st of December in Marseille, France."
0,doi:10.1093/cid/ciab1072,B.1.1.529,"In November 2021, the World Health Organization designated a new SARS-CoV-2 variant of concern, Omicron (PANGO lineage B.1.1.529)."
0,doi:10.1101/2021.06.07.447437,B.1.1.7,"Furthermore, the variant B.1.1.7 with several mutations is dramatically resistant to the anti-viral effect of FXa compared to wild-type SARA-CoV-2 in vivo and in vitro."
0,doi:10.3390/genes12070973,B.1.525,"A signal analysis of the complete genome sequenced for coronavirus variants of concern—B.1.1.7 (Alpha), B.1.135 (Beta) and P1 (Gamma)—and coronavirus variants of interest—B.1.429–B.1.427 (Epsilon) and B.1.525 (Eta)—is presented using open GISAID data."
1,doi:10.3390/genes12070973,B.1.135,"A signal analysis of the complete genome sequenced for coronavirus variants of concern—B.1.1.7 (Alpha), B.1.135 (Beta) and P1 (Gamma)—and coronavirus variants of interest—B.1.429–B.1.427 (Epsilon) and B.1.525 (Eta)—is presented using open GISAID data."
2,doi:10.3390/genes12070973,B.1.1.7,"In Figure 1 we illustrate the genetic similarity plot between SARS-CoV-2 Wuhan-Hu-1 (MN908947.3), and several representative full-length genome sequences of variants known as B.1.1.7 (UK), B.1.135 (South Africa), B.1.429–B.1.427 (California), B.1.525 (Nigeria) and P1 (Brazil)."
0,doi:10.1128/mbio.03617-21,B.1.1.529,"There is a growing concern that ongoing evolution of SARS-CoV-2 could lead to variants of concern (VOC) that are capable of avoiding some or all of the multifaceted immune response generated by both prior infection or vaccination, with the recently described B.1.1.529 (Omicron) VOC being of particular interest."
0,doi:10.1126/sciadv.abk0172,B.1.1.7,A single intranasal vaccination with live attenuated virus provides protection against VOC B.1.1.7 (Alpha) and B.1.351 (Beta)..
1,doi:10.1126/sciadv.abk0172,B.1.351,A single intranasal vaccination with live attenuated virus provides protection against VOC B.1.1.7 (Alpha) and B.1.351 (Beta)..
2,doi:10.1126/sciadv.abk0172,B.1.617.2,"We show that a single intranasal vaccination with sCPD9 elicited strong cross-neutralizing antibody responses against four current SARS-CoV-2 variants of concern, B.1.1.7 (Alpha), B.1.351 (Beta), B.1.1.28.1 (Gamma), and B.1.617.2 (Delta)."
3,doi:10.1126/sciadv.abk0172,B.1,The sCPD9 vaccine offered complete protection from COVID-19–like disease caused by the ancestral SARS-CoV-2 variant B.1 and the two variants of concern B.1.1.7 and B.1.351..
4,doi:10.1126/sciadv.abk0172,P.1,"The B.1.1.28.1 variant, better known as P.1, is similar to B.1.351 in that both share some important mutations in the spike glycoprotein (E484K, K417N/T, and N501Y)."
5,doi:10.1126/sciadv.abk0172,B.1.525,This mutation is also present in B.1.1.28.1 and B.1.525 lineages and was also identified in some viruses of the B.1.1.7 and B.1.526 lineages..
6,doi:10.1126/sciadv.abk0172,B.1.526,This mutation is also present in B.1.1.28.1 and B.1.525 lineages and was also identified in some viruses of the B.1.1.7 and B.1.526 lineages..
7,doi:10.1126/sciadv.abk0172,B.1.617,"SARS-CoV-2 variants B.1 (BetaCoV/Munich/BavPat1/2020) (39), B.1.1.7 (BetaCoV/Germany/ChVir21652/2020), B.1.351 (hCoV-19/Netherlands/NoordHolland_20159/2021), B.1.1.28.1 (hCoV-19/Netherlands/NoordHolland_10915/2021), and B.1.617.2 [SARS-CoV-2, Human, 2021, Germany ex India, 20A/452R (B.1.617)] were grown in Vero E6 cells."
0,doi:10.1093/cid/ciab496,B.1.1.7,"We compared secondary attack rates in households with B.1.1.7 variant of concern
(VOC) versus non-VOC index cases in a matched cohort in Ontario, Canada."
1,doi:10.1093/cid/ciab496,B.1.351,"These patterns of rapid strain
replacement suggest increased transmissibility of variants with the N501Y mutation,
which is present across variants of concern (VOC), including B.1.1.7, B.1.351, and P.1
lineages [2]."
0,doi:10.3389/fmicb.2021.803827,B.1.617.2,"Globally, lineages B.1.1.7 and B.1.617.2/AY.X were identified as the 2 major lineages circulating in the Balearic Islands during the pandemic, distantly followed by lineages B.1.177/B.1.177.X."
1,doi:10.3389/fmicb.2021.803827,B.1.177,"Globally, lineages B.1.1.7 and B.1.617.2/AY.X were identified as the 2 major lineages circulating in the Balearic Islands during the pandemic, distantly followed by lineages B.1.177/B.1.177.X."
2,doi:10.3389/fmicb.2021.803827,B.1.1.7,"Globally, lineages B.1.1.7 and B.1.617.2/AY.X were identified as the 2 major lineages circulating in the Balearic Islands during the pandemic, distantly followed by lineages B.1.177/B.1.177.X."
3,doi:10.3389/fmicb.2021.803827,B.1.221,"However, in Ibiza/Formentera lineage distribution was slightly different and lineage B.1.221 was the third most prevalent."
4,doi:10.3389/fmicb.2021.803827,B.1.5,"Temporal distribution analysis showed that B.1 and B.1.5 lineages dominated the first epidemic wave, lineage B.1.177 dominated the second and third, and lineage B.1.617.2 the fourth."
5,doi:10.3389/fmicb.2021.803827,B.1,"Temporal distribution analysis showed that B.1 and B.1.5 lineages dominated the first epidemic wave, lineage B.1.177 dominated the second and third, and lineage B.1.617.2 the fourth."
6,doi:10.3389/fmicb.2021.803827,B.1.526.2,"Whole genomes sequences were assigned to 46 different PANGO lineages (derivatives of lineages B.1.177 (B.1.177.X), B.1.526 (B.1.526.2), and B.1.617.2 (AY.X) were included within their parental lineage), and according to the WHO variants current definition, 75% of genomes were classified within a VOC, VUI, or VUM variant [World Health Organization [WHO], 2021]."
7,doi:10.3389/fmicb.2021.803827,B.1.526,"Whole genomes sequences were assigned to 46 different PANGO lineages (derivatives of lineages B.1.177 (B.1.177.X), B.1.526 (B.1.526.2), and B.1.617.2 (AY.X) were included within their parental lineage), and according to the WHO variants current definition, 75% of genomes were classified within a VOC, VUI, or VUM variant [World Health Organization [WHO], 2021]."
8,doi:10.3389/fmicb.2021.803827,P.1,"Top ten more prevalent lineages include lineages B.1 (2.8%), B.1.5 (2.6%), B.1.526/B.1.526.X lineages (WHO Iota variant; 2.3%), B.1.221 (2.1%), B.1.525 (WHO Eta variant; 1.5%), P.1/P.1.X (WHO Gamma variant; 1.3%) and A.2 lineage (0.9%) (Figure 2)."
9,doi:10.3389/fmicb.2021.803827,B.1.525,"Top ten more prevalent lineages include lineages B.1 (2.8%), B.1.5 (2.6%), B.1.526/B.1.526.X lineages (WHO Iota variant; 2.3%), B.1.221 (2.1%), B.1.525 (WHO Eta variant; 1.5%), P.1/P.1.X (WHO Gamma variant; 1.3%) and A.2 lineage (0.9%) (Figure 2)."
10,doi:10.3389/fmicb.2021.803827,A.2,"Top ten more prevalent lineages include lineages B.1 (2.8%), B.1.5 (2.6%), B.1.526/B.1.526.X lineages (WHO Iota variant; 2.3%), B.1.221 (2.1%), B.1.525 (WHO Eta variant; 1.5%), P.1/P.1.X (WHO Gamma variant; 1.3%) and A.2 lineage (0.9%) (Figure 2)."
11,doi:10.3389/fmicb.2021.803827,B.1.1.238,"VOC/VUM lineage B.1.351 (n = 9, WHO Beta variant) and VOI/VUM B.1.427/B.1.429 (n = 9, WHO Epsilon variant), B.1.619 (n = 1), B.1.620 (n = 1), B.1.1.238 (n = 2) and R.1 (n = 1) lineages have been rarely detected in the Balearic Islands (Supplementary Material)..

Geographical distribution of the 10 most frequently detected PANGO lineages."
12,doi:10.3389/fmicb.2021.803827,R.1,"VOC/VUM lineage B.1.351 (n = 9, WHO Beta variant) and VOI/VUM B.1.427/B.1.429 (n = 9, WHO Epsilon variant), B.1.619 (n = 1), B.1.620 (n = 1), B.1.1.238 (n = 2) and R.1 (n = 1) lineages have been rarely detected in the Balearic Islands (Supplementary Material)..

Geographical distribution of the 10 most frequently detected PANGO lineages."
13,doi:10.3389/fmicb.2021.803827,B.1.619,"VOC/VUM lineage B.1.351 (n = 9, WHO Beta variant) and VOI/VUM B.1.427/B.1.429 (n = 9, WHO Epsilon variant), B.1.619 (n = 1), B.1.620 (n = 1), B.1.1.238 (n = 2) and R.1 (n = 1) lineages have been rarely detected in the Balearic Islands (Supplementary Material)..

Geographical distribution of the 10 most frequently detected PANGO lineages."
14,doi:10.3389/fmicb.2021.803827,B.1.620,"VOC/VUM lineage B.1.351 (n = 9, WHO Beta variant) and VOI/VUM B.1.427/B.1.429 (n = 9, WHO Epsilon variant), B.1.619 (n = 1), B.1.620 (n = 1), B.1.1.238 (n = 2) and R.1 (n = 1) lineages have been rarely detected in the Balearic Islands (Supplementary Material)..

Geographical distribution of the 10 most frequently detected PANGO lineages."
15,doi:10.3389/fmicb.2021.803827,B.1.427,"VOC/VUM lineage B.1.351 (n = 9, WHO Beta variant) and VOI/VUM B.1.427/B.1.429 (n = 9, WHO Epsilon variant), B.1.619 (n = 1), B.1.620 (n = 1), B.1.1.238 (n = 2) and R.1 (n = 1) lineages have been rarely detected in the Balearic Islands (Supplementary Material)..

Geographical distribution of the 10 most frequently detected PANGO lineages."
16,doi:10.3389/fmicb.2021.803827,B.1.351,"VOC/VUM lineage B.1.351 (n = 9, WHO Beta variant) and VOI/VUM B.1.427/B.1.429 (n = 9, WHO Epsilon variant), B.1.619 (n = 1), B.1.620 (n = 1), B.1.1.238 (n = 2) and R.1 (n = 1) lineages have been rarely detected in the Balearic Islands (Supplementary Material)..

Geographical distribution of the 10 most frequently detected PANGO lineages."
17,doi:10.3389/fmicb.2021.803827,B.1.621,"Of note, 24 of the 42 PANGO lineages were only detected in Majorca, including the B.1.621 lineage (WHO Mu variant)."
18,doi:10.3389/fmicb.2021.803827,A.5,"Since the beginning of the pandemic, four epidemic waves have been registered in the Balearic Islands: first was registered from late February 2020 to epidemiological week 2020-19, second from week 32 to 40-2020, third from week 50-2020 to 05-2021, and fourth from week 25 to 36-2021 (Servei de salut Illes Balears Conselleria Salut i consum, 2021)..

Lineage A viruses (A.2 and A.5) were detected in all the Balearic Islands but only during the first epidemic wave, accounting for almost 25% of the sequenced samples in this period (Supplementary Material)."
19,doi:10.3389/fmicb.2021.803827,A.23.1,"Moreover, up to 31 genomes ascribed to lineage B.1.1.7 harbored the spike substitution S:R287K, a rare mutation with unknown biological effect..

Of note, since July 2021, mutation S:Q613H present in lineage A.23.1 (Bugembe et al., 2021) has been detected in a relative high number of genomes belonging to the P.1 (n = 1) and B.1.617.2/AY.X (n = 24) lineages, mutation which could provide some biological advantages (Bugembe et al., 2021; Harvey et al., 2021)."
0,doi:10.21203/rs.3.rs-1362541/v1,B.1.1.529,"The SARS-CoV-2 B.1.1.529 lineage, Omicron variant, was first detected in November 2021 and carries 32 amino acid mutations in the spike protein (15 in RBD) and exhibits significant escape of neutralizing antibodies targeting the parental SARS-CoV-2 virus."
0,doi:10.1128/mra.00524-21,P.1,Genome sequence of a SARS-CoV-2 P.1 variant of concern (20J/501Y.V3) from Bangladesh.
1,doi:10.1128/mra.00524-21,B.1.1.7,"Variants of the virus have been reported already, among them variants of great concern (B.1.1.7, 20I/501Y.V1, and B.1.351 [20H/501Y.V2]) due to their possible increased transmissibility and demonstrated resistance to neutralizing antibody therapy targeted at the N-terminal domain (NTD) or the receptor-binding domain (RBD) (2)."
2,doi:10.1128/mra.00524-21,B.1.351,"Variants of the virus have been reported already, among them variants of great concern (B.1.1.7, 20I/501Y.V1, and B.1.351 [20H/501Y.V2]) due to their possible increased transmissibility and demonstrated resistance to neutralizing antibody therapy targeted at the N-terminal domain (NTD) or the receptor-binding domain (RBD) (2)."
0,doi:10.15585/mmwr.mm7017a5,B.1.351,"In late January 2021, a clinical laboratory notified the Maryland Department of Health (MDH) that the SARS-CoV-2 variant of concern B.1.351 had been identified in a specimen collected from a Maryland resident with COVID-19 (1)."
0,doi:10.1016/j.rmed.2021.106716,B.1.1.529,"The World Health Organization (WHO) stated that the “highly mutated” Omicron variant, known as B.1.1.529, could represent a very high global risk of sudden increases in infections."
0,doi:10.1128/jcm.00024-22,B.1.1.529,The genomic analysis demonstrated that this Omicron VOC is classified into the Pangolin lineage B.1.1.529 and the Nextstrain clade 21K (https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html).
1,doi:10.1128/jcm.00024-22,P.1,"The assay did not amplify the Wuhan wild type and other variants including B.1.351 (Beta), B.1.617.1 (Kappa), P.1 (Gamma), B.1.617.2 (Delta) and AY.1 (Delta Plus)."
2,doi:10.1128/jcm.00024-22,B.1.617.1,"The assay did not amplify the Wuhan wild type and other variants including B.1.351 (Beta), B.1.617.1 (Kappa), P.1 (Gamma), B.1.617.2 (Delta) and AY.1 (Delta Plus)."
3,doi:10.1128/jcm.00024-22,B.1.617.2,"The assay did not amplify the Wuhan wild type and other variants including B.1.351 (Beta), B.1.617.1 (Kappa), P.1 (Gamma), B.1.617.2 (Delta) and AY.1 (Delta Plus)."
4,doi:10.1128/jcm.00024-22,B.1.351,"The assay did not amplify the Wuhan wild type and other variants including B.1.351 (Beta), B.1.617.1 (Kappa), P.1 (Gamma), B.1.617.2 (Delta) and AY.1 (Delta Plus)."
5,doi:10.1128/jcm.00024-22,B.1.1.7,"While the del69-70 target was detected in the variant B.1.1.7 (Alpha) by the SARS-CoV-2 Omicron variant RT-PCR assay, the ins214EPE target was undetected."
0,doi:10.1016/j.vaccine.2021.11.096,B.1.1.529,"However, because of the lifting of international travel restrictions, amid the many uncertainties induced by the emerging B.1.1.529 variant, it remains unclear about the timeline of reaching herd immunity and when our daily life will return to normalcy."
0,doi:10.1590/s1678-9946202163058,P.2,"The B.1.1.28
lineage has been evolving in Brazil since February 2020 and originated the P.1
variant of concern (VOC), recently named as the Gamma variant by the newly WHO
nomenclature proposal, and P.2 as a variant of interest (VOI)."
1,doi:10.1590/s1678-9946202163058,P.1,"Here we describe
an early case of P.1 primary infection in Southern Brazil in late November 2020,
soon after the emergence of the variant in Manaus, Northern Brazil."
2,doi:10.1590/s1678-9946202163058,B.1.1.28,"The same
male patient was reinfected by another B.1.1.28 variant, namely P.2, in March,
2021."
3,doi:10.1590/s1678-9946202163058,B.1.1.281,"P.1 (VOC), recently named as Gamma variant by
the newly WHO nomenclature proposal5 as well as P.2 (VOI) variants have evolved from the lineage B.1.1.281,2 and harbor E484K (P.1 and P.2) and N501Y (P.1) mutations, which are
associated with increased transmissibility or immune evasion6."
0,doi:10.1590/s1678-9946202264024,B.1.1.33,"The B.1.1.33 lineage was the first with the highest occurrence in ES, remaining predominant until September 2020."
1,doi:10.1590/s1678-9946202264024,P.1.9,"As a result, the presence of nine lineages was observed in the State, according to the classification provided by the Pangolin software: B.40, B.1.1.33, B.1 .1.28, Zeta (P.2), P. 7, Alpha (B.1 .1.7), Gamma (P.1; P.1.2; P.1.7; P.1.9 P.1.10; P.1.11), N.9, and Delta (AY.13; B.1.617.2; AY.26; AY.32; AY.4; AY.5)."
2,doi:10.1590/s1678-9946202264024,N.9,"As a result, the presence of nine lineages was observed in the State, according to the classification provided by the Pangolin software: B.40, B.1.1.33, B.1 .1.28, Zeta (P.2), P. 7, Alpha (B.1 .1.7), Gamma (P.1; P.1.2; P.1.7; P.1.9 P.1.10; P.1.11), N.9, and Delta (AY.13; B.1.617.2; AY.26; AY.32; AY.4; AY.5)."
3,doi:10.1590/s1678-9946202264024,B.1,"As a result, the presence of nine lineages was observed in the State, according to the classification provided by the Pangolin software: B.40, B.1.1.33, B.1 .1.28, Zeta (P.2), P. 7, Alpha (B.1 .1.7), Gamma (P.1; P.1.2; P.1.7; P.1.9 P.1.10; P.1.11), N.9, and Delta (AY.13; B.1.617.2; AY.26; AY.32; AY.4; AY.5)."
4,doi:10.1590/s1678-9946202264024,P.1.11,"As a result, the presence of nine lineages was observed in the State, according to the classification provided by the Pangolin software: B.40, B.1.1.33, B.1 .1.28, Zeta (P.2), P. 7, Alpha (B.1 .1.7), Gamma (P.1; P.1.2; P.1.7; P.1.9 P.1.10; P.1.11), N.9, and Delta (AY.13; B.1.617.2; AY.26; AY.32; AY.4; AY.5)."
5,doi:10.1590/s1678-9946202264024,P.2,"As a result, the presence of nine lineages was observed in the State, according to the classification provided by the Pangolin software: B.40, B.1.1.33, B.1 .1.28, Zeta (P.2), P. 7, Alpha (B.1 .1.7), Gamma (P.1; P.1.2; P.1.7; P.1.9 P.1.10; P.1.11), N.9, and Delta (AY.13; B.1.617.2; AY.26; AY.32; AY.4; AY.5)."
6,doi:10.1590/s1678-9946202264024,B.40,"As a result, the presence of nine lineages was observed in the State, according to the classification provided by the Pangolin software: B.40, B.1.1.33, B.1 .1.28, Zeta (P.2), P. 7, Alpha (B.1 .1.7), Gamma (P.1; P.1.2; P.1.7; P.1.9 P.1.10; P.1.11), N.9, and Delta (AY.13; B.1.617.2; AY.26; AY.32; AY.4; AY.5)."
7,doi:10.1590/s1678-9946202264024,B.1.1.28,"Among the variants found in the period of this study, the most frequent were: Gamma , (44.5%), Delta (19.0%), Zeta (14.8%), B.1.1.33 (11.3%), B.1.1.28 (5.1%), and Alpha (4.5%).."
8,doi:10.1590/s1678-9946202264024,B.1.617.2,"The variant that first gave rise to the Delta lineage was the B.1.617.2, but AY.4, AY.5, AY.13, AY.26, AY.32 are also within the Delta lineage."
9,doi:10.1590/s1678-9946202264024,B.1.1.7,"Regarding the samples available in the database for phylogenetic analysis ( Figure 2 ), the only sample from ES State related to lineage B.1.1.7 was collected on March 2, 2021."
10,doi:10.1590/s1678-9946202264024,P.1,"In Rio de Janeiro, a study conducted with samples collected on December 1, 2020 and May 12, 2021
19
 identified lineages P.2 (43.44%), P.1 (36.47), B.1.1 (5.73%), B .1 (3.69%), B.1.1.28 (3.28%), P.1.2 (3.28%), B.1.1.33 (1.23%), B.1.1.7 (1.23%), P.4 (0.82%, B.1,407 (0.41%) and N.9 (0.41%)."
11,doi:10.1590/s1678-9946202264024,P.4,"In Rio de Janeiro, a study conducted with samples collected on December 1, 2020 and May 12, 2021
19
 identified lineages P.2 (43.44%), P.1 (36.47), B.1.1 (5.73%), B .1 (3.69%), B.1.1.28 (3.28%), P.1.2 (3.28%), B.1.1.33 (1.23%), B.1.1.7 (1.23%), P.4 (0.82%, B.1,407 (0.41%) and N.9 (0.41%)."
12,doi:10.1590/s1678-9946202264024,P.1.2,"In Rio de Janeiro, a study conducted with samples collected on December 1, 2020 and May 12, 2021
19
 identified lineages P.2 (43.44%), P.1 (36.47), B.1.1 (5.73%), B .1 (3.69%), B.1.1.28 (3.28%), P.1.2 (3.28%), B.1.1.33 (1.23%), B.1.1.7 (1.23%), P.4 (0.82%, B.1,407 (0.41%) and N.9 (0.41%)."
13,doi:10.1590/s1678-9946202264024,B.1.1,"In Rio de Janeiro, a study conducted with samples collected on December 1, 2020 and May 12, 2021
19
 identified lineages P.2 (43.44%), P.1 (36.47), B.1.1 (5.73%), B .1 (3.69%), B.1.1.28 (3.28%), P.1.2 (3.28%), B.1.1.33 (1.23%), B.1.1.7 (1.23%), P.4 (0.82%, B.1,407 (0.41%) and N.9 (0.41%)."
0,doi:10.1128/jvi.00404-21,B.1.1.7,"In this study, we investigated cross-neutralization of the B.1.1.7 and B.1.351 SARS-CoV-2 variants in a well-characterized cohort of early pandemic convalescent subjects."
1,doi:10.1128/jvi.00404-21,B.1.351,"In this study, we investigated cross-neutralization of the B.1.1.7 and B.1.351 SARS-CoV-2 variants in a well-characterized cohort of early pandemic convalescent subjects."
0,doi:10.1126/sciadv.abl7682,B.1.1.7,"Here, we developed a rapid test, termed CoVariant-SCAN, that detects neutralizing antibodies (nAbs) capable of blocking interactions between the angiotensin-converting enzyme 2 receptor and the spike protein of wild-type (WT) SARS-CoV-2 and three other variants: B.1.1.7, B.1.351, and P.1."
1,doi:10.1126/sciadv.abl7682,B.1.351,"Here, we developed a rapid test, termed CoVariant-SCAN, that detects neutralizing antibodies (nAbs) capable of blocking interactions between the angiotensin-converting enzyme 2 receptor and the spike protein of wild-type (WT) SARS-CoV-2 and three other variants: B.1.1.7, B.1.351, and P.1."
2,doi:10.1126/sciadv.abl7682,P.1,"For several monoclonal antibodies and most plasma samples, neutralization against B.1.351 and P.1 variants is diminished relative to WT, while B.1.1.7 is largely cross-neutralized."
3,doi:10.1126/sciadv.abl7682,B.1.617,"These variants of concern (VOCs), as well as newly emerging ones, such as the B.1.617 (Delta) lineage identified in India (22), pose new challenges in the effort to contain the spread of the virus..

Assays to detect anti–SARS-CoV-2 antibodies are an important tool to assess natural or vaccine-induced humoral response at the individual patient level and for epidemiological surveillance at the population level."
4,doi:10.1126/sciadv.abl7682,B.1.617.2,"During this study, as the B.1.617.2 (Delta) variant emerged in India, we rapidly incorporated this variant into the CoVariant-SCAN assay without needing to reoptimize the assay, which shows that new VOCs can be easily accommodated, as they emerge..

(A) WT, B.1.1.7, P.1, and B.1.351 RBD capture antigens (cAgs) are inkjet-printed onto a POEGMA surface."
0,doi:10.3201/eid2801.212220,B.1.617.2,"During July 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.617.2 variant infections, including vaccine breakthrough infections, occurred after large public gatherings in Provincetown, Massachusetts, USA, prompting a multistate investigation."
1,doi:10.3201/eid2801.212220,P.1,"Genomic sequencing of primary case specimens identified the B.1.617.2 (Delta) variant of SARS-CoV-2 in 364 (98%) of 371 sequenced specimens, the AY.3 sublineage (Delta) in 1 (0.3%), the AY.4 sublineage (Delta) in 3 (0.8%), and P.1 (Gamma) in 3 (0.8%)..

Primary cluster-associated cases of severe acute respiratory syndrome coronavirus 2 infection (n = 1,098), by vaccination status and date of specimen collection, after large public gatherings in Provincetown, Massachusetts, USA, July 2021."
0,doi:10.3390/microorganisms9122587,B.1.1.7,"Among the 559 child contacts, eight tested positive (1.4%, 95% CI 0.62–2.80), with no significant difference between primary (1.0%, 95% CI 0.27–2.53) and secondary schools (2.6%, 95% CI 0.70–6.39), p = 0.229, nor by viral strain, non-Alpha (1.4%, 95% CI 0.50–2.94) and Alpha variant (B.1.1.7) (1.7%, 95% CI 0.21–5.99), p = 0.665."
1,doi:10.3390/microorganisms9122587,B.1.367,Analysis of the B.1.367 linage showed ≤2 SNPs difference among the index cases (ID-03; 04; 06) from three schools in neighboring communities in September and October 2020.
2,doi:10.3390/microorganisms9122587,K.3,"Similar interpretations can be assigned to the B.1.36.21, B.1.1.305 and K.3 lineages, where index cases were identified with similar viruses (≤2 SNP differences) close in time..

Linkage of the study data with national laboratory data revealed that 63% (434) of the participants had test results from testing outside of the study within two weeks prior to the date of the first saliva sample and four weeks after the date of the second saliva sample; 56% (333) in the pre-Alpha period versus 93% (101) in the Alpha-period."
3,doi:10.3390/microorganisms9122587,B.1.36.21,"Similar interpretations can be assigned to the B.1.36.21, B.1.1.305 and K.3 lineages, where index cases were identified with similar viruses (≤2 SNP differences) close in time..

Linkage of the study data with national laboratory data revealed that 63% (434) of the participants had test results from testing outside of the study within two weeks prior to the date of the first saliva sample and four weeks after the date of the second saliva sample; 56% (333) in the pre-Alpha period versus 93% (101) in the Alpha-period."
4,doi:10.3390/microorganisms9122587,B.1.1.305,"Similar interpretations can be assigned to the B.1.36.21, B.1.1.305 and K.3 lineages, where index cases were identified with similar viruses (≤2 SNP differences) close in time..

Linkage of the study data with national laboratory data revealed that 63% (434) of the participants had test results from testing outside of the study within two weeks prior to the date of the first saliva sample and four weeks after the date of the second saliva sample; 56% (333) in the pre-Alpha period versus 93% (101) in the Alpha-period."
5,doi:10.3390/microorganisms9122587,B.1.617.2,"On September 3rd, 2021, the European Centre for Disease Control downgraded the Alpha variant from a variant of concern to a de-escalated variant, due to its limited impact on vaccine-induced immunity and the drastically reduced circulation following the emergence of the Delta variant (B.1.617.2) [31]."
6,doi:10.3390/microorganisms9122587,B.1.177.82,"Maximum likelihood phylogenetic tree of SARS-CoV-2 strains from cases included in contact investigations (n, 33), Oslo and Viken, August 2020–May 2021; SNP; single nucleotide polymorphism; the whole genome sequencing failed due to low viral load in two of the secondary cases, and one the index case did not consent to participate..

Characteristics of the study population in 43 contact investigations in Oslo and Viken, August 2020 to May 2021..

IPC-score, Infection Prevention and Control (mitigation) measures, scored on a scale from 0–8 with higher scores indicating higher consistency with national guidelines; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); # Participation was calculated as the percentage of included contacts of all identified contacts per contact-investigation, presented as median (%) and range (%–%)..

Primary, secondary and all infected child contacts detected in school contact investigations (n, 43) within 7–10 days following the last exposure, Oslo and Viken, August 2020–May 2021..

* pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); #
n (n) number of contacts, the parentheses represents the number of contacts with a second saliva sample; 18 (3%) child contacts did not provide a second saliva sample and primary cases were excluded; I a contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; II a contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test; III a contact who tested positive for SARS-CoV-2 in either of the two saliva tests, thus including both the primary and secondary cases..

SARS-CoV-2 Pango lineage variants among child index cases (n, 33), Oslo and Viken, August 2020–May 2021..

For one index case, the whole genome sequencing failed due to low viral RNA content in the sample; I Pango lineage nomenclature https://cov-lineages.org/index.html, accessed on 28 September 2021; # Period; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); * The following SARS-CoV-2 lineages occurred in only one index case each: B.1, B.1.1.39, B.1.1.277, B.1.177.44, B.1.177.82, B.1.177, and B.1.36.1..

SARS-CoV-2 variants in contact investigations in which primary and secondary cases were detected (n, 8), Oslo and Viken, August 2020–May 2021..

ID; identifier for each contact-investigation (reference, Appendix A
Table A2); Period; pre-Alpha and Alpha reflects the periods before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); SNP; Single nucleotide polymorphism; I The index case was the child first identified with confirmed SARS-CoV-2 leading to the contact-investigation; II A contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; III A contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test.."
7,doi:10.3390/microorganisms9122587,B.1.1.277,"Maximum likelihood phylogenetic tree of SARS-CoV-2 strains from cases included in contact investigations (n, 33), Oslo and Viken, August 2020–May 2021; SNP; single nucleotide polymorphism; the whole genome sequencing failed due to low viral load in two of the secondary cases, and one the index case did not consent to participate..

Characteristics of the study population in 43 contact investigations in Oslo and Viken, August 2020 to May 2021..

IPC-score, Infection Prevention and Control (mitigation) measures, scored on a scale from 0–8 with higher scores indicating higher consistency with national guidelines; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); # Participation was calculated as the percentage of included contacts of all identified contacts per contact-investigation, presented as median (%) and range (%–%)..

Primary, secondary and all infected child contacts detected in school contact investigations (n, 43) within 7–10 days following the last exposure, Oslo and Viken, August 2020–May 2021..

* pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); #
n (n) number of contacts, the parentheses represents the number of contacts with a second saliva sample; 18 (3%) child contacts did not provide a second saliva sample and primary cases were excluded; I a contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; II a contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test; III a contact who tested positive for SARS-CoV-2 in either of the two saliva tests, thus including both the primary and secondary cases..

SARS-CoV-2 Pango lineage variants among child index cases (n, 33), Oslo and Viken, August 2020–May 2021..

For one index case, the whole genome sequencing failed due to low viral RNA content in the sample; I Pango lineage nomenclature https://cov-lineages.org/index.html, accessed on 28 September 2021; # Period; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); * The following SARS-CoV-2 lineages occurred in only one index case each: B.1, B.1.1.39, B.1.1.277, B.1.177.44, B.1.177.82, B.1.177, and B.1.36.1..

SARS-CoV-2 variants in contact investigations in which primary and secondary cases were detected (n, 8), Oslo and Viken, August 2020–May 2021..

ID; identifier for each contact-investigation (reference, Appendix A
Table A2); Period; pre-Alpha and Alpha reflects the periods before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); SNP; Single nucleotide polymorphism; I The index case was the child first identified with confirmed SARS-CoV-2 leading to the contact-investigation; II A contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; III A contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test.."
8,doi:10.3390/microorganisms9122587,B.1,"Maximum likelihood phylogenetic tree of SARS-CoV-2 strains from cases included in contact investigations (n, 33), Oslo and Viken, August 2020–May 2021; SNP; single nucleotide polymorphism; the whole genome sequencing failed due to low viral load in two of the secondary cases, and one the index case did not consent to participate..

Characteristics of the study population in 43 contact investigations in Oslo and Viken, August 2020 to May 2021..

IPC-score, Infection Prevention and Control (mitigation) measures, scored on a scale from 0–8 with higher scores indicating higher consistency with national guidelines; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); # Participation was calculated as the percentage of included contacts of all identified contacts per contact-investigation, presented as median (%) and range (%–%)..

Primary, secondary and all infected child contacts detected in school contact investigations (n, 43) within 7–10 days following the last exposure, Oslo and Viken, August 2020–May 2021..

* pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); #
n (n) number of contacts, the parentheses represents the number of contacts with a second saliva sample; 18 (3%) child contacts did not provide a second saliva sample and primary cases were excluded; I a contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; II a contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test; III a contact who tested positive for SARS-CoV-2 in either of the two saliva tests, thus including both the primary and secondary cases..

SARS-CoV-2 Pango lineage variants among child index cases (n, 33), Oslo and Viken, August 2020–May 2021..

For one index case, the whole genome sequencing failed due to low viral RNA content in the sample; I Pango lineage nomenclature https://cov-lineages.org/index.html, accessed on 28 September 2021; # Period; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); * The following SARS-CoV-2 lineages occurred in only one index case each: B.1, B.1.1.39, B.1.1.277, B.1.177.44, B.1.177.82, B.1.177, and B.1.36.1..

SARS-CoV-2 variants in contact investigations in which primary and secondary cases were detected (n, 8), Oslo and Viken, August 2020–May 2021..

ID; identifier for each contact-investigation (reference, Appendix A
Table A2); Period; pre-Alpha and Alpha reflects the periods before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); SNP; Single nucleotide polymorphism; I The index case was the child first identified with confirmed SARS-CoV-2 leading to the contact-investigation; II A contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; III A contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test.."
9,doi:10.3390/microorganisms9122587,B.1.177.44,"Maximum likelihood phylogenetic tree of SARS-CoV-2 strains from cases included in contact investigations (n, 33), Oslo and Viken, August 2020–May 2021; SNP; single nucleotide polymorphism; the whole genome sequencing failed due to low viral load in two of the secondary cases, and one the index case did not consent to participate..

Characteristics of the study population in 43 contact investigations in Oslo and Viken, August 2020 to May 2021..

IPC-score, Infection Prevention and Control (mitigation) measures, scored on a scale from 0–8 with higher scores indicating higher consistency with national guidelines; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); # Participation was calculated as the percentage of included contacts of all identified contacts per contact-investigation, presented as median (%) and range (%–%)..

Primary, secondary and all infected child contacts detected in school contact investigations (n, 43) within 7–10 days following the last exposure, Oslo and Viken, August 2020–May 2021..

* pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); #
n (n) number of contacts, the parentheses represents the number of contacts with a second saliva sample; 18 (3%) child contacts did not provide a second saliva sample and primary cases were excluded; I a contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; II a contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test; III a contact who tested positive for SARS-CoV-2 in either of the two saliva tests, thus including both the primary and secondary cases..

SARS-CoV-2 Pango lineage variants among child index cases (n, 33), Oslo and Viken, August 2020–May 2021..

For one index case, the whole genome sequencing failed due to low viral RNA content in the sample; I Pango lineage nomenclature https://cov-lineages.org/index.html, accessed on 28 September 2021; # Period; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); * The following SARS-CoV-2 lineages occurred in only one index case each: B.1, B.1.1.39, B.1.1.277, B.1.177.44, B.1.177.82, B.1.177, and B.1.36.1..

SARS-CoV-2 variants in contact investigations in which primary and secondary cases were detected (n, 8), Oslo and Viken, August 2020–May 2021..

ID; identifier for each contact-investigation (reference, Appendix A
Table A2); Period; pre-Alpha and Alpha reflects the periods before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); SNP; Single nucleotide polymorphism; I The index case was the child first identified with confirmed SARS-CoV-2 leading to the contact-investigation; II A contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; III A contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test.."
10,doi:10.3390/microorganisms9122587,B.1.177,"Maximum likelihood phylogenetic tree of SARS-CoV-2 strains from cases included in contact investigations (n, 33), Oslo and Viken, August 2020–May 2021; SNP; single nucleotide polymorphism; the whole genome sequencing failed due to low viral load in two of the secondary cases, and one the index case did not consent to participate..

Characteristics of the study population in 43 contact investigations in Oslo and Viken, August 2020 to May 2021..

IPC-score, Infection Prevention and Control (mitigation) measures, scored on a scale from 0–8 with higher scores indicating higher consistency with national guidelines; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); # Participation was calculated as the percentage of included contacts of all identified contacts per contact-investigation, presented as median (%) and range (%–%)..

Primary, secondary and all infected child contacts detected in school contact investigations (n, 43) within 7–10 days following the last exposure, Oslo and Viken, August 2020–May 2021..

* pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); #
n (n) number of contacts, the parentheses represents the number of contacts with a second saliva sample; 18 (3%) child contacts did not provide a second saliva sample and primary cases were excluded; I a contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; II a contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test; III a contact who tested positive for SARS-CoV-2 in either of the two saliva tests, thus including both the primary and secondary cases..

SARS-CoV-2 Pango lineage variants among child index cases (n, 33), Oslo and Viken, August 2020–May 2021..

For one index case, the whole genome sequencing failed due to low viral RNA content in the sample; I Pango lineage nomenclature https://cov-lineages.org/index.html, accessed on 28 September 2021; # Period; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); * The following SARS-CoV-2 lineages occurred in only one index case each: B.1, B.1.1.39, B.1.1.277, B.1.177.44, B.1.177.82, B.1.177, and B.1.36.1..

SARS-CoV-2 variants in contact investigations in which primary and secondary cases were detected (n, 8), Oslo and Viken, August 2020–May 2021..

ID; identifier for each contact-investigation (reference, Appendix A
Table A2); Period; pre-Alpha and Alpha reflects the periods before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); SNP; Single nucleotide polymorphism; I The index case was the child first identified with confirmed SARS-CoV-2 leading to the contact-investigation; II A contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; III A contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test.."
11,doi:10.3390/microorganisms9122587,B.1.1.39,"Maximum likelihood phylogenetic tree of SARS-CoV-2 strains from cases included in contact investigations (n, 33), Oslo and Viken, August 2020–May 2021; SNP; single nucleotide polymorphism; the whole genome sequencing failed due to low viral load in two of the secondary cases, and one the index case did not consent to participate..

Characteristics of the study population in 43 contact investigations in Oslo and Viken, August 2020 to May 2021..

IPC-score, Infection Prevention and Control (mitigation) measures, scored on a scale from 0–8 with higher scores indicating higher consistency with national guidelines; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); # Participation was calculated as the percentage of included contacts of all identified contacts per contact-investigation, presented as median (%) and range (%–%)..

Primary, secondary and all infected child contacts detected in school contact investigations (n, 43) within 7–10 days following the last exposure, Oslo and Viken, August 2020–May 2021..

* pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); #
n (n) number of contacts, the parentheses represents the number of contacts with a second saliva sample; 18 (3%) child contacts did not provide a second saliva sample and primary cases were excluded; I a contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; II a contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test; III a contact who tested positive for SARS-CoV-2 in either of the two saliva tests, thus including both the primary and secondary cases..

SARS-CoV-2 Pango lineage variants among child index cases (n, 33), Oslo and Viken, August 2020–May 2021..

For one index case, the whole genome sequencing failed due to low viral RNA content in the sample; I Pango lineage nomenclature https://cov-lineages.org/index.html, accessed on 28 September 2021; # Period; pre-Alpha and Alpha reflects the period before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); * The following SARS-CoV-2 lineages occurred in only one index case each: B.1, B.1.1.39, B.1.1.277, B.1.177.44, B.1.177.82, B.1.177, and B.1.36.1..

SARS-CoV-2 variants in contact investigations in which primary and secondary cases were detected (n, 8), Oslo and Viken, August 2020–May 2021..

ID; identifier for each contact-investigation (reference, Appendix A
Table A2); Period; pre-Alpha and Alpha reflects the periods before and after the Alpha variant (B.1.1.7) was established (August–February versus March–May); SNP; Single nucleotide polymorphism; I The index case was the child first identified with confirmed SARS-CoV-2 leading to the contact-investigation; II A contact of the index case who tested positive for SARS-CoV-2 in the first saliva sample; III A contact of the index case who tested positive for SARS-CoV-2 in the second saliva sample, following a first negative test.."
0,doi:10.1016/j.cmi.2021.05.022,B.1.1.7,"Many new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been termed variants of concern/interest (VOC/I) because of the greater risk they pose due to possible enhanced transmissibility and/or severity, immune escape, diagnostic and/or treatment failure, and reduced vaccine efficacy..

We sought to review the current knowledge of emerging SARS-CoV-2 variants, particularly those deemed VOC/Is: B.1.351, B.1.1.7, and P.1..

MEDLINE and BioRxiv databases, as well as the grey literature, were searched for reports of SARS-CoV-2 variants since November 2020."
1,doi:10.1016/j.cmi.2021.05.022,B.1.351,"Many new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been termed variants of concern/interest (VOC/I) because of the greater risk they pose due to possible enhanced transmissibility and/or severity, immune escape, diagnostic and/or treatment failure, and reduced vaccine efficacy..

We sought to review the current knowledge of emerging SARS-CoV-2 variants, particularly those deemed VOC/Is: B.1.351, B.1.1.7, and P.1..

MEDLINE and BioRxiv databases, as well as the grey literature, were searched for reports of SARS-CoV-2 variants since November 2020."
2,doi:10.1016/j.cmi.2021.05.022,P.1,"The N501Y mutation is shared by the three main VOCs: B.1.1.7, first identified in the United Kingdom, P.1, originating from Brazil, and B.1.351, first described in South Africa."
3,doi:10.1016/j.cmi.2021.05.022,P.2,"A study conducted in South Africa found a >5% reinfection rate that did not differ between seropositive and seronegative people, suggesting a lack of protection in response to previous infections [44].Table 4Effects of the different variants on therapeutics and vaccinesTable 4VaccinesB.1.1.7B1.351P.1Other VOC/IsmRNA VaccinePfizer/BioNTech BNT162b290–95% efficacy in a setting of 81.5% B.1.1.7 prevalence, estimated by SGTF [66]100% effective (53–100% CI), based on six cases in placebo group versus none in vaccine group [42]No published dataNo published dataProtein subunit vaccineNovavaxNVX-CoV237385.6% efficacy against B.1.1.795.6% efficacy against non-B.1.1.7Only one severe case [67]60% efficacy in HIV(–) subjects in South Africa (92.7% of sequences were B.1.351),51% against B.1.351 specificallyNo severe cases, too few events to conclude [67]No published dataNo published dataAdenovirus vaccineJanssen (J&J)Ad26.COV2.SNo published data52% efficacy against moderate disease and 72% against severe/critical disease in South Africa (>95% of sequences were B.1.351), versus 72% efficacy in USA100% protection against death [68]No published dataInsufficient data for P.2, No data for othersAdenovirus vaccineAstraZeneca AZD122270% efficacy versus B.1.1.7 versus 81% against non-B.1.1.7 [69]10% efficacy against mild and moderate disease in young people, no data against severe disease [45]No published dataNo published datamAb therapies:LY-CoV555 (Bamlanivimab)SusceptibleResistant [22,55]Resistant [22,55]B.1.429: Resistant [64]EtesevimabResistant [33]Resistant [33]Resistant [33]No dataREGN10933 and REGN10987 (Casirivimab + Imdevimab)SusceptiblePartially resistant to Casirimivab, but Imdevimab is effective [33,55]Partially resistant to Casirivimab but Imdevimab is effective [33,55]B.1.526 with E484k is resists Casirivimab [70]Vaccine efficacy is given as efficacy against symptomatic infection unless otherwise specified).SGTF, S-gene target failure.."
4,doi:10.1016/j.cmi.2021.05.022,B.1.617,"There are now three recognized sub-variants of B.1.617: B.1.617.1 (all with E484Q), B.1.617.2 (all with Δ157,158), and B.1.617.3, although E484Q and Δ157,158 can also be found in B.1.617 and B.1.617.3."
5,doi:10.1016/j.cmi.2021.05.022,B.1.617.2,"There are now three recognized sub-variants of B.1.617: B.1.617.1 (all with E484Q), B.1.617.2 (all with Δ157,158), and B.1.617.3, although E484Q and Δ157,158 can also be found in B.1.617 and B.1.617.3."
6,doi:10.1016/j.cmi.2021.05.022,B.1.617.3,"There are now three recognized sub-variants of B.1.617: B.1.617.1 (all with E484Q), B.1.617.2 (all with Δ157,158), and B.1.617.3, although E484Q and Δ157,158 can also be found in B.1.617 and B.1.617.3."
7,doi:10.1016/j.cmi.2021.05.022,B.1.617.1,"There are now three recognized sub-variants of B.1.617: B.1.617.1 (all with E484Q), B.1.617.2 (all with Δ157,158), and B.1.617.3, although E484Q and Δ157,158 can also be found in B.1.617 and B.1.617.3."
8,doi:10.1016/j.cmi.2021.05.022,N.10,"The known instances of variants with the E484K are too numerous to list here, but include: P.2, P.3, and some isolates of A.23.1 and B.1.111, B.1.525, B.1.619, N.9, N.10, and A.VOI.V2."
9,doi:10.1016/j.cmi.2021.05.022,N.9,"The known instances of variants with the E484K are too numerous to list here, but include: P.2, P.3, and some isolates of A.23.1 and B.1.111, B.1.525, B.1.619, N.9, N.10, and A.VOI.V2."
10,doi:10.1016/j.cmi.2021.05.022,P.3,"The known instances of variants with the E484K are too numerous to list here, but include: P.2, P.3, and some isolates of A.23.1 and B.1.111, B.1.525, B.1.619, N.9, N.10, and A.VOI.V2."
11,doi:10.1016/j.cmi.2021.05.022,B.1.619,"The known instances of variants with the E484K are too numerous to list here, but include: P.2, P.3, and some isolates of A.23.1 and B.1.111, B.1.525, B.1.619, N.9, N.10, and A.VOI.V2."
12,doi:10.1016/j.cmi.2021.05.022,B.1.525,"The known instances of variants with the E484K are too numerous to list here, but include: P.2, P.3, and some isolates of A.23.1 and B.1.111, B.1.525, B.1.619, N.9, N.10, and A.VOI.V2."
13,doi:10.1016/j.cmi.2021.05.022,A.23.1,"The known instances of variants with the E484K are too numerous to list here, but include: P.2, P.3, and some isolates of A.23.1 and B.1.111, B.1.525, B.1.619, N.9, N.10, and A.VOI.V2."
14,doi:10.1016/j.cmi.2021.05.022,B.1.111,"The known instances of variants with the E484K are too numerous to list here, but include: P.2, P.3, and some isolates of A.23.1 and B.1.111, B.1.525, B.1.619, N.9, N.10, and A.VOI.V2."
15,doi:10.1016/j.cmi.2021.05.022,P.4,"In Brazil, a new lineage, provisionally named ‘MG’ (with a suggested designation of P.4, but the designation is still pending) has been identified with N501T and E484Q mutations in Minas Gerais [57]."
0,doi:10.3390/diagnostics11071229,B.1.1.7,"In addition, molecular analyses showed the presence of SARS-CoV-2 lineage B.1.1.7 (UK variant with high titer in the myocardium."
0,doi:10.1093/jtm/taac036,B.1.617.2,"Inactivated vaccine BBIBP-CorV (Sinopharm; 95% (95%CI: 94%,97%)) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech; 98% (95%CI: 86%,99%)) demonstrated protection against COVID-19 related hospitalizations from the Delta (B.1.617.2) variant."
0,doi:10.1101/2021.10.12.464114,B.1.351,designed the B.1.351 spike plasmid.
1,doi:10.1101/2021.10.12.464114,B.1.617.2,"B.1.351 was the dominant lineage in South Africa by the end of 2020, although it has subsequently been displaced by the B.1.617.2 (Delta) lineage (18)."
0,doi:10.2147/idr.s335583,B.1.1.7,"In addition, five controls comprised of synthetic RNA B.1.1.7_601443, B.1.351_678597, P.1_792683, B.1.617.1_1662307 and MN908947.3-Wuhan-hu-1 from Twist bioscience and B.1.1.7 (England/204820464/2020) and B.1.351 (South Africa/KRISP-K005325/2020) from Zeptometrix, NY, USA were used for validation."
1,doi:10.2147/idr.s335583,B.1.351,"In addition, five controls comprised of synthetic RNA B.1.1.7_601443, B.1.351_678597, P.1_792683, B.1.617.1_1662307 and MN908947.3-Wuhan-hu-1 from Twist bioscience and B.1.1.7 (England/204820464/2020) and B.1.351 (South Africa/KRISP-K005325/2020) from Zeptometrix, NY, USA were used for validation."
2,doi:10.2147/idr.s335583,P.1,"Out of 150 SARS-CoV-2 positive specimens, 69 (46%) were B.1.617.2, 49 (32.7%) were B.1.1.7, P.1 and P.2 were 4 (2.7%) each and B.1.351 and B.1.427/B.1429 were 2 (1.3%) each."
3,doi:10.2147/idr.s335583,B.1.617.2,"Out of 150 SARS-CoV-2 positive specimens, 69 (46%) were B.1.617.2, 49 (32.7%) were B.1.1.7, P.1 and P.2 were 4 (2.7%) each and B.1.351 and B.1.427/B.1429 were 2 (1.3%) each."
4,doi:10.2147/idr.s335583,P.2,"Out of 150 SARS-CoV-2 positive specimens, 69 (46%) were B.1.617.2, 49 (32.7%) were B.1.1.7, P.1 and P.2 were 4 (2.7%) each and B.1.351 and B.1.427/B.1429 were 2 (1.3%) each."
5,doi:10.2147/idr.s335583,B.1.427,"Out of 150 SARS-CoV-2 positive specimens, 69 (46%) were B.1.617.2, 49 (32.7%) were B.1.1.7, P.1 and P.2 were 4 (2.7%) each and B.1.351 and B.1.427/B.1429 were 2 (1.3%) each."
6,doi:10.2147/idr.s335583,B.1.526,"Three (2%) were B.1.526, and 17 (11.3%) have a mutation in D614G."
7,doi:10.2147/idr.s335583,B.1.617.1,"Genotyping results from the present study showing B.1.617.2, B.1.1.7, and B.1.526 variants and their mutation genes were concordant with sequencing results..

Our study indicates that TaqMan SARS-CoV-2 mutation panel molecular genotyping assays detect and differentiate all published common variants B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.526 (Iota), B.1.351 (Beta), P.1 (Gamma), P.2 (Zeta), B.1.617.1 (Kappa) and B.1.427/B.1.429 (Epsilon) that can be used for surveillance and epidemic control and prevention.."
8,doi:10.2147/idr.s335583,C.37,"These include variants of interest (VOI): Iota (B.1.526), Eta (B.1.525), Kappa (B.1.617.1), B.1.617.3, Epsilon (B.1.427/B.1.429), Lambda (C.37) and Zeta (P.2); variants of concern (VOC): Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and variants of high consequence.1,2 Currently, SARS-CoV-2 lineages have been determined by whole-genome sequencing (WGS) of positive SARS-CoV-2 samples which detects new emerging variants and any new changes in viral genomes.3,4 WGS is considered as the gold standard method of identifying new circulating SARS-CoV-2 variants worldwide."
9,doi:10.2147/idr.s335583,B.1.617.3,"These include variants of interest (VOI): Iota (B.1.526), Eta (B.1.525), Kappa (B.1.617.1), B.1.617.3, Epsilon (B.1.427/B.1.429), Lambda (C.37) and Zeta (P.2); variants of concern (VOC): Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and variants of high consequence.1,2 Currently, SARS-CoV-2 lineages have been determined by whole-genome sequencing (WGS) of positive SARS-CoV-2 samples which detects new emerging variants and any new changes in viral genomes.3,4 WGS is considered as the gold standard method of identifying new circulating SARS-CoV-2 variants worldwide."
10,doi:10.2147/idr.s335583,B.1.525,"These include variants of interest (VOI): Iota (B.1.526), Eta (B.1.525), Kappa (B.1.617.1), B.1.617.3, Epsilon (B.1.427/B.1.429), Lambda (C.37) and Zeta (P.2); variants of concern (VOC): Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and variants of high consequence.1,2 Currently, SARS-CoV-2 lineages have been determined by whole-genome sequencing (WGS) of positive SARS-CoV-2 samples which detects new emerging variants and any new changes in viral genomes.3,4 WGS is considered as the gold standard method of identifying new circulating SARS-CoV-2 variants worldwide."
11,doi:10.2147/idr.s335583,B.1.429,"Therefore, we have evaluated the performance characteristics of the Thermo Fisher TaqMan SARS-CoV-2 mutation panel molecular genotyping assay6 for detection and identifying the most common variants (B.1.526, B.1.525, B.1.617, B.1.617.1, B.1.617.3, P.1, B.1.1.7, B.1.351, P.2, B.1.427, B.1.429 and B.1.617.2) using specific RT-PCR assays targeting single nucleotide polymorphisms (SNP).."
12,doi:10.2147/idr.s335583,B.1.617,"Therefore, we have evaluated the performance characteristics of the Thermo Fisher TaqMan SARS-CoV-2 mutation panel molecular genotyping assay6 for detection and identifying the most common variants (B.1.526, B.1.525, B.1.617, B.1.617.1, B.1.617.3, P.1, B.1.1.7, B.1.351, P.2, B.1.427, B.1.429 and B.1.617.2) using specific RT-PCR assays targeting single nucleotide polymorphisms (SNP).."
0,doi:10.1038/s41591-021-01540-1,B.1.1.7,"A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF50) for pseudovirus and live-virus neutralization, respectively."
1,doi:10.1038/s41591-021-01540-1,B.1.351,"Similarly, ChAdOx1 nCoV-19-vaccinated hamsters, with low neutralizing titers against B.1.351, were fully protected against LRTI following challenge with B.1.351, despite no evidence of protection against shedding of virus from the upper airway29."
2,doi:10.1038/s41591-021-01540-1,B.1.177,"These analyses are based on cases of COVID-19 detected in a mainly white population in the United Kingdom, which were mostly due to B.1.177 and B.1.1.7 variants."
0,doi:10.1093/cid/ciab371,B.1.1.7,"CoV-2-STs with a similarly functional and non-alloreactive, albeit highly cytotoxic, profile against SARS-CoV-2 could be expanded from both convalescent and vaccinated donors generating clinical-scale, SARS-CoV-2–specific T-cell products with functional activity against both the unmutated virus and its B.1.1.7 and B.1.351 variants."
1,doi:10.1093/cid/ciab371,B.1.351,"CoV-2-STs with a similarly functional and non-alloreactive, albeit highly cytotoxic, profile against SARS-CoV-2 could be expanded from both convalescent and vaccinated donors generating clinical-scale, SARS-CoV-2–specific T-cell products with functional activity against both the unmutated virus and its B.1.1.7 and B.1.351 variants."
0,doi:10.1101/2021.04.07.438818,P.1,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD."
1,doi:10.1101/2021.04.07.438818,B.1.427,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD."
2,doi:10.1101/2021.04.07.438818,B.1.351,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD."
3,doi:10.1101/2021.04.07.438818,B.1.1.7,"S2X259 broadly neutralizes spike-mediated entry of SARS-CoV-2 including the B.1.1.7, B.1.351, P.1 and B.1.427/B.1.429 VOC, as well as a wide spectrum of human and zoonotic sarbecoviruses through inhibition of ACE2 binding to the RBD."
4,doi:10.1101/2021.04.07.438818,B.1.429,"SARS-CoV-2 genetic drift has resulted in new emerging variants of concern (VOC) characterized by higher transmissibility, immune evasion and/or disease severity such as B.1.1.7, B.1.351, B.1.429, and P.1 originally identified in the UK, South Africa, California, and Brazil, respectively3–6."
0,doi:10.1056/nejmoa2119451,B.1.1.529,"Andrews and Stowe contributed equally to this article..

A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines..

We used a test-negative case–control design to estimate vaccine effectiveness against symptomatic disease caused by the omicron and delta (B.1.617.2) variants in England."
1,doi:10.1056/nejmoa2119451,B.1.617.2,"Andrews and Stowe contributed equally to this article..

A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines..

We used a test-negative case–control design to estimate vaccine effectiveness against symptomatic disease caused by the omicron and delta (B.1.617.2) variants in England."
2,doi:10.1056/nejmoa2119451,B.1.1.7,"Coronavirus disease 2019 (Covid-19) vaccines are highly effective against symptomatic disease and, more so, against severe disease and fatal outcomes caused by the original strain of SARS-CoV-2 as well as the alpha (B.1.1.7) variant that predominated in early 2021.9-15 Modest reductions in vaccine effectiveness against infection and mild disease have been observed with the beta (B.1.351) and delta variants, although effectiveness against severe disease has remained high for at least 6 months after primary immunization with two Covid-19 vaccine doses.16-19 Waning of protection has been observed with time since vaccination, especially with the delta variant, which is able to at least partially evade natural and vaccine-induced immunity.20 However, third (booster) doses provide a rapid and substantial increase in protection against both mild and severe disease.19,21-25."
3,doi:10.1056/nejmoa2119451,B.1.351,"Coronavirus disease 2019 (Covid-19) vaccines are highly effective against symptomatic disease and, more so, against severe disease and fatal outcomes caused by the original strain of SARS-CoV-2 as well as the alpha (B.1.1.7) variant that predominated in early 2021.9-15 Modest reductions in vaccine effectiveness against infection and mild disease have been observed with the beta (B.1.351) and delta variants, although effectiveness against severe disease has remained high for at least 6 months after primary immunization with two Covid-19 vaccine doses.16-19 Waning of protection has been observed with time since vaccination, especially with the delta variant, which is able to at least partially evade natural and vaccine-induced immunity.20 However, third (booster) doses provide a rapid and substantial increase in protection against both mild and severe disease.19,21-25."
0,doi:10.21203/rs.3.rs-509143/v1,B.1.351,The B.1.351 variant carrying the escape mutation E484K in the receptor binding domain is of particular concern due to reduced immunological protection following vaccination.
1,doi:10.21203/rs.3.rs-509143/v1,B.1.1.7,"It is known that the first vaccine dose is not fully protective22 but data available indicate that as early as 12 days following first vaccination there may be a response against the dominant variants B.1.1.7 and B.1.3517,23."
0,doi:10.1128/jcm.01736-21,B.1.575.2,"Emergence of SARS-CoV-2 variant B.1.575.2, containing the E484K mutation in the spike protein, in Pamplona, Spain, May to June 2021."
1,doi:10.1128/jcm.01736-21,B.1.575,"We report the emergence and spread of a new SARS-CoV-2 variant within the B.1.575 lineage, containing the E484K mutation in the spike protein (named B.1.575.2), in a region in northern Spain in May and June 2021."
2,doi:10.1128/jcm.01736-21,P.1,"As of 23 June 2021, the four important lineages with evident impact on transmissibility, severity, and immunity are lineages B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and P.1 (Gamma) (1–4)."
3,doi:10.1128/jcm.01736-21,B.1.1.7,"As of 23 June 2021, the four important lineages with evident impact on transmissibility, severity, and immunity are lineages B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and P.1 (Gamma) (1–4)."
4,doi:10.1128/jcm.01736-21,B.1.617.2,"As of 23 June 2021, the four important lineages with evident impact on transmissibility, severity, and immunity are lineages B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and P.1 (Gamma) (1–4)."
5,doi:10.1128/jcm.01736-21,B.1.351,"As of 23 June 2021, the four important lineages with evident impact on transmissibility, severity, and immunity are lineages B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and P.1 (Gamma) (1–4)."
6,doi:10.1128/jcm.01736-21,B.1.575.1,"The B.1.575.1 sublineage was classified in the Phylogenetic Assignment of Named Global Outbreak (PANGO) lineage system as a Spanish sublineage of B.1.575 with spike mutations P681H, S494P, and T716I, and the B.1.575.2 sublineage, whose main characteristic is the presence of the E484K spike mutation, also originated in Spain (8).."
7,doi:10.1128/jcm.01736-21,B.1.525,"The E484K mutation has been identified in SARS-CoV-2 variants considered VOCs, such as B.1.351, P.1, and B.1.1.7+E484K and in VOI variants, such as B.1.525, B.1.620, and B1.621, among others (1–3); therefore, the presence of this mutation should be monitored.."
8,doi:10.1128/jcm.01736-21,B.1.620,"The E484K mutation has been identified in SARS-CoV-2 variants considered VOCs, such as B.1.351, P.1, and B.1.1.7+E484K and in VOI variants, such as B.1.525, B.1.620, and B1.621, among others (1–3); therefore, the presence of this mutation should be monitored.."
0,doi:10.1038/s41564-021-00955-3,B.1.1.25,"We found that most (85%) of the sequenced isolates were Pango lineage B.1.1.25 (58%), B.1.1 (19%) or B.1.36 (8%) in early-mid 2020."
1,doi:10.1038/s41564-021-00955-3,B.1.36,"We found that most (85%) of the sequenced isolates were Pango lineage B.1.1.25 (58%), B.1.1 (19%) or B.1.36 (8%) in early-mid 2020."
2,doi:10.1038/s41564-021-00955-3,B.1.1,"We found that most (85%) of the sequenced isolates were Pango lineage B.1.1.25 (58%), B.1.1 (19%) or B.1.36 (8%) in early-mid 2020."
3,doi:10.1038/s41564-021-00955-3,B.1.351,Further analysis of an additional 85 genomes (November 2020 to April 2021) found that importation of variant of concern Beta (B.1.351) had occurred and that Beta had become dominant in Dhaka.
4,doi:10.1038/s41564-021-00955-3,P.1,"Pango lineages4 B.1.1.7, B.1.351, P.1 and B.1.617.2 have been designated as VOCs on the basis of their observed heightened risk in terms of transmissibility, severity, vaccine or immune evasion, and have been renamed Alpha, Beta, Gamma and Delta, respectively."
5,doi:10.1038/s41564-021-00955-3,B.1.1.7,"Pango lineages4 B.1.1.7, B.1.351, P.1 and B.1.617.2 have been designated as VOCs on the basis of their observed heightened risk in terms of transmissibility, severity, vaccine or immune evasion, and have been renamed Alpha, Beta, Gamma and Delta, respectively."
6,doi:10.1038/s41564-021-00955-3,B.1.617.2,"Pango lineages4 B.1.1.7, B.1.351, P.1 and B.1.617.2 have been designated as VOCs on the basis of their observed heightened risk in terms of transmissibility, severity, vaccine or immune evasion, and have been renamed Alpha, Beta, Gamma and Delta, respectively."
7,doi:10.1038/s41564-021-00955-3,B.1.1.1,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
8,doi:10.1038/s41564-021-00955-3,B.1.1.60,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
9,doi:10.1038/s41564-021-00955-3,B.1.2,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
10,doi:10.1038/s41564-021-00955-3,A.9,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
11,doi:10.1038/s41564-021-00955-3,B.1.93,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
12,doi:10.1038/s41564-021-00955-3,B.1.79,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
13,doi:10.1038/s41564-021-00955-3,B.1,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
14,doi:10.1038/s41564-021-00955-3,B.2.1,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
15,doi:10.1038/s41564-021-00955-3,B.1.159,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
16,doi:10.1038/s41564-021-00955-3,B.1.1.59,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
17,doi:10.1038/s41564-021-00955-3,B.1.5.12,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
18,doi:10.1038/s41564-021-00955-3,B.1.5,"The 391 isolates from Bangladesh fell into 19 lineages, assigned by the Pangolin lineage software4 (Pango lineages A, A.9, B, B.1, B.1.1, B.1.1.1, B.1.1.25, B.1.1.25.2, B.1.1.59, B.1.1.60, B.1.148, B.1.159, B.1.2, B.1.36, B.1.5, B.1.5.12, B.1.79, B.1.93 and B.2.1)."
19,doi:10.1038/s41564-021-00955-3,B.1.1.315,"Of these 85 sequences, 30 were lineage B.1.1.25 (35%), 13 were VOC Alpha (B.1.1.7; 15%), 40 were VOC Beta (B.1.351; 47%), 1 was lineage B.1.1.315 and 1 was lineage B.1.525..

To investigate the emergence of lineages of concern Alpha (B.1.1.7) and Beta (B.1.351) in Bangladesh, a Nextstrain phylogenetic tree was built (Fig."
0,doi:10.1128/spectrum.00506-21,B.1.1.7,Rapid and high-throughput reverse transcriptase quantitative PCR (RT-qPCR) assay for identification and differentiation between SARS-CoV-2 variants B.1.1.7 and B.1.351.
1,doi:10.1128/spectrum.00506-21,B.1.351,We developed a multiplex reverse transcriptase quantitative PCR (RT-qPCR) assay that can specifically identify and differentiate between the emerging B.1.1.7 and B.1.351 SC-2 variants.
2,doi:10.1128/spectrum.00506-21,P.1,"For diagnostic purposes, however, the N501Y mutation is not variant-specific, as it was identified in several variants other than variant B.1.1.7, such as B.1.351 and the P.1 variant (14)."
0,doi:10.1101/2021.12.06.471446,B.1.1.529,"There is a growing concern that ongoing evolution of SARS-CoV-2 could lead to variants of concern (VOC) that are capable of avoiding some or all of the multi-faceted immune response generated by both prior infection or vaccination, with the recently described B.1.1.529 (Omicron) VOC being of particular interest."
0,doi:10.1093/ve/veab086,B.1.1.7,"This pattern changed with the arrival of the B.1.1.7 lineage, which was able to establish a stable presence concomitant with the imposition of severe border restrictions..

Click here for additional data file.."
0,doi:10.1016/j.imlet.2022.02.002,B.1.1.529,"These mutations are responsible for the appearance of new variants, the most recent of which is Omicron (line B.1.1.529)."
1,doi:10.1016/j.imlet.2022.02.002,P.1,"These mutations mainly concern the Spike protein domain, which has given rise to several variants of concern (VOC) which have had a special designation by the World Health Organization (WHO): Alpha (line B.1.1.7), Beta (line B.1.351), Gamma (line P.1), Delta (line B.1.617.2) and more recently Omicron (line B.1.1.529)."
2,doi:10.1016/j.imlet.2022.02.002,B.1.1.7,"These mutations mainly concern the Spike protein domain, which has given rise to several variants of concern (VOC) which have had a special designation by the World Health Organization (WHO): Alpha (line B.1.1.7), Beta (line B.1.351), Gamma (line P.1), Delta (line B.1.617.2) and more recently Omicron (line B.1.1.529)."
3,doi:10.1016/j.imlet.2022.02.002,B.1.617.2,"These mutations mainly concern the Spike protein domain, which has given rise to several variants of concern (VOC) which have had a special designation by the World Health Organization (WHO): Alpha (line B.1.1.7), Beta (line B.1.351), Gamma (line P.1), Delta (line B.1.617.2) and more recently Omicron (line B.1.1.529)."
4,doi:10.1016/j.imlet.2022.02.002,B.1.351,"These mutations mainly concern the Spike protein domain, which has given rise to several variants of concern (VOC) which have had a special designation by the World Health Organization (WHO): Alpha (line B.1.1.7), Beta (line B.1.351), Gamma (line P.1), Delta (line B.1.617.2) and more recently Omicron (line B.1.1.529)."
5,doi:10.1016/j.imlet.2022.02.002,A.2.2,"(In vitro data)PfizerWith 2 doses of Pfizer: limited ability to neutralize Omicron.With 3 doses, antibody titers were boosted but were reduced 4-fold for Omicron compared to lineage A.2.2 SARS-CoV-2."
0,doi:10.1038/s41467-021-25982-w,P.2,"Protection against any symptomatic COVID-19 caused by the Zeta (P.2) variant was assessed in 153 cases with vaccine efficacy (VE) of 69% (95% CI 55, 78)."
1,doi:10.1038/s41467-021-25982-w,B.1.1.28,"49 cases of B.1.1.28 occurred and VE was 73% (46, 86)."
2,doi:10.1038/s41467-021-25982-w,P.1,The Gamma (P.1) variant arose later in the trial and fewer cases (N = 18) were available for analysis.
3,doi:10.1038/s41467-021-25982-w,B.1.1.7,"These theoretical concerns are broadly supported by in vitro data showing reduction in neutralising antibody titres, but efficacy or clinical effectiveness of existing spike-based vaccines against the Alpha (B.1.1.7) variant of concern (VOC) does not seem to be compromised3,4."
4,doi:10.1038/s41467-021-25982-w,B.1.351,"However, such vaccines have a reduced efficacy against the Beta (B.1.351) VOC that possesses additional spike mutations5–7 and may translate into reduced vaccine effectiveness8."
5,doi:10.1038/s41467-021-25982-w,B.1.1.33,Lineages B.1.1.33 and B.1.1.28 were dominant throughout Brazil during 202011.
6,doi:10.1038/s41467-021-25982-w,B.1,This contrasts with the protection from reinfection for a median of 7 months duration seen in a large healthcare worker (HCW) study in the UK during a period when B.1 lineages were circulating and the Alpha (B.1.1.7) variant arose14.
7,doi:10.1038/s41467-021-25982-w,B.1.133,"Symptomatic reinfections in immunocompetent adults with Gamma (P.1) and Zeta (P.2) sublineages have been described (following B.1 and B.1.133 infections respectively)15,16.."
8,doi:10.1038/s41467-021-25982-w,N.6,"Efficacy was not computed for cases of N.9 (N = 4), N.6 (N = 1) or Alpha (B.1.1.7) (N = 1) as there were fewer than 5 instances of each."
9,doi:10.1038/s41467-021-25982-w,N.9,"Efficacy was not computed for cases of N.9 (N = 4), N.6 (N = 1) or Alpha (B.1.1.7) (N = 1) as there were fewer than 5 instances of each."
10,doi:10.1038/s41467-021-25982-w,B.1.1.331,"74) for the Zeta (P.2) (Table 2).Table 2Efficacy of 2 doses of ChAdOx1 nCoV-19 against primary symptomatic COVID-19, by SARS-CoV-2 lineage.LineageChAdOx1 nCoV-19n (%)N = 4772Controln (%)N = 4661Vaccine efficacy(95% CI)Vaccine efficacy using multiple imputation for unavailable swabs(95% CI)B.1.1.331 (0.0%)8 (0.2%)88.2 (5.4, 98.5)B.1.1.2811 (0.2%)38 (0.8%)72.6 (46.4, 86.0)P.2 (Zeta)38 (0.8%)115 (2.5%)68.7 (54.9, 78.3)65.2 (52.5, 74.4)P.1 (Gamma)5 (0.1%)13 (0.3%)63.6 (−2.1, 87.0)65.8 (4.9, 87.7)Undetermined22 (0.5%)48 (1.0%)56.6 (28.2, 73.8)*Undetermined lineage are those where a lineage could not be assigned due to low viral load or degraded RNA..

Efficacy of 2 doses of ChAdOx1 nCoV-19 against primary symptomatic COVID-19, by SARS-CoV-2 lineage..

*Undetermined lineage are those where a lineage could not be assigned due to low viral load or degraded RNA..

Primary outcome hospitalisation cases, occurring more than two weeks after a second dose, were present in 1 and 18 participants in the ChAdOx1 nCoV-19 and control groups respectively, VE 95% (95% CI 61, 99)."
0,doi:10.1016/s0140-6736(22)00462-7,B.1.1.529,"The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2)."
1,doi:10.1016/s0140-6736(22)00462-7,B.1.617.2,"The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2)."
0,doi:10.1371/journal.pntd.0009591,P.1,"Here, we report genetic evidence for circulation of the P.1 variant in Northeast Brazil."
1,doi:10.1371/journal.pntd.0009591,B.1.1.7,"Currently, three variants (B.1.1.7 or VOC202012/01, B.1.351 or 20H/501Y.V2 and P.1) carrying several mutations in the receptor-binding domain (RBD) of the spike (S) protein, raise concerns about their potential to shift the dynamics and public health impact of the pandemic [2–5]."
2,doi:10.1371/journal.pntd.0009591,B.1.351,"Currently, three variants (B.1.1.7 or VOC202012/01, B.1.351 or 20H/501Y.V2 and P.1) carrying several mutations in the receptor-binding domain (RBD) of the spike (S) protein, raise concerns about their potential to shift the dynamics and public health impact of the pandemic [2–5]."
0,doi:10.1016/j.jinf.2021.08.015,B.1.1.7,"In this context, a novel SARS-CoV-2 variant lineage (B.1.1.7), first detected in the UK at the end of 2020 has transmission advantage over other lineages.2 Increased transmissibility of the B.1.1.7 variant has been linked to enhanced ACE2 affinity3 allegedly resulting in higher viral loads in URT, an observation that has been reported in some,3, 4, 5, 6 but not all7 large series published to date."
0,doi:10.1101/2021.08.15.456341,B.1.1.7,"In addition, we examined the competition of two SARS-CoV-2 isolates, representatives of the ancestral lineage A (SARS-CoV-2/human/USA/WA1/2020) and the alpha variant of concern (VOC) B.1.1.7 (SARS-CoV-2/human/USA/CA_CDC_5574/2020), through co-infection of white-tailed deer."
0,doi:10.1016/j.jgg.2021.12.003,B.1.1,"Here, we identified 45 point mutations that Omicron acquired since divergence from the B.1.1 lineage."
0,doi:10.46234/ccdcw2021.147,B.1.617.2,"Notably, eight variation sites of amino acid residues (T19R, L452R, T478K, D614G, P681R, D950N, F157del, and R158del), which were identical to those in Indian B.1.617.2 variants, were observed in all five isolates."
1,doi:10.46234/ccdcw2021.147,B.1.617,"The B.1.617 variant had been detected in Chongqing (4) and had been identified in dozens of countries worldwide, posing a serious challenge to the global pandemic."
2,doi:10.46234/ccdcw2021.147,B.1.617.3,"Among the sub-variants of B.1.617, the B.1.617.3 shares the L452R and E484Q mutations found in B.1.617.1 (VOI, Kappa), whereas B.1.617.2 does not have the mutation E484Q but has the T478K mutation not found in B.1.617.1 and B.1.617.3."
3,doi:10.46234/ccdcw2021.147,B.1.617.1,"Among the sub-variants of B.1.617, the B.1.617.3 shares the L452R and E484Q mutations found in B.1.617.1 (VOI, Kappa), whereas B.1.617.2 does not have the mutation E484Q but has the T478K mutation not found in B.1.617.1 and B.1.617.3."
0,doi:10.1016/j.jinf.2021.07.019,P.1,"Three strains of SARS-CoV-2 have been tested: 20A.EU1, B.1.1.7 (alpha) and P.1 (gamma)."
1,doi:10.1016/j.jinf.2021.07.019,B.1.1.7,"Three strains of SARS-CoV-2 have been tested: 20A.EU1, B.1.1.7 (alpha) and P.1 (gamma)."
2,doi:10.1016/j.jinf.2021.07.019,B.1.351,"The most relevant variants emerged in United Kingdom (known as 20I/501Y.V1, VOC 202,012/01, B.1.1.7, or alpha), South Africa (known as 20H/501Y.V2, B.1.351, or beta) and Brazil (known as P.1, or gamma) during 2020 but started to spread all around the world between December 2020 and January 2021.2 These variants possess different mutations on the receptor-binding domain (RBD) of the spike protein responsible for binding to the ACE2 receptor on the human cell surface."
3,doi:10.1016/j.jinf.2021.07.019,B.1,"In Italy, the SARS-CoV-2 lineage B.1, clade 20A.EU1 circulating across Europe was first identified in March 2020 and remained dominant up to November 2020.4 By the end of February 2021, surveillance data of Umbria region, Italy, revealed the SARS-CoV-2 variants B.1.1.7 and P.1 as accounting for 36.2% and 51.1% of the total cases analyzed, respectively.5
."
4,doi:10.1016/j.jinf.2021.07.019,A.1,"found significant differences only from A.1 to B.1 and B.1.1.7, but not from B.1 and B.1.1.7.16 In our study, no differences were found in post-vaccination sera for NT-Abs titers to the 20A.EU1 and B.1.1.7 strains.."
0,doi:10.1093/ofid/ofab553,B.1.617.2,"These breakthrough infections presented with regular B.1.1.7 (Alpha) and B.1.617.2 (Delta) variants and high viral loads, despite normal vaccine induced B- and T-cell immune responses detected by live virus neutralization assays and ELISpot."
1,doi:10.1093/ofid/ofab553,B.1.1.7,"These breakthrough infections presented with regular B.1.1.7 (Alpha) and B.1.617.2 (Delta) variants and high viral loads, despite normal vaccine induced B- and T-cell immune responses detected by live virus neutralization assays and ELISpot."
0,doi:10.15252/emmm.202114544,P.1,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters."
1,doi:10.15252/emmm.202114544,B.1.617.2,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters."
2,doi:10.15252/emmm.202114544,B.1.1.7,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters."
3,doi:10.15252/emmm.202114544,B.1.351,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters."
4,doi:10.15252/emmm.202114544,B.1.1.298,"Y453F increases the ACE2 binding affinity, and with A475V and F490L, is found in independent mink‐related SARS‐CoV‐2 variants (Larsen et al, 2021; Oude Munnink et al, 2021) identified in Denmark and the Netherlands (B1.1 and B.1.1.298) that may escape human antisera and REG10933 (Starr et al, 2021)."
5,doi:10.15252/emmm.202114544,B.1.177,"A222V and S477N are described in 20A.EU1 (B.1.177) and 20A.EU2 (B.1.160) that emerged in early summer 2020 and subsequently spread to multiple locations in Europe at the end of 2020 (Lemey et al, 2021)."
6,doi:10.15252/emmm.202114544,B.1.160,"A222V and S477N are described in 20A.EU1 (B.1.177) and 20A.EU2 (B.1.160) that emerged in early summer 2020 and subsequently spread to multiple locations in Europe at the end of 2020 (Lemey et al, 2021)."
7,doi:10.15252/emmm.202114544,B.1.258,"N439K is in B.1.141, B.1.258, and in mink strains; it increases affinity to ACE2 and reduces neutralization of sera from convalescent patients (Thomson et al, 2021)."
8,doi:10.15252/emmm.202114544,B.1.141,"N439K is in B.1.141, B.1.258, and in mink strains; it increases affinity to ACE2 and reduces neutralization of sera from convalescent patients (Thomson et al, 2021)."
0,doi:10.4110/in.2021.21.e32,B.1.617.3,"This review describes four SARS-CoV-2 α, β, γ, and δ variants of concern including SARS-CoV-2 ε, ζ, η, ι, κ, and B.1.617.3 variants of interest and alert."
1,doi:10.4110/in.2021.21.e32,B.1.617.2,"Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) δ (B.1.617.2) is the most notorious variant among numerous SARS-CoV-2 variants."
2,doi:10.4110/in.2021.21.e32,B.1.1.7,"As well as we include SARS-CoV-2 ε, ζ, η, ι, κ, and B.1.617.3 variants of interest and alert from US-CDC (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html) to identify critical mutation sites of δ variant to analyze the current crisis of COVID-19 pandemic..

SARS-CoV-2 α (B.1.1.7) variant was originally reported in United Kingdom (UK) (38) and studies suggested this variant increased 50% infectivity as well as severity based on hospitalizations and the case of fatality (39)."
3,doi:10.4110/in.2021.21.e32,B.1.351,"*Detected in some sequences but not all..

SARS-CoV-2 β (B.1.351) variant was first reported from South Africa and it has 10 mutation sites in S gene (Fig."
4,doi:10.4110/in.2021.21.e32,P.1,"A single point mutation A701V presents in the S2 region that is distinct from SARS-CoV-2 α variant..

SARS-CoV-2 γ (P.1) variant first reported in two countries Brazil and Japan, and it has completely different Pango linage, P.1 (Table 1) (45)."
5,doi:10.4110/in.2021.21.e32,B.1.617.1,The SARS-CoV-2 κ (B.1.617.1) (51) and B.1.617.3 (50) variants were reported in India at the same time between October and December 2020.
6,doi:10.4110/in.2021.21.e32,B.1.427,SARS-CoV-2 ε (B.1.427/B.1.429) variant was detected in California US whereas ι (B.1.526) variant was reported in New York US (Table 1).
7,doi:10.4110/in.2021.21.e32,B.1.526,SARS-CoV-2 ε (B.1.427/B.1.429) variant was detected in California US whereas ι (B.1.526) variant was reported in New York US (Table 1).
8,doi:10.4110/in.2021.21.e32,B.1.525,"E484 mutation site presents in eight SARS-CoV-2 α, β, γ, ζ, η, ι, κ, and B.1.617.3 variants, however, SARS-CoV-2 κ and B.1.617.3 variants have Q substitution instead of K. Interestingly, E484 mutation site is not present in only two SARS-CoV-2 δ and ε variants (Table 1)..

SARS-CoV-2 η (B.1.525) variant of UK and Nigeria has 8 mutations sites containing 3 deletion sites, H69del, V70del, and Y144del in NTD of S1 region."
0,doi:10.4269/ajtmh.21-0812,B.1.617,"Among the observed clades, 21A-Delta and 21B-Kappa belonging to the B.1.617 and its sublineages are the two notable clades that dominated approximately 78% of the total SARS-COV-2 genomes reported during April and May 2021."
1,doi:10.4269/ajtmh.21-0812,B.1.1.7,"As the COVID-19 pandemic expands, SARS-COV-2 has undergone several mutations and genetic variations, resulting in the formation of different evolutionary groups used to classify viral strains into clades, lineages, and sublineages.1–3 In late 2020, new variants of SARS-COV-2, designated as “specific variants of interest (VOIs) and variants of concern (VOCs),” emerged with a greater risk to global public health.4,5 These variants possess multiple mutations across the genome, including several in the S protein and its receptor-binding domain.6–8 The resurgences in COVID-19 cases in the United Kingdom, South Africa, and Brazil coincides with a high prevalence of newly emerged VOCs such as B.1.1.7, B.1.351, and B.1.1.28; which has also disseminated to multiple countries worldwide.9–12 These three VOCs are likely to be associated with the increased transmission, higher infectivity and severity, and immune escape.2,13 Much like other countries, the second wave of COVID-19 in India, which started in January 2021, was also characterized by the emergence and/or circulation of a new variant named B.1.617.8,14 This newly emerged variant was characterized by having common signature mutations—D111D, G142D, L452R, E484Q, D614G, and P681R—in the spike protein, including within the receptor-binding domain (RBD).14 This newfound variant B.1.617 has seemingly replaced previous circulating SARS-COV-2 variants in India and even transmission across continents.15 Laboratory investigations have established the higher infectivity and increased pathological changes associated with the infection of newly emerged B.1.617 variants in laboratory animals."
2,doi:10.4269/ajtmh.21-0812,B.1.351,"As the COVID-19 pandemic expands, SARS-COV-2 has undergone several mutations and genetic variations, resulting in the formation of different evolutionary groups used to classify viral strains into clades, lineages, and sublineages.1–3 In late 2020, new variants of SARS-COV-2, designated as “specific variants of interest (VOIs) and variants of concern (VOCs),” emerged with a greater risk to global public health.4,5 These variants possess multiple mutations across the genome, including several in the S protein and its receptor-binding domain.6–8 The resurgences in COVID-19 cases in the United Kingdom, South Africa, and Brazil coincides with a high prevalence of newly emerged VOCs such as B.1.1.7, B.1.351, and B.1.1.28; which has also disseminated to multiple countries worldwide.9–12 These three VOCs are likely to be associated with the increased transmission, higher infectivity and severity, and immune escape.2,13 Much like other countries, the second wave of COVID-19 in India, which started in January 2021, was also characterized by the emergence and/or circulation of a new variant named B.1.617.8,14 This newly emerged variant was characterized by having common signature mutations—D111D, G142D, L452R, E484Q, D614G, and P681R—in the spike protein, including within the receptor-binding domain (RBD).14 This newfound variant B.1.617 has seemingly replaced previous circulating SARS-COV-2 variants in India and even transmission across continents.15 Laboratory investigations have established the higher infectivity and increased pathological changes associated with the infection of newly emerged B.1.617 variants in laboratory animals."
3,doi:10.4269/ajtmh.21-0812,B.1.1,"The VOCs are the genome sequences as categorized into Basel sequences: B.1, B.1.1, B.1.1.7, and B.1.617."
4,doi:10.4269/ajtmh.21-0812,B.1,"The VOCs are the genome sequences as categorized into Basel sequences: B.1, B.1.1, B.1.1.7, and B.1.617."
5,doi:10.4269/ajtmh.21-0812,B.1.617.2,"Among the several sublineages of B; the newly emerged variants such as B.1.617.1 and B.1.617.2 lineage belonging to the next strain clade 21A-Delta and 21B-Kappa constitute 17.2% and 12.7%, respectively, of the total SARS-COV-2 sequences reported from India."
6,doi:10.4269/ajtmh.21-0812,B.1.617.1,"Among the several sublineages of B; the newly emerged variants such as B.1.617.1 and B.1.617.2 lineage belonging to the next strain clade 21A-Delta and 21B-Kappa constitute 17.2% and 12.7%, respectively, of the total SARS-COV-2 sequences reported from India."
7,doi:10.4269/ajtmh.21-0812,B.1.167,"Furthermore, pairwise comparison tests were performed, and the results showed a statistically significant difference in mortality occurring from the infection of variant B.1 and variant B.1.167 (Supplemental Table 1)."
0,doi:10.1016/j.jep.2021.114797,P.1,"Using Vero E6 cells, we measured anti-SARS-CoV-2 activity of dried-leaf hot-water A. annua L. extracts of four cultivars, A3, BUR, MED, and SAM, to determine their efficacy against five infectious variants of the virus: alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2), and kappa (B.1.617.1).."
1,doi:10.1016/j.jep.2021.114797,B.1.1.7,"Using Vero E6 cells, we measured anti-SARS-CoV-2 activity of dried-leaf hot-water A. annua L. extracts of four cultivars, A3, BUR, MED, and SAM, to determine their efficacy against five infectious variants of the virus: alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2), and kappa (B.1.617.1).."
2,doi:10.1016/j.jep.2021.114797,B.1.617.2,"Using Vero E6 cells, we measured anti-SARS-CoV-2 activity of dried-leaf hot-water A. annua L. extracts of four cultivars, A3, BUR, MED, and SAM, to determine their efficacy against five infectious variants of the virus: alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2), and kappa (B.1.617.1).."
3,doi:10.1016/j.jep.2021.114797,B.1.617.1,"Using Vero E6 cells, we measured anti-SARS-CoV-2 activity of dried-leaf hot-water A. annua L. extracts of four cultivars, A3, BUR, MED, and SAM, to determine their efficacy against five infectious variants of the virus: alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2), and kappa (B.1.617.1).."
4,doi:10.1016/j.jep.2021.114797,B.1.351,"Using Vero E6 cells, we measured anti-SARS-CoV-2 activity of dried-leaf hot-water A. annua L. extracts of four cultivars, A3, BUR, MED, and SAM, to determine their efficacy against five infectious variants of the virus: alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2), and kappa (B.1.617.1).."
0,doi:10.1016/j.diagmicrobio.2021.115606,P.2,"Among those, signature SNPs were linked to 2 Zeta-VOI (P.2) samples and one to the Alpha-VOC (B.1.17)."
1,doi:10.1016/j.diagmicrobio.2021.115606,B.1.1.7,"Samples were previously sequenced by an Illumina COVIDSeq SARS-CoV-2 NGS test, where 3 samples were VOC/VOI (2 samples were Zeta/P.2, one sample was Alpha/B.1.1.7)..

A significant difference was observed in the purified DNA concentration after S gene amplification when samples were grouped by SARS-CoV-2 diagnosis (positive: 13.8 ± 15.0 vs negative: 1.0 ± 0.2 ng/µL; P-value = 0.03, Mann-Whitney test)."
0,doi:10.3390/biomedicines9050525,B.1.1.7,"The B.1.1.7 variant of the SARS-CoV-2 virus shows enhanced infectiousness over the wild type virus, leading to increasing patient numbers in affected areas."
1,doi:10.3390/biomedicines9050525,P.1,"To date, we only have a vague understanding of the molecular reasons leading to enhanced contagion and cellular uptake of SARS-CoV-2 variants like the B.1.1.7 (British), but also the B.1.351 (South African) and P.1 (Brazilian/Japanese) variants."
2,doi:10.3390/biomedicines9050525,B.1.351,"To date, we only have a vague understanding of the molecular reasons leading to enhanced contagion and cellular uptake of SARS-CoV-2 variants like the B.1.1.7 (British), but also the B.1.351 (South African) and P.1 (Brazilian/Japanese) variants."
0,doi:10.1101/2021.06.25.449609,B.1.1.7,"Lastly, we demonstrated efficacy against several variants including SARS-CoV-2 Strain England 2 (England 02/2020/407073), B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta)."
1,doi:10.1101/2021.06.25.449609,B.1.617.2,"Lastly, we demonstrated efficacy against several variants including SARS-CoV-2 Strain England 2 (England 02/2020/407073), B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta)."
2,doi:10.1101/2021.06.25.449609,B.1.351,"Lastly, we demonstrated efficacy against several variants including SARS-CoV-2 Strain England 2 (England 02/2020/407073), B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta)."
0,doi:10.1002/jmv.26823,B.1.1.7,"In that regard, the recent emergence of the B.1.1.7 lineage in the UK has called the attention of global authorities."
0,doi:10.15252/emmm.202115227,B.1.617.2,The SARS‐CoV‐2 Delta (B.1.617.2) variant is capable of infecting vaccinated persons.
1,doi:10.15252/emmm.202115227,P.1,"Several Variants of Concern (VOCs) have emerged in the course of the COVID‐19 pandemic, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)."
2,doi:10.15252/emmm.202115227,B.1.1.7,"Several Variants of Concern (VOCs) have emerged in the course of the COVID‐19 pandemic, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)."
3,doi:10.15252/emmm.202115227,B.1.351,"Several Variants of Concern (VOCs) have emerged in the course of the COVID‐19 pandemic, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2)."
0,doi:10.1038/s41598-021-99014-4,B.1,We observe a shift of lineage prevalence from the strain B.1 to B.1.1.1.
1,doi:10.1038/s41598-021-99014-4,B.1.2,"The top Frequent Mutations in Egypt and in the world during the first waves..

We collected the mutations of related to the variants/lineages of interest from the UK B.1.1.7 lineage, B.1.351 South African lineage, the B.1.1.28 Brazilian lineage, US B.1.2 lineage and the 20A.EU1 lineage."
2,doi:10.1038/s41598-021-99014-4,B.1.1.7,"The top Frequent Mutations in Egypt and in the world during the first waves..

We collected the mutations of related to the variants/lineages of interest from the UK B.1.1.7 lineage, B.1.351 South African lineage, the B.1.1.28 Brazilian lineage, US B.1.2 lineage and the 20A.EU1 lineage."
3,doi:10.1038/s41598-021-99014-4,B.1.1.28,"The top Frequent Mutations in Egypt and in the world during the first waves..

We collected the mutations of related to the variants/lineages of interest from the UK B.1.1.7 lineage, B.1.351 South African lineage, the B.1.1.28 Brazilian lineage, US B.1.2 lineage and the 20A.EU1 lineage."
4,doi:10.1038/s41598-021-99014-4,B.1.351,"The top Frequent Mutations in Egypt and in the world during the first waves..

We collected the mutations of related to the variants/lineages of interest from the UK B.1.1.7 lineage, B.1.351 South African lineage, the B.1.1.28 Brazilian lineage, US B.1.2 lineage and the 20A.EU1 lineage."
5,doi:10.1038/s41598-021-99014-4,B.1.1.1,"Lineage B.1 represented 40% of cases in the first wave, while lineage B.1.1.1 represented 59% of cases in the second wave.Figure 3Dominant Lineages/Types of the virus in Egypt during the first and the second waves of infection."
6,doi:10.1038/s41598-021-99014-4,P.1,"Notable variants with multiple mutations in the spike protein have emerged in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1)."
7,doi:10.1038/s41598-021-99014-4,B.1.1.36,"In these samples, we observed the emergence of the lineage C.36 (B.1.1.36) (without L452R) ranking the third place (18%) after B.1.1.1 and B.1 in the late second wave."
8,doi:10.1038/s41598-021-99014-4,C.36,"In these samples, we observed the emergence of the lineage C.36 (B.1.1.36) (without L452R) ranking the third place (18%) after B.1.1.1 and B.1 in the late second wave."
0,doi:10.3389/fpubh.2021.686958,B.1.1.7,"The outcome variables were HCWs' knowledge and awareness of the SARS-CoV-2 B.1.1.7 lineage that was recently reported as the UK variant of concern, and its associated travel worry and Generalized Anxiety Disorder (GAD-7) score.."
0,doi:10.1128/jvi.00203-21,P.1,"We found that all trimeric S proteins induced a T cell response and long-lived, strongly neutralizing antibody responses against 2019 SARS-CoV-2 and variants of concern P.1 and B.1.351."
1,doi:10.1128/jvi.00203-21,B.1.1.7,"However, recently emerged variants of concern (VOCs) first reported in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) are partially resistant to neutralizing antibodies generated against approved vaccines based on the S protein from 2019 strains (17–21)."
2,doi:10.1128/jvi.00203-21,B.1.351,"However, recently emerged variants of concern (VOCs) first reported in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) are partially resistant to neutralizing antibodies generated against approved vaccines based on the S protein from 2019 strains (17–21)."
0,doi:10.1101/2021.06.30.450632,A.23.1,"Here we analyzed A.23.1, first identified in Uganda, as a P681R-containing virus several months prior to the emergence of B.1.617.2 (Delta variant)."
1,doi:10.1101/2021.06.30.450632,B.1.617.2,"Here we analyzed A.23.1, first identified in Uganda, as a P681R-containing virus several months prior to the emergence of B.1.617.2 (Delta variant)."
2,doi:10.1101/2021.06.30.450632,B.1.617,We performed assays using peptides mimicking the S1/S2 from A.23.1 and B.1.617 and observed significantly increased cleavability with furin compared to both an original B lineage (Wuhan-Hu1) and B.1.1.7 (Alpha variant).
3,doi:10.1101/2021.06.30.450632,B.1.1.7,We performed assays using peptides mimicking the S1/S2 from A.23.1 and B.1.617 and observed significantly increased cleavability with furin compared to both an original B lineage (Wuhan-Hu1) and B.1.1.7 (Alpha variant).
4,doi:10.1101/2021.06.30.450632,B.1,"While the B.1 lineage became the dominant virus following its introduction into Northern Italy and spread through Europe/UK in February 2020, both A and B lineages remain in circulation globally (2)."
5,doi:10.1101/2021.06.30.450632,A.23,"Both lineages have undergone significant diversification as they expanded; this expansion is apparently linked to a key S gene mutation—D614G in lineage B.1 and all sublineages, which has been linked to modest increase in virus transmissibility (3) and with Q613H found in lineage A.23/A.23.1."
6,doi:10.1101/2021.06.30.450632,P.1,"Compared with the lineage B.1 viruses that have successfully evolved into multiple variants of concern (VOC), including B.1.1.7 (Alpha) B.1.351 (Beta), B.1.1.28.1/P.1 (Gamma), B.1.617.2 (Delta), most of lineage A viruses remained at fairly lower frequency and were more prevalent at the beginning of the pandemic in Asia."
7,doi:10.1101/2021.06.30.450632,B.1.351,"Compared with the lineage B.1 viruses that have successfully evolved into multiple variants of concern (VOC), including B.1.1.7 (Alpha) B.1.351 (Beta), B.1.1.28.1/P.1 (Gamma), B.1.617.2 (Delta), most of lineage A viruses remained at fairly lower frequency and were more prevalent at the beginning of the pandemic in Asia."
8,doi:10.1101/2021.06.30.450632,B.1.466.2,"Notably, the P681R substitution appears in several other lineages, most notably B.1.617.2 (Delta) (N = 617590 genomes) but also the AY.X sub-lineages of B.1.617.2, B.1.617.1 (N=6138), B.1.466.2 (N=2208), the B.1.1.7 sub-lineage Q.4 (2067), B.1.551 (N=722), AU.2 (N=302), B.1.1.25 (N=509), B.1.466.2 (N=538), and other lineages (updated 22 Oct 21, https://outbreak.info; https://outbreak.info/situation-reports?pango&muts=S%3AP681R) suggesting that the substitution may provide an advantage for viruses encoding the substitution..

We previously studied the role of proteolytic activation of the spike protein of the lineage B SARS-CoV-2 isolates Wuhan-Hu1 and B.1.1.7 (14)."
9,doi:10.1101/2021.06.30.450632,B.1.1.25,"Notably, the P681R substitution appears in several other lineages, most notably B.1.617.2 (Delta) (N = 617590 genomes) but also the AY.X sub-lineages of B.1.617.2, B.1.617.1 (N=6138), B.1.466.2 (N=2208), the B.1.1.7 sub-lineage Q.4 (2067), B.1.551 (N=722), AU.2 (N=302), B.1.1.25 (N=509), B.1.466.2 (N=538), and other lineages (updated 22 Oct 21, https://outbreak.info; https://outbreak.info/situation-reports?pango&muts=S%3AP681R) suggesting that the substitution may provide an advantage for viruses encoding the substitution..

We previously studied the role of proteolytic activation of the spike protein of the lineage B SARS-CoV-2 isolates Wuhan-Hu1 and B.1.1.7 (14)."
10,doi:10.1101/2021.06.30.450632,B.1.551,"Notably, the P681R substitution appears in several other lineages, most notably B.1.617.2 (Delta) (N = 617590 genomes) but also the AY.X sub-lineages of B.1.617.2, B.1.617.1 (N=6138), B.1.466.2 (N=2208), the B.1.1.7 sub-lineage Q.4 (2067), B.1.551 (N=722), AU.2 (N=302), B.1.1.25 (N=509), B.1.466.2 (N=538), and other lineages (updated 22 Oct 21, https://outbreak.info; https://outbreak.info/situation-reports?pango&muts=S%3AP681R) suggesting that the substitution may provide an advantage for viruses encoding the substitution..

We previously studied the role of proteolytic activation of the spike protein of the lineage B SARS-CoV-2 isolates Wuhan-Hu1 and B.1.1.7 (14)."
11,doi:10.1101/2021.06.30.450632,B.1.617.1,"Notably, the P681R substitution appears in several other lineages, most notably B.1.617.2 (Delta) (N = 617590 genomes) but also the AY.X sub-lineages of B.1.617.2, B.1.617.1 (N=6138), B.1.466.2 (N=2208), the B.1.1.7 sub-lineage Q.4 (2067), B.1.551 (N=722), AU.2 (N=302), B.1.1.25 (N=509), B.1.466.2 (N=538), and other lineages (updated 22 Oct 21, https://outbreak.info; https://outbreak.info/situation-reports?pango&muts=S%3AP681R) suggesting that the substitution may provide an advantage for viruses encoding the substitution..

We previously studied the role of proteolytic activation of the spike protein of the lineage B SARS-CoV-2 isolates Wuhan-Hu1 and B.1.1.7 (14)."
12,doi:10.1101/2021.06.30.450632,Q.4,"Notably, the P681R substitution appears in several other lineages, most notably B.1.617.2 (Delta) (N = 617590 genomes) but also the AY.X sub-lineages of B.1.617.2, B.1.617.1 (N=6138), B.1.466.2 (N=2208), the B.1.1.7 sub-lineage Q.4 (2067), B.1.551 (N=722), AU.2 (N=302), B.1.1.25 (N=509), B.1.466.2 (N=538), and other lineages (updated 22 Oct 21, https://outbreak.info; https://outbreak.info/situation-reports?pango&muts=S%3AP681R) suggesting that the substitution may provide an advantage for viruses encoding the substitution..

We previously studied the role of proteolytic activation of the spike protein of the lineage B SARS-CoV-2 isolates Wuhan-Hu1 and B.1.1.7 (14)."
13,doi:10.1101/2021.06.30.450632,A.1,"Sequences of representative S1/S2 sequences are summarized in Figure 3A..

As an initial bioinformatic approach to assess biochemical function, we utilized the PiTou (15) and ProP (16) protein cleavage prediction tools, comparing the spike proteins from A.23.1 to B.1.1.7 and the prototype SARS-CoV-2 from the A.1 and B.1 lineages (e.g., Wuhan-Hu-1), as well as to MERS-CoV and selected other human respiratory betacoronaviruses (HCoV-HKU1 and HCoV-OC43) with identifiable furin cleavage sites (Figure 3B)."
14,doi:10.1101/2021.06.30.450632,B.1.617.3,"Most recently, the VOC (B.1.617.2, or Delta) has replaced B.1.1.7(Alpha) as the dominant circulating virus globally, which like A.23.1 and sub-lineages B.1.617.1, B.1.617.2 and B.1.617.3 encodes a P681R substitution, and is more conventionally “polybasic” in the S1/S2 cleavage motif, than the P681H of B.1.1.7 (Alpha) and is suggested to affect transmissibility and pathogenesis (26)."
15,doi:10.1101/2021.06.30.450632,B.1.529,"It is interesting to note that B.1.617.2 (Delta) has been shown to be a genetic outlier compared to other VOCs (29), raising the question of whether P681R (found in A.23.1 and B.1.617) ultimately results in a more successful viral variant compared to P681H, found in B.1.1.7 (Alpha) and B.1.529 (Omicron BA.1/BA.2)."
16,doi:10.1101/2021.06.30.450632,B.1.1.529,"In all cases, the position 681 change occurred after a change of position 613/614 (B to B.1 to B.1.1.7 (Alpha), B to B.1 to B.1.617.2 (Delta), A to A.23 to A.23.1, B to B.1 to B.1.1.7 to Q.4), and most recently B to B.1 to B.1.1.529 (Omicron)."
17,doi:10.1101/2021.06.30.450632,C.11,"Despite these limitations, we consider that our data support our conclusion that the spike mutation P681R—by itself—is a not a primary driver of virus transmissibility in the population, with A.23.1 giving unique insight into these aspects of the ongoing COVID-19 pandemic, but requires the full context of additional spike and other viral changes seen in A.23.1, B.1.617.2 and Q.4 for transmission success..

A.23.1 was a key SARS-CoV-2 variant spreading within Africa during the early part of 2021, and has been defined (along with C.11) as an African VOI (30) having have multiple mutations on the spike glycoprotein and evolving in a clocklike manner along with other variants."
0,doi:10.1016/j.medj.2021.11.004,B.1.617.2,"Here we assessed a cohort of 77 individuals with CID treated as monotherapy with chronic immunosuppressive drugs for antibody responses in serum against historical and variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses after immunization with the BNT162b2 mRNA vaccine..

Longitudinal analysis showed the greatest reductions in neutralizing antibodies and Fc effector function capacity in individuals treated with tumor necrosis factor alpha (TNF-α) inhibitors (TNFi), and this pattern appeared to be worse against the B.1.617.2 delta virus."
1,doi:10.1016/j.medj.2021.11.004,B.1.351,Individuals receiving TNF-α inhibitors (TNFi) had reduced antibody neutralizing and Fc effector function activity against the B.1.351 and B.1.617.2 variants.
2,doi:10.1016/j.medj.2021.11.004,B.1.1.7,"While the efficacy of mRNA vaccine protection in immunocompetent volunteers has been high (>90%) against historical and some emerging SARS-CoV-2 strains (e.g., B.1.1.7 [alpha]),21
,
22 there are concerns regarding breakthrough infections in immunosuppressed individuals or those receiving immunomodulatory drugs because of blunted immune responses, waning immunity, or evasion by variants, including B.1.351 (beta) and B.1.617.2 (delta)."
0,doi:10.5365/wpsar.2021.12.2.008,B.1.1.7,"SARS-CoV-2 variant B.1.1.7, first detected in September 2020 in the United Kingdom of Great Britain and Northern Ireland, has spread quickly to many countries around the world."
0,doi:10.15585/mmwr.mm7046a5,B.1.617.2,"The study period included the months during which the highly transmissible SARS-CoV-2 B.1.617.2 (Delta) variant became predominant in the United States.† The negative binomial regression model used to calculate estimated deaths predicted that, if intensive care unit (ICU) bed use nationwide reached 75% capacity an estimated 12,000 additional excess deaths would occur nationally over the next 2 weeks."
0,doi:10.1016/j.ymthe.2022.01.042,B.1.617.2,"Further, immunization induced strong cross-protective neutralizing antibodies (NAbs) against the B.1.617.2 delta variant (clade G)."
1,doi:10.1016/j.ymthe.2022.01.042,B.1.351,"Indeed, recently concluded clinical trials have observed a staggering drop in efficacy from 96% to 48% for Novavax vaccine (NVX-CoV2373), 85% to 57% for Johnson & Johnson vaccine (JNJ-78436,735), and 62% to 10% for Oxford-AstraZeneca vaccine (ChAdOx1d) against the B.1.351 variant.3,4."
2,doi:10.1016/j.ymthe.2022.01.042,B.1.1.7,"The VOCs are B.1.1.7 (Alpha), B.1.351 (501Y.V2, Beta), P1 (Gamma), and B.1.617.2 (Delta)."
3,doi:10.1016/j.ymthe.2022.01.042,B.1.526,"The VOIs include B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa), and C.37 (Lambda)."
4,doi:10.1016/j.ymthe.2022.01.042,B.1.525,"The VOIs include B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa), and C.37 (Lambda)."
5,doi:10.1016/j.ymthe.2022.01.042,B.1.617.1,"The VOIs include B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa), and C.37 (Lambda)."
6,doi:10.1016/j.ymthe.2022.01.042,C.37,"The VOIs include B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa), and C.37 (Lambda)."
0,doi:10.1016/j.jviromet.2021.114422,P.1,"Variants may dominate local epidemics, as Gamma (P.1) in Brazil, emerging in 2020 and prevailing until mid-2021."
1,doi:10.1016/j.jviromet.2021.114422,B.1.1.28,"Analyses of sequences from 95 individuals (late 2020/early 2021) identified extensive amino acid variation, 57 % with at least one key mutation at the Receptor Binding Domain, with B.1.1.28 lineage most prevalent, followed by Gamma and Zeta variants, with no Delta variant observed."
2,doi:10.1016/j.jviromet.2021.114422,P.2,"2
, 34 % (23/67) were classified as B.1.1.28 variant, followed by P.1 (Gamma variant) 28 % (19/67), P.2 (Zeta variant) 23 % (15/67) and 15 % (10/67) remained unclassified.Fig."
3,doi:10.1016/j.jviromet.2021.114422,B.1.617.2,"It can also monitor mutations associated with newer variants of concern, as the L452R, and E484Q (VOC Delta, B.1.617.2) initially described in India and mutations found in the US isolates as the S477 N (CDC, 2021a,b)."
4,doi:10.1016/j.jviromet.2021.114422,B.1.351,"It also allows the discrimination of South African B.1.351 (Beta) amino acid substitution, Asparagine at position 417 of Spike protein, whereas the Gamma, the Brazilian P.1 variant, has a mutation to amino acid Threonine..

Misincorporation of base pairs during PCR, more commonly A to G and T to C transitions (Potapov and Ong, 2017), may lead to the identification of artificial amino acid signatures that do not reflect the actual viral genome."
5,doi:10.1016/j.jviromet.2021.114422,B.1.1.7,"Therefore, the RBD is the active immunogen of most vaccines products and harbors many of the mutations described in emerging and established variants as seen in the Alpha UK variant (B.1.1.7), the Beta, South African (B.1.351), the Gamma, Brazilian (P.1) and the VOC Delta (B.1.617.2) variants emerging along with the recent surge of cases in India; (CDC, 2021a,b, WHO, 2021)."
0,doi:10.1038/s41467-021-25729-7,B.1.1.7,"The newly emerging coronavirus variant B.1.1.7, as well as SARS-CoV and MERS-CoV similarly depended on TMPRSS2."
1,doi:10.1038/s41467-021-25729-7,B.1.617.2,A similar mutation (P681R) was detected in the Delta variant (clade B.1.617.2).
0,doi:10.1056/nejmoa2114228,B.1.617.2,Possible reasons for the resurgence were reduced vaccine effectiveness against the delta (B.1.617.2) variant and waning immunity.
1,doi:10.1056/nejmoa2114228,B.1.351,"Several studies investigating the effectiveness of the BNT162b2 vaccine (Pfizer–BioNTech) against the beta (B.1.351)2,3 and delta (B.1.617.2)4-6 variants showed only modest rates of breakthrough infection and disease, whereas other studies showed higher rates.7,8."
2,doi:10.1056/nejmoa2114228,B.1.1.7,"Nevertheless, some sources of bias might remain; for instance, any effects that were due to differences in coexisting conditions between the vaccination periods could not be controlled for, because coexisting conditions are not recorded in the national database..

We did not separate the contribution of vaccine breakthrough due to waning immunity from the contribution due to the change in the dominant variant from alpha (B.1.1.7) to delta."
0,doi:10.1007/s10787-021-00915-7,B.1.617.2,A systematic literature search with no language restriction was performed in electronic databases to identify eligible observational studies that reported the effectiveness of the BNT162b2 mRNA vaccine to prevent reverse transcription-polymerase chain reaction (RT-PCR) confirmed COVID-19 caused by Delta variant of SARS-CoV-2 (B.1.617.2).
1,doi:10.1007/s10787-021-00915-7,B.1.1.7,2021) has reported that antibodies elicited by the BNT162b2 mRNA vaccine were efficacious against the Delta variant but about three- to five-fold less potent than they were against the alpha variant (B.1.1.7).
0,doi:10.1016/j.cmi.2021.11.010,B.1.617.2,"Highly effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed but variants of concerns are worrisome, especially B.1.617.2 (Delta) which has rapidly spread across the world."
1,doi:10.1016/j.cmi.2021.11.010,P.1,"Emerging variants of concern (VOCs), such as B.1.1.7 (Alpha in the World Health Organization classification), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) exhibit sequence changes and alteration of amino acid sequences of the spike protein."
2,doi:10.1016/j.cmi.2021.11.010,B.1.1.7,"Emerging variants of concern (VOCs), such as B.1.1.7 (Alpha in the World Health Organization classification), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) exhibit sequence changes and alteration of amino acid sequences of the spike protein."
3,doi:10.1016/j.cmi.2021.11.010,B.1.351,"Emerging variants of concern (VOCs), such as B.1.1.7 (Alpha in the World Health Organization classification), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) exhibit sequence changes and alteration of amino acid sequences of the spike protein."
0,doi:10.15585/mmwr.mm7037e1,B.1.617.2,"COVID-19 vaccine breakthrough infection surveillance helps monitor trends in disease incidence and severe outcomes in fully vaccinated persons, including the impact of the highly transmissible B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19."
0,doi:10.1371/journal.pbio.3001236,B.1.1.7,"It was found that the B.1.1.7 (also 501Y.V1) variant, first detected in the United Kingdom, could be serendipitously detected by the Thermo Fisher TaqPath COVID-19 PCR assay because a key deletion in these viruses, spike Δ69–70, would cause a “spike gene target failure” (SGTF) result."
1,doi:10.1371/journal.pbio.3001236,P.1,"However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern (VOC) that lack spike Δ69–70, such as B.1.351 (also 501Y.V2), detected in South Africa, and P.1 (also 501Y.V3), recently detected in Brazil."
2,doi:10.1371/journal.pbio.3001236,B.1.351,"However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern (VOC) that lack spike Δ69–70, such as B.1.351 (also 501Y.V2), detected in South Africa, and P.1 (also 501Y.V3), recently detected in Brazil."
3,doi:10.1371/journal.pbio.3001236,B.1.375,"The 6-nucleotide deletion in the spike gene at amino acid positions 69 and 70 (spike Δ69–70) that causes the TaqPath SGTF is also present in other SARS-CoV-2 lineages (Fig 1, S1 Table), most notably in Pango lineages B.1.258 detected throughout Europe and in B.1.375 detected primarily in the United States [9,10], meaning that SGTF results are not definitive for B.1.1.7."
4,doi:10.1371/journal.pbio.3001236,B.1.258,"The 6-nucleotide deletion in the spike gene at amino acid positions 69 and 70 (spike Δ69–70) that causes the TaqPath SGTF is also present in other SARS-CoV-2 lineages (Fig 1, S1 Table), most notably in Pango lineages B.1.258 detected throughout Europe and in B.1.375 detected primarily in the United States [9,10], meaning that SGTF results are not definitive for B.1.1.7."
5,doi:10.1371/journal.pbio.3001236,B.1.429,"Of the samples without both deletions (expected outcome = detection with all 3 primer/probe sets), 1.2% (6/481) were P.2 (variants of interest [VOI]), 2.1% (10/481) were B.1.427 (VOC), 4.2% (20/481) were B.1.429 (VOC), and 92.5% (445/481) were other lineages not of current interest (Fig 2A)."
6,doi:10.1371/journal.pbio.3001236,B.1.427,"Of the samples without both deletions (expected outcome = detection with all 3 primer/probe sets), 1.2% (6/481) were P.2 (variants of interest [VOI]), 2.1% (10/481) were B.1.427 (VOC), 4.2% (20/481) were B.1.429 (VOC), and 92.5% (445/481) were other lineages not of current interest (Fig 2A)."
7,doi:10.1371/journal.pbio.3001236,P.2,"Of the samples without both deletions (expected outcome = detection with all 3 primer/probe sets), 1.2% (6/481) were P.2 (variants of interest [VOI]), 2.1% (10/481) were B.1.427 (VOC), 4.2% (20/481) were B.1.429 (VOC), and 92.5% (445/481) were other lineages not of current interest (Fig 2A)."
8,doi:10.1371/journal.pbio.3001236,B.1.525,"Of the samples with both ORF1a Δ3675–3677 and spike Δ69–70 deletions (expected outcome = target failure with both the ORF1a and spike sets), 98.2% (595/606) were B.1.1.7 (VOC), 1.3% (8/606) were B.1.525 (VOI), and 0.5% (3/606) were other lineages not of current interest (Fig 2B)."
9,doi:10.1371/journal.pbio.3001236,B.1.526.1,"Of the samples with ORF1a Δ3675–3677, 11.5% (26/227) were B.1.351 (VOC), 9.3% (21/227) were P.1 (VOC), 70.9% (161/227) were B.1.526 (VOI; includes B.1.526.1 and B.1.526.2), and 8.4% (19/227) were other lineages not of current interest (Fig 2C)."
10,doi:10.1371/journal.pbio.3001236,B.1.526,"Of the samples with ORF1a Δ3675–3677, 11.5% (26/227) were B.1.351 (VOC), 9.3% (21/227) were P.1 (VOC), 70.9% (161/227) were B.1.526 (VOI; includes B.1.526.1 and B.1.526.2), and 8.4% (19/227) were other lineages not of current interest (Fig 2C)."
11,doi:10.1371/journal.pbio.3001236,B.1.526.2,"Of the samples with ORF1a Δ3675–3677, 11.5% (26/227) were B.1.351 (VOC), 9.3% (21/227) were P.1 (VOC), 70.9% (161/227) were B.1.526 (VOI; includes B.1.526.1 and B.1.526.2), and 8.4% (19/227) were other lineages not of current interest (Fig 2C)."
0,doi:10.15585/mmwr.mm7008e2,B.1.351,"As of January 10, 2021, eight countries had reported cases with the B.1.351 variant."
0,doi:10.1126/sciadv.abm0300,B.1.526,"Present address: Council of State and Territorial Epidemiologists, Atlanta, GA, USA..

To characterize the epidemiological properties of the B.1.526 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) variant of interest, here we used nine epidemiological and population datasets and model-inference methods to reconstruct SARS-CoV-2 transmission dynamics in New York City, where B.1.526 emerged."
1,doi:10.1126/sciadv.abm0300,B.1.1.7,"Last, we use findings from the first two model systems to estimate variant-specific infection fatality risk (IFR; i.e., the fraction of all persons with SARS-CoV-2 infection who died from the disease), for B.1.526 and B.1.1.7, separately."
2,doi:10.1126/sciadv.abm0300,B.1.429,"The vaccination model components vi,1A and vi,2A are also variant specific and can additionally account for the reduction in VE against the new variants if needed; however, here we used the same VE estimates for all variants included (i.e., B.1.526, B.1.1.7, B.1.427, and B.1.429) based on observations (4, 30, 35, 36)."
3,doi:10.1126/sciadv.abm0300,B.1.427,"The vaccination model components vi,1A and vi,2A are also variant specific and can additionally account for the reduction in VE against the new variants if needed; however, here we used the same VE estimates for all variants included (i.e., B.1.526, B.1.1.7, B.1.427, and B.1.429) based on observations (4, 30, 35, 36)."
0,doi:10.1016/j.micpath.2022.105404,B.1.1.7,"The significant predominance of the SARS-CoV-2 variant of concern (VOC), Delta (lineage B.1.617.2) identified in sixty-four (77.1%) cases in contrast to B.1 and its sublineage in eleven (13.2%), variant under monitoring (VUM), Kappa (lineage B.1.617.1) in five (6.0%) and another VOC Alpha (lineage B.1.1.7) in three (3.6%) cases respectively (p < 0.05, χ2 = 162.49)."
1,doi:10.1016/j.micpath.2022.105404,B.1,"The significant predominance of the SARS-CoV-2 variant of concern (VOC), Delta (lineage B.1.617.2) identified in sixty-four (77.1%) cases in contrast to B.1 and its sublineage in eleven (13.2%), variant under monitoring (VUM), Kappa (lineage B.1.617.1) in five (6.0%) and another VOC Alpha (lineage B.1.1.7) in three (3.6%) cases respectively (p < 0.05, χ2 = 162.49)."
2,doi:10.1016/j.micpath.2022.105404,B.1.617.1,"The significant predominance of the SARS-CoV-2 variant of concern (VOC), Delta (lineage B.1.617.2) identified in sixty-four (77.1%) cases in contrast to B.1 and its sublineage in eleven (13.2%), variant under monitoring (VUM), Kappa (lineage B.1.617.1) in five (6.0%) and another VOC Alpha (lineage B.1.1.7) in three (3.6%) cases respectively (p < 0.05, χ2 = 162.49)."
3,doi:10.1016/j.micpath.2022.105404,B.1.617.2,"The significant predominance of the SARS-CoV-2 variant of concern (VOC), Delta (lineage B.1.617.2) identified in sixty-four (77.1%) cases in contrast to B.1 and its sublineage in eleven (13.2%), variant under monitoring (VUM), Kappa (lineage B.1.617.1) in five (6.0%) and another VOC Alpha (lineage B.1.1.7) in three (3.6%) cases respectively (p < 0.05, χ2 = 162.49)."
4,doi:10.1016/j.micpath.2022.105404,P.1,"As per WHO information latest on 25th November 2021, SARS-CoV-2 variants along with their country of origin, namely Alpha (B.1.1.7), United Kingdom, Beta (B.1.351), South Africa, Gamma (P.1), Brazil, and Delta (B.1.617.2), India have been classified as VOC while Kappa (B.1.617.1) variant was reclassified from earlier Variant of Interest (VOI) on 4th April 2021 to Variant under Monitoring (VUM) on 20th September 2021 (Fig."
5,doi:10.1016/j.micpath.2022.105404,B.1.351,"As per WHO information latest on 25th November 2021, SARS-CoV-2 variants along with their country of origin, namely Alpha (B.1.1.7), United Kingdom, Beta (B.1.351), South Africa, Gamma (P.1), Brazil, and Delta (B.1.617.2), India have been classified as VOC while Kappa (B.1.617.1) variant was reclassified from earlier Variant of Interest (VOI) on 4th April 2021 to Variant under Monitoring (VUM) on 20th September 2021 (Fig."
6,doi:10.1016/j.micpath.2022.105404,B.1.617,"Delta variant lineage B.1.617.2 outpacing B.1.1.7 in Delhi and B.1.617 identification from Maharashtra have been reported [3,4]..

Chhattisgarh, one of the largest central states of India, was also severely affected by COVID-19 2nd wave, with majorly affected cities were Raipur (capital city of Chhattisgarh), Bhilai and Durg."
7,doi:10.1016/j.micpath.2022.105404,B.1.216,"Importantly, eleven (13.2%) sequences belonged to B.1 lineage, and on its sub-lineages analysis, two sequences belonged to B.1 whereas others nine belonged to B.1 sublineage (02- B.1.216, 01- B.1.1.306, 01- B.1.1.326, 01- B.1.36.10, 01- B.1.36.17 and 03- B.1.36.29)."
8,doi:10.1016/j.micpath.2022.105404,B.1.36.17,"Importantly, eleven (13.2%) sequences belonged to B.1 lineage, and on its sub-lineages analysis, two sequences belonged to B.1 whereas others nine belonged to B.1 sublineage (02- B.1.216, 01- B.1.1.306, 01- B.1.1.326, 01- B.1.36.10, 01- B.1.36.17 and 03- B.1.36.29)."
9,doi:10.1016/j.micpath.2022.105404,B.1.36.10,"Importantly, eleven (13.2%) sequences belonged to B.1 lineage, and on its sub-lineages analysis, two sequences belonged to B.1 whereas others nine belonged to B.1 sublineage (02- B.1.216, 01- B.1.1.306, 01- B.1.1.326, 01- B.1.36.10, 01- B.1.36.17 and 03- B.1.36.29)."
10,doi:10.1016/j.micpath.2022.105404,B.1.1.326,"Importantly, eleven (13.2%) sequences belonged to B.1 lineage, and on its sub-lineages analysis, two sequences belonged to B.1 whereas others nine belonged to B.1 sublineage (02- B.1.216, 01- B.1.1.306, 01- B.1.1.326, 01- B.1.36.10, 01- B.1.36.17 and 03- B.1.36.29)."
11,doi:10.1016/j.micpath.2022.105404,B.1.36.29,"Importantly, eleven (13.2%) sequences belonged to B.1 lineage, and on its sub-lineages analysis, two sequences belonged to B.1 whereas others nine belonged to B.1 sublineage (02- B.1.216, 01- B.1.1.306, 01- B.1.1.326, 01- B.1.36.10, 01- B.1.36.17 and 03- B.1.36.29)."
12,doi:10.1016/j.micpath.2022.105404,B.1.1.306,"Importantly, eleven (13.2%) sequences belonged to B.1 lineage, and on its sub-lineages analysis, two sequences belonged to B.1 whereas others nine belonged to B.1 sublineage (02- B.1.216, 01- B.1.1.306, 01- B.1.1.326, 01- B.1.36.10, 01- B.1.36.17 and 03- B.1.36.29)."
13,doi:10.1016/j.micpath.2022.105404,B.1.1.216,"4).Table 1Mutational pattern and GISAID allotted lineage of the eighty three sequences observed on alignment of spike region against reference Wuhan sequence.Table 1LineageMutationAccession numberClinical statusB.1.1.7 (3)H69del, V70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HEPI_ISL_1731751Vaccinated (1)EPI_ISL_2098713Dead (1)EPI_ISL_1914586Mild (1)B.1.617.2 (64)L452R, T478K, D614G, P681REPI_ISL_2307104, EPI_ISL_2620739Dead (2)EPI_ISL_1914588Mild (1)L452R, T478K, D614G, P681R, D950 NEPI_ISL_1914594, EPI_ISL_2620743Severe (2)T19R, L452R, T478K, D614G, P681R, D950 NEPI_ISL_2307110, EPI_ISL_2307123, EPI_ISL_2307126, EPI_ISL_2307134, EPI_ISL_2620742Dead (5)EPI_ISL_2307114, EPI_ISL_2307121, EPI_ISL_2307125, EPI_ISL_1914596Severe (4)EPI_ISL_2098720, EPI_ISL_1914597, EPI_ISL_1969753Mild (3)T19R, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950 NEPI_ISL_1731755, EPI_ISL_2307136Vaccinated (2)EPI_ISL_1914592, EPI_ISL_2307117, EPI_ISL_2307120Dead (3)EPI_ISL_1914584, EPI_ISL_1914593, EPI_ISL_1914595, EPI_ISL_2098714, EPI_ISL_2098716-19, EPI_ISL_2098721Mild (9)EPI_ISL_2307105, EPI_ISL_2307112-13, EPI_ISL_2307115, EPI_ISL_2307124, EPI_ISL_2307128Severe (6)T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950 NEPI_ISL_1731752-54, EPI_ISL_2307132-33, EPI_ISL_2307135Vaccinated (6)EPI_ISL_2307107, EPI_ISL_2620740, EPI_ISL_2620741, EPI_ISL_2307102, EPI_ISL_2307109, EPI_ISL_2307116, EPI_ISL_2307118, EPI_ISL_2307119, EPI_ISL_2307122, EPI_ISL_2307129, EPI_ISL_2307130, EPI_ISL_2307131Dead (12)EPI_ISL_1914591, EPI_ISL_1914598, EPI_ISL_2098715, EPI_ISL_2098722, EPI_ISL_2307108Mild (5)EPI_ISL_2620738, EPI_ISL_2098710-11, EPI_ISL_2307127Severe (4)B.1.617.1 (5)L452R, E484Q, D614G, P681REPI_ISL_1914585, EPI_ISL_1914587, EPI_ISL_1969752Mild (3)E154K, L452R, E484Q, D614G, P681R, Q1071HEPI_ISL_1914583Mild (1)G142D, E154K, L452R, E484Q, D614G, P681R, Q1071HEPI_ISL_1731757Mild (1)B.1 (2)D614GEPI_ISL_2307103Dead (1)D614G, P681R, D950 NEPI_ISL_2307106Dead (1)B.1.1.216 (3)D614GEPI_ISL_1731756Dead (1)EPI_ISL_1914579Mild (1)B.1.1.306 (1)D614GEPI_ISL_1914589Mild (1)B.1.1.326 (1)D614GEPI_ISL_2098711Severe (1)B.1.36.10 (1)D614GEPI_ISL_1914590Mild (1)B.1.36.17 (1)N440K, D614GEPI_ISL_1914580Mild (1)B.1.36.29 (2)N440K, D614GEPI_ISL_2098712Dead (1)N440K, D614GEPI_ISL_1914581, EPI_ISL_1914582Mild (2)Fig."
0,doi:10.1093/jtm/taac033,B.1,"Comparative analysis at one- and six-months post-vaccination showed modest reduction in S1-RBD IgG antibody and NAb titers against B.1, Alpha, Beta and Delta variants in heterologous and homologous vaccine recipients groups."
0,doi:10.1016/j.xcrm.2021.100255,P.1,"Individual mutations that escape binding by each antibody are combined in the circulating B.1.351 and P.1 SARS-CoV-2 lineages (E484K escapes LY-CoV555, K417N/T escapes LY-CoV016)."
1,doi:10.1016/j.xcrm.2021.100255,B.1.351,"Individual mutations that escape binding by each antibody are combined in the circulating B.1.351 and P.1 SARS-CoV-2 lineages (E484K escapes LY-CoV555, K417N/T escapes LY-CoV016)."
2,doi:10.1016/j.xcrm.2021.100255,B.1.429,"In addition, the L452R mutation in the B.1.429 lineage escapes LY-CoV555."
3,doi:10.1016/j.xcrm.2021.100255,B.1.1.7,"Lineages are described in the following references: B.1.1.7,11 B.1.351,10 P.1,12 and B.1.429.13."
0,doi:10.1021/acschembio.1c00756,B.1.1.7,"Here, we demonstrate that ARB binds to the spike
viral fusion glycoprotein of the SARS-CoV-2 Wuhan strain as well as its more virulent
variants from the United Kingdom (strain B.1.1.7) and South Africa (strain B.1.351)."
1,doi:10.1021/acschembio.1c00756,B.1.351,"Here, we demonstrate that ARB binds to the spike
viral fusion glycoprotein of the SARS-CoV-2 Wuhan strain as well as its more virulent
variants from the United Kingdom (strain B.1.1.7) and South Africa (strain B.1.351)."
0,doi:10.1016/s2468-2667(21)00133-x,B.1.1.7,"We did phylodynamic analyses to estimate the growth rate, doubling time, and number of days from the first local infection to the collection of the first sequenced genome for the dominant local cluster, and compared our growth estimates to previously published estimates from a similar growth phase of lineage B.1.1.7 (also known as the Alpha variant) in the UK.."
1,doi:10.1016/s2468-2667(21)00133-x,D.2,"Genomic analysis revealed that 10 426 cases, including 10 416 (98·4%) of 10 584 locally acquired cases, diagnosed during the second wave (between June and October, 2020) were derived from a single incursion from hotel quarantine, with the outbreak lineage (transmission network G, lineage D.2) rapidly detected in other Australian states and territories."
2,doi:10.1016/s2468-2667(21)00133-x,D.3,"Two further breaches of hotel quarantine occurred at a separate hotel in early June, resulting in 26 cases (transmission network E, lineage B.1.1.136) and 145 cases (transmission network F, lineage D.3), respectively (Figure 2, Figure 3)."
3,doi:10.1016/s2468-2667(21)00133-x,B.1.1.136,"Two further breaches of hotel quarantine occurred at a separate hotel in early June, resulting in 26 cases (transmission network E, lineage B.1.1.136) and 145 cases (transmission network F, lineage D.3), respectively (Figure 2, Figure 3)."
4,doi:10.1016/s2468-2667(21)00133-x,B.1.351,Regions of the phylogenetic tree containing B.1.1.7 and B.1.351 variants of concern are also labelled.
0,doi:10.1016/j.vacun.2021.06.003,P.1,"Entre las nuevas variantes que se han ido propagando se incluyen la Británica B.1.1.7 (20I/501Y.V1), la Sudafricana B.1.351 (20H/501.V2), la Brasileña P.1 (20J/501Y.V3), las Californianas B.1.427 y B.1.429 (20C/S:452R) y la más reciente, la India B.1.617 (VUI-21APR-01)..

El método de referencia para la identificación de las variantes es la secuenciación del genoma completo."
1,doi:10.1016/j.vacun.2021.06.003,B.1.1.7,"Entre las nuevas variantes que se han ido propagando se incluyen la Británica B.1.1.7 (20I/501Y.V1), la Sudafricana B.1.351 (20H/501.V2), la Brasileña P.1 (20J/501Y.V3), las Californianas B.1.427 y B.1.429 (20C/S:452R) y la más reciente, la India B.1.617 (VUI-21APR-01)..

El método de referencia para la identificación de las variantes es la secuenciación del genoma completo."
2,doi:10.1016/j.vacun.2021.06.003,B.1.617,"Entre las nuevas variantes que se han ido propagando se incluyen la Británica B.1.1.7 (20I/501Y.V1), la Sudafricana B.1.351 (20H/501.V2), la Brasileña P.1 (20J/501Y.V3), las Californianas B.1.427 y B.1.429 (20C/S:452R) y la más reciente, la India B.1.617 (VUI-21APR-01)..

El método de referencia para la identificación de las variantes es la secuenciación del genoma completo."
3,doi:10.1016/j.vacun.2021.06.003,B.1.429,"Entre las nuevas variantes que se han ido propagando se incluyen la Británica B.1.1.7 (20I/501Y.V1), la Sudafricana B.1.351 (20H/501.V2), la Brasileña P.1 (20J/501Y.V3), las Californianas B.1.427 y B.1.429 (20C/S:452R) y la más reciente, la India B.1.617 (VUI-21APR-01)..

El método de referencia para la identificación de las variantes es la secuenciación del genoma completo."
4,doi:10.1016/j.vacun.2021.06.003,B.1.427,"Entre las nuevas variantes que se han ido propagando se incluyen la Británica B.1.1.7 (20I/501Y.V1), la Sudafricana B.1.351 (20H/501.V2), la Brasileña P.1 (20J/501Y.V3), las Californianas B.1.427 y B.1.429 (20C/S:452R) y la más reciente, la India B.1.617 (VUI-21APR-01)..

El método de referencia para la identificación de las variantes es la secuenciación del genoma completo."
5,doi:10.1016/j.vacun.2021.06.003,B.1.351,"Entre las nuevas variantes que se han ido propagando se incluyen la Británica B.1.1.7 (20I/501Y.V1), la Sudafricana B.1.351 (20H/501.V2), la Brasileña P.1 (20J/501Y.V3), las Californianas B.1.427 y B.1.429 (20C/S:452R) y la más reciente, la India B.1.617 (VUI-21APR-01)..

El método de referencia para la identificación de las variantes es la secuenciación del genoma completo."
6,doi:10.1016/j.vacun.2021.06.003,B.1.617.1,"**También presente en B.1.617.1 y B.1.617.3..

Principales variantes de SARS-COV-2 actualmente circulantes7."
7,doi:10.1016/j.vacun.2021.06.003,B.1.526.1,"Ejemplos de variantes de interés son B.1.525 (20A/S:484K) B.1.526 (20C/S:484K), B.1.526.1 (20C), B.1.617 (20A), B.1.617.1 (20A/S:154K), B.1.617.2 (20A/S:478K), B.1.617.3 (20A) y P.2 (20J)7..

Variantes de preocupación (VOC) incluyen aquellas en las que existe evidencia de un aumento de la transmisibilidad, gravedad, disminución de la capacidad neutralizante de los anticuerpos naturales o generados tras la vacunación, reducción de la efectividad del tratamiento o fallos en los test de diagnóstico."
8,doi:10.1016/j.vacun.2021.06.003,B.1.526,"Ejemplos de variantes de interés son B.1.525 (20A/S:484K) B.1.526 (20C/S:484K), B.1.526.1 (20C), B.1.617 (20A), B.1.617.1 (20A/S:154K), B.1.617.2 (20A/S:478K), B.1.617.3 (20A) y P.2 (20J)7..

Variantes de preocupación (VOC) incluyen aquellas en las que existe evidencia de un aumento de la transmisibilidad, gravedad, disminución de la capacidad neutralizante de los anticuerpos naturales o generados tras la vacunación, reducción de la efectividad del tratamiento o fallos en los test de diagnóstico."
9,doi:10.1016/j.vacun.2021.06.003,B.1.525,"Ejemplos de variantes de interés son B.1.525 (20A/S:484K) B.1.526 (20C/S:484K), B.1.526.1 (20C), B.1.617 (20A), B.1.617.1 (20A/S:154K), B.1.617.2 (20A/S:478K), B.1.617.3 (20A) y P.2 (20J)7..

Variantes de preocupación (VOC) incluyen aquellas en las que existe evidencia de un aumento de la transmisibilidad, gravedad, disminución de la capacidad neutralizante de los anticuerpos naturales o generados tras la vacunación, reducción de la efectividad del tratamiento o fallos en los test de diagnóstico."
10,doi:10.1016/j.vacun.2021.06.003,B.1.617.3,"Ejemplos de variantes de interés son B.1.525 (20A/S:484K) B.1.526 (20C/S:484K), B.1.526.1 (20C), B.1.617 (20A), B.1.617.1 (20A/S:154K), B.1.617.2 (20A/S:478K), B.1.617.3 (20A) y P.2 (20J)7..

Variantes de preocupación (VOC) incluyen aquellas en las que existe evidencia de un aumento de la transmisibilidad, gravedad, disminución de la capacidad neutralizante de los anticuerpos naturales o generados tras la vacunación, reducción de la efectividad del tratamiento o fallos en los test de diagnóstico."
11,doi:10.1016/j.vacun.2021.06.003,P.2,"Ejemplos de variantes de interés son B.1.525 (20A/S:484K) B.1.526 (20C/S:484K), B.1.526.1 (20C), B.1.617 (20A), B.1.617.1 (20A/S:154K), B.1.617.2 (20A/S:478K), B.1.617.3 (20A) y P.2 (20J)7..

Variantes de preocupación (VOC) incluyen aquellas en las que existe evidencia de un aumento de la transmisibilidad, gravedad, disminución de la capacidad neutralizante de los anticuerpos naturales o generados tras la vacunación, reducción de la efectividad del tratamiento o fallos en los test de diagnóstico."
12,doi:10.1016/j.vacun.2021.06.003,B.1.617.2,"Ejemplos de variantes de interés son B.1.525 (20A/S:484K) B.1.526 (20C/S:484K), B.1.526.1 (20C), B.1.617 (20A), B.1.617.1 (20A/S:154K), B.1.617.2 (20A/S:478K), B.1.617.3 (20A) y P.2 (20J)7..

Variantes de preocupación (VOC) incluyen aquellas en las que existe evidencia de un aumento de la transmisibilidad, gravedad, disminución de la capacidad neutralizante de los anticuerpos naturales o generados tras la vacunación, reducción de la efectividad del tratamiento o fallos en los test de diagnóstico."
0,doi:10.1016/j.virusres.2022.198674,B.1.1.529,"Comparatively, very little attention had been directed towards spike insertion mutations prior to the emergence of the B.1.1.529 (omicron) lineage."
1,doi:10.1016/j.virusres.2022.198674,B.1.214.2,"Even though RIR1 is unlikely to confer antibody escape, its association with two distinct formerly widespread lineages (A.2.5 and B.1.214.2), with the quickly spreading omicron and with other VOCs and VOIs warrants further investigation concerning its effects on spike structure and viral infectivity..


AbbreviationsACE2angiotensin converting enzyme 2NTDN-terminal domainRBDreceptor binding domainRBMreceptor binding motifRGYRradius of gyrationRIR1recurrent insertion region 1RMSDroot mean square deviation of backbone beadsRMSFroot mean square fluctuationsRDRrecurrent deletion regionVOCvariant of concernVOIvariant of interest
."
2,doi:10.1016/j.virusres.2022.198674,A.2.5,"Even though RIR1 is unlikely to confer antibody escape, its association with two distinct formerly widespread lineages (A.2.5 and B.1.214.2), with the quickly spreading omicron and with other VOCs and VOIs warrants further investigation concerning its effects on spike structure and viral infectivity..


AbbreviationsACE2angiotensin converting enzyme 2NTDN-terminal domainRBDreceptor binding domainRBMreceptor binding motifRGYRradius of gyrationRIR1recurrent insertion region 1RMSDroot mean square deviation of backbone beadsRMSFroot mean square fluctuationsRDRrecurrent deletion regionVOCvariant of concernVOIvariant of interest
."
3,doi:10.1016/j.virusres.2022.198674,P.1,"B.1.351 (beta) and P.1 (gamma), were linked with major outbreaks in geographical regions with very high estimated seroprevalence, i.e."
4,doi:10.1016/j.virusres.2022.198674,B.1.617.2,"In the spring of 2021, the lineage B.1.617.2 (delta) was internationally recognized as the fourth VOC."
5,doi:10.1016/j.virusres.2022.198674,A.2.5.1,"In detail, all available sequenced genomes belonging to the lineage A.2.5, to the related sublineages A.2.5.1, A.2.5.2 and A.2.5.3, and to the sister lineage A.2.4 were downloaded, along with associated metadata."
6,doi:10.1016/j.virusres.2022.198674,A.2.5.3,"In detail, all available sequenced genomes belonging to the lineage A.2.5, to the related sublineages A.2.5.1, A.2.5.2 and A.2.5.3, and to the sister lineage A.2.4 were downloaded, along with associated metadata."
7,doi:10.1016/j.virusres.2022.198674,A.2.5.2,"In detail, all available sequenced genomes belonging to the lineage A.2.5, to the related sublineages A.2.5.1, A.2.5.2 and A.2.5.3, and to the sister lineage A.2.4 were downloaded, along with associated metadata."
8,doi:10.1016/j.virusres.2022.198674,A.2.4,"In detail, all available sequenced genomes belonging to the lineage A.2.5, to the related sublineages A.2.5.1, A.2.5.2 and A.2.5.3, and to the sister lineage A.2.4 were downloaded, along with associated metadata."
9,doi:10.1016/j.virusres.2022.198674,B.1.1.7,"2Table 1Summary of the 49 independent RIR1 insertions found in the SARS-CoV-2 genome, ordered by the earliest date of detection, as of January 5th, 2022.Table 1DesignationInsertionInsertion typeLineageGISAID entriesOther spike mutationsEarliest detectionLatest detection*I214:AKKNambiguous (codon 215 phase0/I)B1noneMar 5th, 2020Mar 5th, 2020II214:KLGPin-frame (codon 215 phase 0)B.1.1771E154K, A222V, D614GNov 13th, 2020Nov 13th, 2020III214:AAGout-of-frame (codon 215 phase I)A.2.51844L141del, G142del, V143del, D215Y, L452R, D614GNov 20th, 2020Nov 5th, 2021IV214:TDRin-frame (codon 215 phase 0)B.1.214.21228Q414K, N450K, D614G, T716INov 22nd, 2020Jun 28th, 2021V214:ANRNambiguous (codon 215 phase0/I)γ(P.1)12L18F, P26S, D138Y, K417T, E484K, N501Y, D614G, D1139H, V1176FDec 23rd, 2020Apr 5th, 2021VI214:KRIin-frame (codon 215 phase 0)B4V367F, E990ADec 28th, 2020Mar 15th, 2021VII214:AQERambiguous (codon 215 phase0/I)ε(B.1.429)2S13I, P26S, S98F, W152C, L452R, D614G, T1027IJan 15th, 2021Jan 18th, 2021VIII214:DLAambiguous (codon 215 phase0/I/II, codon 216 phase 0/I/II)B.1.25D614GJan 17th, 2021Feb 2nd, 2021IX214:QASin-frame (codon 215 phase 0)B.1.63945H69del, V70del, Y144del, M153T, T478K, E484K, D614G, T859N, D936YJan 19th, 2021Nov 4th, 2021X216:ADLambiguous (codon 216 phase I/II)B.1.21D614GJan 25th, 2021Jan 25th, 2021XI214:DRSout-of-frame (codon 215 phaseI/II)B.11D215N, V382L, D614G, M1237IFeb 1st, 2021Feb 1st, 2021XII214:KFHin-frame (codon 215 phase 0)α(B.1.1.7)3H69del, V70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HFeb 12th, 2021Feb 22nd, 2021XIII214:KAFKQin-frame (codon 215 phase 0)α(B.1.1.7)2H69del, V70del, Y144del, A262S, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HFeb 25th, 2021Feb 25th, 2021XIV214:ERout-of-frame (codon 215 phase II)α(B.1.1.7)1H69del, V70del, Y144del, D215G, N501Y, A570D, D614G, P681H, I712V, T716I, S982A, D1118HMar 11th, 2021Mar 11th, 2021XV214:NWAHWin-frame (codon 215 phase 0)B.1.5471T19I, T95I, H69del, V70del, D614G, E484A, A879T, T1027IMar 22nd, 2021Mar 22nd, 2021XVI214:APRambiguous (codon 215 phase0/I)α(B.1.1.7)1H69del, V70del, Y144del, A262S, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HMar 31st, 2021Mar 31st, 2021XVII213:KARout-of-frame (codon 213 phase II)B.1.1771A222V, A262S, P272L, D614G, P681H, M1229IApr 2nd, 2021Apr 2nd, 2021XVIII214:KLRSambiguous (codon 215 phase II, codon 216 phase 0)A.286T76I, D215S, N501T, F592S, H655YApr 23rd, 2021Jun 22nd, 2021XIX214:KGEin-frame (codon 215 phase 0)B.1.1.5191T732A, T478K, D614G, P681HApr 24th, 2021Apr 24th, 2021XX214:Win-frame (codon 215 phase 0)B.11T19I, F140del, P139del, L141del, G142del, V143del, Y144del, Y145del, I210del, L242del, A243del, L244del, T470N, S494P, D614G, H655Y, T859NMay 14th, 2021May 14th, 2021XXI216:QMRout-of-frame (codon 216 phase I)α(B.1.1.7)1L5F, S13I, H69del, V70del, Y144del, D215R, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HMay 25th, 2021May 25th, 2021XXII214:KLLIRGDin-frame (codon 215 phase 0)B.12Q14del, C15del, V16del, N17del, L18del, W64R, T95I, C136Y, N137del, L141del, G142del, V143del, W152R, I210del, G252V, T415A, N440T, E484K, D614G, H655Y, P681H, T859N, Q1011H, G1219CJun 4th, 2021Jun 4th, 2021XXIII213:KRLRout-of-frame (codon 213 phase II)B.1.11R214Q, D614G, E484DJun 6th, 2021Jun 6th, 2021XXIV214:EARambiguous (codon 215 phase I/II/III)δ(B.1.617.2)1T19R, N137K, G142D, E156G, F157del, R158del, L452R, T478K, E484Q, D614G,  P681R, D950NJun 8th, 2021Jun 8th, 2021XXV214:QCEEin-frame (codon 215 phase 0)B.1.2471P209S, A222V, T572IJul 15th, 2021Jul 15th, 2021XXVI214:ELCDambiguous (codon 215 phase I/II/III)δ(AY.12)1T19R, T95I, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NJul 17th, 2021Jul 17th, 2022XXVII214:NFGGGin-frame (codon 215 phase 0)δ(AY.4)2T19R, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NJul 22nd, 2021Jul 22nd, 2021XXVIII214:NESin-frame (codon 215 phase 0)δ(AY.16)1T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NJul 30th, 2021Jul 30th, 2021XXIX214:VPWIambiguous (codon 215 phase 0/I)δ(AY.4)9T19R, T95I, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R,V622F, D950NAug 4th, 2020Aug 21st, 2021XXX214:HSGin-frame (codon 215 phase 0)δ(AY.4)7T19R, T95I, D138H, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NAug 4th, 2021Aug 25st, 2021XXXI214:SYCTKSKCin-frame (codon 215 phase 0)η(B.1.525)1A67V, H69del, V70del, Y144del, E484K, D614G, A653V, N679del, Q677H, F888LAug 5th, 2021Aug 5th, 2021XXXII214:ESHambiguous (codon 215 phase 0/I/II)B.1.2401C15F, L141del, G142del, V143del,  Y144del, L242del, A243del, L244del, G446V, E484A, D614G, A688V, V1176FAug 6th, 2021Aug 6th, 2021XXXIII214:NFGin-frame (codon 215 phase 0)δ(AY.25)3T19R, S112L, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NAug 20th, 2021Sep 14th, 2021XXXIV214:DQAFout-of-frame (codon 214 phase II)δ(B.1.617.2)1T19R, G142D, E156G, F157del, R158del, A222V, V289I, L452R, T478K, D614G, P681R, D950NAug 21st, 2021Aug 21st, 2021XXXV214:EGAEambiguous (codon 215 phase 0/I/II)δ(AY.4)2T19R, T95I, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NSep 2nd, 2021Sep 2nd, 2021XXXVI214:RLRin-frame (codon 215 phase 0)δ(AY.3)2T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NSep 20th, 2021Sep 20th, 2021XXXVII214:GLKGout-of-frame (codon 215 phase I)δ(AY.101)1T19R, T95I, G142D, E156G, F157del,  R158del, L452R, T478K,D614G, P681R, D950NOct 1st, 2021Oct 1st, 2021XXXVIII215:EARout-of-frame (codon 215 phase II)δ(AY.4)1T19R, T95I, E156G, F157del, R158del, D215N, L452R, T478K, D614G, P681R, D950NOct 3rd, 2021Oct 3rd, 2021XXXIX214:RGGout-of-frame (codon 214 phase II)δ(AY.100)2T19R, T95I, G142D, E156G, F157del, R158del, N394S, D614G, P681R, D950NOct 19th, 2021Nov 8th, 2021XL214:VRRout-of-frame (codon 215 phase I)δ(AY.113)1T19R, G142D, E156G, F157del, R158del, D215H, L452R, D614G, P681R, D950NOct 26th, 2021Oct 26th, 2021XLI214:EPEambiguous (codon 215 phase 0/I/II)ο (BA.1)>140,000A67V, H69del,  V70del, T95I, G142D, V143del, Y144del, Y145del, N211del, L212I, G339D, S371L, S373P, S375F, G446S, S477N, T478K, E484A, Q493R,  G496S, Q498R, N501Y, Y505H,T547K, D614G, H655Y, P681H, N679K, N764K, N679K, D796Y, N856K, Q954H, N969K, L981FNov 8th, 2021Jan 2nd, 2022XLII214:ASPNout-of-frame (codon 215 phase I)α(B.1.1.7)1H69del, V70del, Y144del, L242del, A243del, L244del, G446V, E484K, Q498K, N501Y, A570D, D614G, P681H, T716I, W886L, S982A, D1118HNov 14th, 2021Nov 14th, 2021XLIII215:KGDambiguos (codon 215 phase II, codon 216 phase 0)δ(AY.4.2)1T19R,T95I,Y145H,E156G,F157del,R158del,G142D,A222V,L452R,T478K,D614G,P681R,D950NNov 18th, 2021Jan 3rd, 2021XLIV213:RWRout-of-frame (codon 213 phase II)δ(AY.4)2T19R, T95I, G142D, E156G, F157del,  R158del, L452R, T478K, D614G, P681R, D950NNov 19th, 2021Nov 22nd, 2021XLV215:AGSout-of-frame (codon 215 phase II)δ(AY.122)1T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NNov 29th, 2021Nov 29th, 2021XLVI215:GGDin-frame (codon 216 phase 0)δ(AY.25)5T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NDec 5th, 2021Dec 7th, 2021XLVII214:SRAin-frame (codon 215 phase 0)δ(AY.4.2.1)1T19R, V36F, T95I, G142D, Y145H, E156G, F157del, R158del, A222V, L452R, T478K, P681R, D614G, D950NDec 6th, 2021Dec 6th, 2021XLVIII214:AAVEout-of-frame (codon 215 phase I)δ(AY.4)1T19R, T95I, G142D, E156G, F157del, R158del, D215N, N282S, L452R, T478K, D614G, P681R, D950N, A1020SDec 9th, 2021Dec 9th, 2021XLIX213:SGin-frame (codon 214 phase 0)δ(AY.4)1T19R, T95I, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NDec 16th, 2021Dec 16th, 2021⁎as of January 5th, 2022.."
10,doi:10.1016/j.virusres.2022.198674,B.1.525,"2Table 1Summary of the 49 independent RIR1 insertions found in the SARS-CoV-2 genome, ordered by the earliest date of detection, as of January 5th, 2022.Table 1DesignationInsertionInsertion typeLineageGISAID entriesOther spike mutationsEarliest detectionLatest detection*I214:AKKNambiguous (codon 215 phase0/I)B1noneMar 5th, 2020Mar 5th, 2020II214:KLGPin-frame (codon 215 phase 0)B.1.1771E154K, A222V, D614GNov 13th, 2020Nov 13th, 2020III214:AAGout-of-frame (codon 215 phase I)A.2.51844L141del, G142del, V143del, D215Y, L452R, D614GNov 20th, 2020Nov 5th, 2021IV214:TDRin-frame (codon 215 phase 0)B.1.214.21228Q414K, N450K, D614G, T716INov 22nd, 2020Jun 28th, 2021V214:ANRNambiguous (codon 215 phase0/I)γ(P.1)12L18F, P26S, D138Y, K417T, E484K, N501Y, D614G, D1139H, V1176FDec 23rd, 2020Apr 5th, 2021VI214:KRIin-frame (codon 215 phase 0)B4V367F, E990ADec 28th, 2020Mar 15th, 2021VII214:AQERambiguous (codon 215 phase0/I)ε(B.1.429)2S13I, P26S, S98F, W152C, L452R, D614G, T1027IJan 15th, 2021Jan 18th, 2021VIII214:DLAambiguous (codon 215 phase0/I/II, codon 216 phase 0/I/II)B.1.25D614GJan 17th, 2021Feb 2nd, 2021IX214:QASin-frame (codon 215 phase 0)B.1.63945H69del, V70del, Y144del, M153T, T478K, E484K, D614G, T859N, D936YJan 19th, 2021Nov 4th, 2021X216:ADLambiguous (codon 216 phase I/II)B.1.21D614GJan 25th, 2021Jan 25th, 2021XI214:DRSout-of-frame (codon 215 phaseI/II)B.11D215N, V382L, D614G, M1237IFeb 1st, 2021Feb 1st, 2021XII214:KFHin-frame (codon 215 phase 0)α(B.1.1.7)3H69del, V70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HFeb 12th, 2021Feb 22nd, 2021XIII214:KAFKQin-frame (codon 215 phase 0)α(B.1.1.7)2H69del, V70del, Y144del, A262S, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HFeb 25th, 2021Feb 25th, 2021XIV214:ERout-of-frame (codon 215 phase II)α(B.1.1.7)1H69del, V70del, Y144del, D215G, N501Y, A570D, D614G, P681H, I712V, T716I, S982A, D1118HMar 11th, 2021Mar 11th, 2021XV214:NWAHWin-frame (codon 215 phase 0)B.1.5471T19I, T95I, H69del, V70del, D614G, E484A, A879T, T1027IMar 22nd, 2021Mar 22nd, 2021XVI214:APRambiguous (codon 215 phase0/I)α(B.1.1.7)1H69del, V70del, Y144del, A262S, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HMar 31st, 2021Mar 31st, 2021XVII213:KARout-of-frame (codon 213 phase II)B.1.1771A222V, A262S, P272L, D614G, P681H, M1229IApr 2nd, 2021Apr 2nd, 2021XVIII214:KLRSambiguous (codon 215 phase II, codon 216 phase 0)A.286T76I, D215S, N501T, F592S, H655YApr 23rd, 2021Jun 22nd, 2021XIX214:KGEin-frame (codon 215 phase 0)B.1.1.5191T732A, T478K, D614G, P681HApr 24th, 2021Apr 24th, 2021XX214:Win-frame (codon 215 phase 0)B.11T19I, F140del, P139del, L141del, G142del, V143del, Y144del, Y145del, I210del, L242del, A243del, L244del, T470N, S494P, D614G, H655Y, T859NMay 14th, 2021May 14th, 2021XXI216:QMRout-of-frame (codon 216 phase I)α(B.1.1.7)1L5F, S13I, H69del, V70del, Y144del, D215R, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HMay 25th, 2021May 25th, 2021XXII214:KLLIRGDin-frame (codon 215 phase 0)B.12Q14del, C15del, V16del, N17del, L18del, W64R, T95I, C136Y, N137del, L141del, G142del, V143del, W152R, I210del, G252V, T415A, N440T, E484K, D614G, H655Y, P681H, T859N, Q1011H, G1219CJun 4th, 2021Jun 4th, 2021XXIII213:KRLRout-of-frame (codon 213 phase II)B.1.11R214Q, D614G, E484DJun 6th, 2021Jun 6th, 2021XXIV214:EARambiguous (codon 215 phase I/II/III)δ(B.1.617.2)1T19R, N137K, G142D, E156G, F157del, R158del, L452R, T478K, E484Q, D614G,  P681R, D950NJun 8th, 2021Jun 8th, 2021XXV214:QCEEin-frame (codon 215 phase 0)B.1.2471P209S, A222V, T572IJul 15th, 2021Jul 15th, 2021XXVI214:ELCDambiguous (codon 215 phase I/II/III)δ(AY.12)1T19R, T95I, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NJul 17th, 2021Jul 17th, 2022XXVII214:NFGGGin-frame (codon 215 phase 0)δ(AY.4)2T19R, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NJul 22nd, 2021Jul 22nd, 2021XXVIII214:NESin-frame (codon 215 phase 0)δ(AY.16)1T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NJul 30th, 2021Jul 30th, 2021XXIX214:VPWIambiguous (codon 215 phase 0/I)δ(AY.4)9T19R, T95I, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R,V622F, D950NAug 4th, 2020Aug 21st, 2021XXX214:HSGin-frame (codon 215 phase 0)δ(AY.4)7T19R, T95I, D138H, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NAug 4th, 2021Aug 25st, 2021XXXI214:SYCTKSKCin-frame (codon 215 phase 0)η(B.1.525)1A67V, H69del, V70del, Y144del, E484K, D614G, A653V, N679del, Q677H, F888LAug 5th, 2021Aug 5th, 2021XXXII214:ESHambiguous (codon 215 phase 0/I/II)B.1.2401C15F, L141del, G142del, V143del,  Y144del, L242del, A243del, L244del, G446V, E484A, D614G, A688V, V1176FAug 6th, 2021Aug 6th, 2021XXXIII214:NFGin-frame (codon 215 phase 0)δ(AY.25)3T19R, S112L, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NAug 20th, 2021Sep 14th, 2021XXXIV214:DQAFout-of-frame (codon 214 phase II)δ(B.1.617.2)1T19R, G142D, E156G, F157del, R158del, A222V, V289I, L452R, T478K, D614G, P681R, D950NAug 21st, 2021Aug 21st, 2021XXXV214:EGAEambiguous (codon 215 phase 0/I/II)δ(AY.4)2T19R, T95I, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NSep 2nd, 2021Sep 2nd, 2021XXXVI214:RLRin-frame (codon 215 phase 0)δ(AY.3)2T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NSep 20th, 2021Sep 20th, 2021XXXVII214:GLKGout-of-frame (codon 215 phase I)δ(AY.101)1T19R, T95I, G142D, E156G, F157del,  R158del, L452R, T478K,D614G, P681R, D950NOct 1st, 2021Oct 1st, 2021XXXVIII215:EARout-of-frame (codon 215 phase II)δ(AY.4)1T19R, T95I, E156G, F157del, R158del, D215N, L452R, T478K, D614G, P681R, D950NOct 3rd, 2021Oct 3rd, 2021XXXIX214:RGGout-of-frame (codon 214 phase II)δ(AY.100)2T19R, T95I, G142D, E156G, F157del, R158del, N394S, D614G, P681R, D950NOct 19th, 2021Nov 8th, 2021XL214:VRRout-of-frame (codon 215 phase I)δ(AY.113)1T19R, G142D, E156G, F157del, R158del, D215H, L452R, D614G, P681R, D950NOct 26th, 2021Oct 26th, 2021XLI214:EPEambiguous (codon 215 phase 0/I/II)ο (BA.1)>140,000A67V, H69del,  V70del, T95I, G142D, V143del, Y144del, Y145del, N211del, L212I, G339D, S371L, S373P, S375F, G446S, S477N, T478K, E484A, Q493R,  G496S, Q498R, N501Y, Y505H,T547K, D614G, H655Y, P681H, N679K, N764K, N679K, D796Y, N856K, Q954H, N969K, L981FNov 8th, 2021Jan 2nd, 2022XLII214:ASPNout-of-frame (codon 215 phase I)α(B.1.1.7)1H69del, V70del, Y144del, L242del, A243del, L244del, G446V, E484K, Q498K, N501Y, A570D, D614G, P681H, T716I, W886L, S982A, D1118HNov 14th, 2021Nov 14th, 2021XLIII215:KGDambiguos (codon 215 phase II, codon 216 phase 0)δ(AY.4.2)1T19R,T95I,Y145H,E156G,F157del,R158del,G142D,A222V,L452R,T478K,D614G,P681R,D950NNov 18th, 2021Jan 3rd, 2021XLIV213:RWRout-of-frame (codon 213 phase II)δ(AY.4)2T19R, T95I, G142D, E156G, F157del,  R158del, L452R, T478K, D614G, P681R, D950NNov 19th, 2021Nov 22nd, 2021XLV215:AGSout-of-frame (codon 215 phase II)δ(AY.122)1T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NNov 29th, 2021Nov 29th, 2021XLVI215:GGDin-frame (codon 216 phase 0)δ(AY.25)5T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NDec 5th, 2021Dec 7th, 2021XLVII214:SRAin-frame (codon 215 phase 0)δ(AY.4.2.1)1T19R, V36F, T95I, G142D, Y145H, E156G, F157del, R158del, A222V, L452R, T478K, P681R, D614G, D950NDec 6th, 2021Dec 6th, 2021XLVIII214:AAVEout-of-frame (codon 215 phase I)δ(AY.4)1T19R, T95I, G142D, E156G, F157del, R158del, D215N, N282S, L452R, T478K, D614G, P681R, D950N, A1020SDec 9th, 2021Dec 9th, 2021XLIX213:SGin-frame (codon 214 phase 0)δ(AY.4)1T19R, T95I, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NDec 16th, 2021Dec 16th, 2021⁎as of January 5th, 2022.."
11,doi:10.1016/j.virusres.2022.198674,B.1.429,"2Table 1Summary of the 49 independent RIR1 insertions found in the SARS-CoV-2 genome, ordered by the earliest date of detection, as of January 5th, 2022.Table 1DesignationInsertionInsertion typeLineageGISAID entriesOther spike mutationsEarliest detectionLatest detection*I214:AKKNambiguous (codon 215 phase0/I)B1noneMar 5th, 2020Mar 5th, 2020II214:KLGPin-frame (codon 215 phase 0)B.1.1771E154K, A222V, D614GNov 13th, 2020Nov 13th, 2020III214:AAGout-of-frame (codon 215 phase I)A.2.51844L141del, G142del, V143del, D215Y, L452R, D614GNov 20th, 2020Nov 5th, 2021IV214:TDRin-frame (codon 215 phase 0)B.1.214.21228Q414K, N450K, D614G, T716INov 22nd, 2020Jun 28th, 2021V214:ANRNambiguous (codon 215 phase0/I)γ(P.1)12L18F, P26S, D138Y, K417T, E484K, N501Y, D614G, D1139H, V1176FDec 23rd, 2020Apr 5th, 2021VI214:KRIin-frame (codon 215 phase 0)B4V367F, E990ADec 28th, 2020Mar 15th, 2021VII214:AQERambiguous (codon 215 phase0/I)ε(B.1.429)2S13I, P26S, S98F, W152C, L452R, D614G, T1027IJan 15th, 2021Jan 18th, 2021VIII214:DLAambiguous (codon 215 phase0/I/II, codon 216 phase 0/I/II)B.1.25D614GJan 17th, 2021Feb 2nd, 2021IX214:QASin-frame (codon 215 phase 0)B.1.63945H69del, V70del, Y144del, M153T, T478K, E484K, D614G, T859N, D936YJan 19th, 2021Nov 4th, 2021X216:ADLambiguous (codon 216 phase I/II)B.1.21D614GJan 25th, 2021Jan 25th, 2021XI214:DRSout-of-frame (codon 215 phaseI/II)B.11D215N, V382L, D614G, M1237IFeb 1st, 2021Feb 1st, 2021XII214:KFHin-frame (codon 215 phase 0)α(B.1.1.7)3H69del, V70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HFeb 12th, 2021Feb 22nd, 2021XIII214:KAFKQin-frame (codon 215 phase 0)α(B.1.1.7)2H69del, V70del, Y144del, A262S, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HFeb 25th, 2021Feb 25th, 2021XIV214:ERout-of-frame (codon 215 phase II)α(B.1.1.7)1H69del, V70del, Y144del, D215G, N501Y, A570D, D614G, P681H, I712V, T716I, S982A, D1118HMar 11th, 2021Mar 11th, 2021XV214:NWAHWin-frame (codon 215 phase 0)B.1.5471T19I, T95I, H69del, V70del, D614G, E484A, A879T, T1027IMar 22nd, 2021Mar 22nd, 2021XVI214:APRambiguous (codon 215 phase0/I)α(B.1.1.7)1H69del, V70del, Y144del, A262S, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HMar 31st, 2021Mar 31st, 2021XVII213:KARout-of-frame (codon 213 phase II)B.1.1771A222V, A262S, P272L, D614G, P681H, M1229IApr 2nd, 2021Apr 2nd, 2021XVIII214:KLRSambiguous (codon 215 phase II, codon 216 phase 0)A.286T76I, D215S, N501T, F592S, H655YApr 23rd, 2021Jun 22nd, 2021XIX214:KGEin-frame (codon 215 phase 0)B.1.1.5191T732A, T478K, D614G, P681HApr 24th, 2021Apr 24th, 2021XX214:Win-frame (codon 215 phase 0)B.11T19I, F140del, P139del, L141del, G142del, V143del, Y144del, Y145del, I210del, L242del, A243del, L244del, T470N, S494P, D614G, H655Y, T859NMay 14th, 2021May 14th, 2021XXI216:QMRout-of-frame (codon 216 phase I)α(B.1.1.7)1L5F, S13I, H69del, V70del, Y144del, D215R, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, D1118HMay 25th, 2021May 25th, 2021XXII214:KLLIRGDin-frame (codon 215 phase 0)B.12Q14del, C15del, V16del, N17del, L18del, W64R, T95I, C136Y, N137del, L141del, G142del, V143del, W152R, I210del, G252V, T415A, N440T, E484K, D614G, H655Y, P681H, T859N, Q1011H, G1219CJun 4th, 2021Jun 4th, 2021XXIII213:KRLRout-of-frame (codon 213 phase II)B.1.11R214Q, D614G, E484DJun 6th, 2021Jun 6th, 2021XXIV214:EARambiguous (codon 215 phase I/II/III)δ(B.1.617.2)1T19R, N137K, G142D, E156G, F157del, R158del, L452R, T478K, E484Q, D614G,  P681R, D950NJun 8th, 2021Jun 8th, 2021XXV214:QCEEin-frame (codon 215 phase 0)B.1.2471P209S, A222V, T572IJul 15th, 2021Jul 15th, 2021XXVI214:ELCDambiguous (codon 215 phase I/II/III)δ(AY.12)1T19R, T95I, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NJul 17th, 2021Jul 17th, 2022XXVII214:NFGGGin-frame (codon 215 phase 0)δ(AY.4)2T19R, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NJul 22nd, 2021Jul 22nd, 2021XXVIII214:NESin-frame (codon 215 phase 0)δ(AY.16)1T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NJul 30th, 2021Jul 30th, 2021XXIX214:VPWIambiguous (codon 215 phase 0/I)δ(AY.4)9T19R, T95I, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R,V622F, D950NAug 4th, 2020Aug 21st, 2021XXX214:HSGin-frame (codon 215 phase 0)δ(AY.4)7T19R, T95I, D138H, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NAug 4th, 2021Aug 25st, 2021XXXI214:SYCTKSKCin-frame (codon 215 phase 0)η(B.1.525)1A67V, H69del, V70del, Y144del, E484K, D614G, A653V, N679del, Q677H, F888LAug 5th, 2021Aug 5th, 2021XXXII214:ESHambiguous (codon 215 phase 0/I/II)B.1.2401C15F, L141del, G142del, V143del,  Y144del, L242del, A243del, L244del, G446V, E484A, D614G, A688V, V1176FAug 6th, 2021Aug 6th, 2021XXXIII214:NFGin-frame (codon 215 phase 0)δ(AY.25)3T19R, S112L, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NAug 20th, 2021Sep 14th, 2021XXXIV214:DQAFout-of-frame (codon 214 phase II)δ(B.1.617.2)1T19R, G142D, E156G, F157del, R158del, A222V, V289I, L452R, T478K, D614G, P681R, D950NAug 21st, 2021Aug 21st, 2021XXXV214:EGAEambiguous (codon 215 phase 0/I/II)δ(AY.4)2T19R, T95I, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NSep 2nd, 2021Sep 2nd, 2021XXXVI214:RLRin-frame (codon 215 phase 0)δ(AY.3)2T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NSep 20th, 2021Sep 20th, 2021XXXVII214:GLKGout-of-frame (codon 215 phase I)δ(AY.101)1T19R, T95I, G142D, E156G, F157del,  R158del, L452R, T478K,D614G, P681R, D950NOct 1st, 2021Oct 1st, 2021XXXVIII215:EARout-of-frame (codon 215 phase II)δ(AY.4)1T19R, T95I, E156G, F157del, R158del, D215N, L452R, T478K, D614G, P681R, D950NOct 3rd, 2021Oct 3rd, 2021XXXIX214:RGGout-of-frame (codon 214 phase II)δ(AY.100)2T19R, T95I, G142D, E156G, F157del, R158del, N394S, D614G, P681R, D950NOct 19th, 2021Nov 8th, 2021XL214:VRRout-of-frame (codon 215 phase I)δ(AY.113)1T19R, G142D, E156G, F157del, R158del, D215H, L452R, D614G, P681R, D950NOct 26th, 2021Oct 26th, 2021XLI214:EPEambiguous (codon 215 phase 0/I/II)ο (BA.1)>140,000A67V, H69del,  V70del, T95I, G142D, V143del, Y144del, Y145del, N211del, L212I, G339D, S371L, S373P, S375F, G446S, S477N, T478K, E484A, Q493R,  G496S, Q498R, N501Y, Y505H,T547K, D614G, H655Y, P681H, N679K, N764K, N679K, D796Y, N856K, Q954H, N969K, L981FNov 8th, 2021Jan 2nd, 2022XLII214:ASPNout-of-frame (codon 215 phase I)α(B.1.1.7)1H69del, V70del, Y144del, L242del, A243del, L244del, G446V, E484K, Q498K, N501Y, A570D, D614G, P681H, T716I, W886L, S982A, D1118HNov 14th, 2021Nov 14th, 2021XLIII215:KGDambiguos (codon 215 phase II, codon 216 phase 0)δ(AY.4.2)1T19R,T95I,Y145H,E156G,F157del,R158del,G142D,A222V,L452R,T478K,D614G,P681R,D950NNov 18th, 2021Jan 3rd, 2021XLIV213:RWRout-of-frame (codon 213 phase II)δ(AY.4)2T19R, T95I, G142D, E156G, F157del,  R158del, L452R, T478K, D614G, P681R, D950NNov 19th, 2021Nov 22nd, 2021XLV215:AGSout-of-frame (codon 215 phase II)δ(AY.122)1T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NNov 29th, 2021Nov 29th, 2021XLVI215:GGDin-frame (codon 216 phase 0)δ(AY.25)5T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NDec 5th, 2021Dec 7th, 2021XLVII214:SRAin-frame (codon 215 phase 0)δ(AY.4.2.1)1T19R, V36F, T95I, G142D, Y145H, E156G, F157del, R158del, A222V, L452R, T478K, P681R, D614G, D950NDec 6th, 2021Dec 6th, 2021XLVIII214:AAVEout-of-frame (codon 215 phase I)δ(AY.4)1T19R, T95I, G142D, E156G, F157del, R158del, D215N, N282S, L452R, T478K, D614G, P681R, D950N, A1020SDec 9th, 2021Dec 9th, 2021XLIX213:SGin-frame (codon 214 phase 0)δ(AY.4)1T19R, T95I, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950NDec 16th, 2021Dec 16th, 2021⁎as of January 5th, 2022.."
12,doi:10.1016/j.virusres.2022.198674,B.1.639,"This is the case of insertion IX (lineage B.1.639), which is characterized by the contemporary presence of E484K, T478K and by the deletions Δ69/70 (found in RDR1) and Δ144 (found in RDR2), which are shared by several VOCs and VOIs."
13,doi:10.1016/j.virusres.2022.198674,A.23.1,"∼33 vs ∼25)..

A.2.5 belongs to one of the very few surviving children lineages of the ancestral lineage A, which, after several months of limited global spread, has led to a few major clusters of infections in 2021, such as the one which involved A.23.1 in Uganda (Bugembe et al., 2021)."
0,doi:10.3390/microorganisms9020454,B.1.5,"All the known major lineages were found in this set of samples, though B.1 and B.1.5 were the most frequent ones, accounting for more than 60% of the sequences."
1,doi:10.3390/microorganisms9020454,B.1,"All the known major lineages were found in this set of samples, though B.1 and B.1.5 were the most frequent ones, accounting for more than 60% of the sequences."
2,doi:10.3390/microorganisms9020454,A.5,"The most frequent sublineages were A.2 and A.5 for lineage A, and B.1, B.1.1 and B.1.5 for lineage B."
3,doi:10.3390/microorganisms9020454,A.2,"The most frequent sublineages were A.2 and A.5 for lineage A, and B.1, B.1.1 and B.1.5 for lineage B."
4,doi:10.3390/microorganisms9020454,B.1.1,"The most frequent sublineages were A.2 and A.5 for lineage A, and B.1, B.1.1 and B.1.5 for lineage B."
0,doi:10.1080/22221751.2021.2017757,B.1.1.529,"However, on 24 November 2021, a new SARS-CoV-2 variant B.1.1.529/BA.1 was reported, which caused a great disturbance all over the world [1]."
0,doi:10.15585/mmwr.mm7034e5,B.1.617.2,"During May 1–July 25, the percentages of B.1.617.2 (Delta) variant infections estimated from 6,752 samples with lineage data increased among fully vaccinated persons (from 8.6% to 91.2%), partially vaccinated persons (from 0% to 88.1%), and unvaccinated persons (from 8.2% to 87.1%)."
0,doi:10.1002/jmv.27394,B.1.1.7,"In this study, we analyzed SARS‐CoV‐2 infections in two healthcare workers (HCWs) fully vaccinated with the Pfizer‐BioNTech COVID‐19 vaccine (BNT162b2) and subsequently diagnosed with postvaccination SARS‐CoV‐2 on a background of IgG antibodies..

Epidemiological and clinical data including, symptoms initial analysis and observations were obtained from the National electronic system for COVID‐19 (Table 1)..

SARS‐CoV‐2 Alpha (B.1.1.7) postvaccination infections among two healthcare workers, March 08–18, 2021."
0,doi:10.3390/v13122434,B.1.351,"Here, we found that the propagation of a B.1.351 SARS-CoV-2 stock on Calu-3 cells eliminated viruses that previously accumulated mutations in the furin cleavage site."
1,doi:10.3390/v13122434,B.1.617.2,Future studies will need to evaluate whether other SARS-CoV-2 lineage variants (such as B.1.617.2) would acquire the same nucleotide variants when grown on Calu-3 cells or whether the nucleotide variants described here are restricted to the B.1.351 lineage..
0,doi:10.3389/fimmu.2021.789905,B.1.617.2,"Importantly, the immunized sera exhibit sustained neutralizing efficacy against multiple dominant SARS-CoV-2 variant strains, including B.1.617.2 that carries a point mutation (SL452R) within the sequence of RBD9.1."
1,doi:10.3389/fimmu.2021.789905,P.1,"Consequently, mutations in the RBD, such as SE484K/Q shared by P.1, B.1.351, B.1.617.1, and B.1.617.2, or SL452R presented in B.1.617.1 and B.1.617.2, may cause allosteric alterations within the Angiotensin-converting enzyme 2 (ACE2)-binding surface and consequently compromise the immune protection from vaccination (2, 18–20)."
2,doi:10.3389/fimmu.2021.789905,B.1.617.1,"Consequently, mutations in the RBD, such as SE484K/Q shared by P.1, B.1.351, B.1.617.1, and B.1.617.2, or SL452R presented in B.1.617.1 and B.1.617.2, may cause allosteric alterations within the Angiotensin-converting enzyme 2 (ACE2)-binding surface and consequently compromise the immune protection from vaccination (2, 18–20)."
3,doi:10.3389/fimmu.2021.789905,B.1.351,"Consequently, mutations in the RBD, such as SE484K/Q shared by P.1, B.1.351, B.1.617.1, and B.1.617.2, or SL452R presented in B.1.617.1 and B.1.617.2, may cause allosteric alterations within the Angiotensin-converting enzyme 2 (ACE2)-binding surface and consequently compromise the immune protection from vaccination (2, 18–20)."
4,doi:10.3389/fimmu.2021.789905,B.1.1.7,"Pseudovirus neutralization curves for SARS-CoV-2 (wild-type), B.1.1.7, P.1, B.1.351, B.1.617.1, and B.1.617.2 strains by mouse sera taken 10 days following the last dose of the RBD (C, D) and the RBD9.1 (E, F) vaccines."
5,doi:10.3389/fimmu.2021.789905,B.1.617,"Coincidentally, with B.1.617 and B.1.617.2 containing a close point mutation (SL452R) in the RBD9.1 region, the immunized sera still exhibited effective neutralizing potency that was comparative to the wide type of the virus."
0,doi:10.1080/22221751.2022.2044271,B.1.1.529,"The immunity potency upon natural infection or vaccination is the main concern for the vaccine strategy of severe acute respiratory syndrome coronavirus 2 (SARS COV-2 variant), especially the recently reported Omicron variant (B.1.1.529)."
0,doi:10.1016/j.tmaid.2021.102210,B.1.1.214,"We also analyzed the statistics on the person-nights of travelers in the island of Hokkaido from the Greater Tokyo Area in 2019 versus 2020..

At least eight sub-lineages belonging to the B.1.1.214 lineage were introduced to the island of Hokkaido from the island of Honshu, the mainland of Japan from late July to November 2020, during the governmental travel promotion program."
1,doi:10.1016/j.tmaid.2021.102210,B.1.1.284,"These reports define the mobility changes for the following six categories, that is, Retail and recreation, Grocery and pharmacy, Parks, Transit stations, Workplaces, Residential, as compared to the baseline defined as the median mobility in January 2020 before the start of the global pandemic of COVID-19..

Our previous work and other work on the genome sequence of SARS-CoV-2 obtained from Japan showed that most, if not all, of the lineages observed between June and November 2020 were the B.1.1.284 or B.1.1.214 lineages, both of which have been observed almost exclusively in Japan [11,16]."
2,doi:10.1016/j.tmaid.2021.102210,B.1.214,Further analysis of the metadata of B.1.1.284 and B.1.214 from Hokkaido alone and all Japan showed that the B.1.1.284 lineage was the most prevalent lineage during the late summer of 2020 and the B.1.1.214 lineage became more prevalent after October 2020 (Fig.
0,doi:10.1016/s2468-2667(21)00055-4,B.1.1.7,"The SARS-CoV-2 variant B.1.1.7 was first identified in December, 2020, in England."
0,doi:10.1016/j.vaccine.2021.11.083,B.1.617.2,"The neutralizing activities in a subset of serum samples were tested against the wild type and variants of concern (B.1.1.7, B.1.617.2, and B.1.351) using an enzyme-linked immunosorbent assay-based surrogate virus neutralization test."
1,doi:10.1016/j.vaccine.2021.11.083,B.1.1.7,"The neutralizing activities in a subset of serum samples were tested against the wild type and variants of concern (B.1.1.7, B.1.617.2, and B.1.351) using an enzyme-linked immunosorbent assay-based surrogate virus neutralization test."
2,doi:10.1016/j.vaccine.2021.11.083,B.1.351,"The neutralizing activities in a subset of serum samples were tested against the wild type and variants of concern (B.1.1.7, B.1.617.2, and B.1.351) using an enzyme-linked immunosorbent assay-based surrogate virus neutralization test."
0,doi:10.1093/infdis/jiab283,B.1.1.7,Frequencies of B.1.1.7 increased from <1% in November 2020 to 82% of subjects in January 2021.
1,doi:10.1093/infdis/jiab283,P.1,"A variant of SARS-CoV-2 with a D614G mutation in the spike protein has been described [12, 13], along with more recent mutants such as B.1.1.7 in the UK, B.1.351 in South Africa [14], and P.1 in Brazil [15], all potentially more transmissible [16–18]; furthermore, B.1.1.7 may result in a higher mortality than the original pandemic strain [19, 20]."
2,doi:10.1093/infdis/jiab283,B.1.351,"A variant of SARS-CoV-2 with a D614G mutation in the spike protein has been described [12, 13], along with more recent mutants such as B.1.1.7 in the UK, B.1.351 in South Africa [14], and P.1 in Brazil [15], all potentially more transmissible [16–18]; furthermore, B.1.1.7 may result in a higher mortality than the original pandemic strain [19, 20]."
0,doi:10.1038/s41598-021-04440-z,B.1.617.2,"However, the imposition of the delta variant (B.1.617.2 lineage) in late summer 2021 may have expanded the range of R0 to 4.02–8.96 and pushed the upper bound of the HIT to 90%..

On 11 March 2020, the World Health Organization declared the COVID-19 pandemic, and by 11 March 2021, 2.63 million people had died because of it1."
1,doi:10.1038/s41598-021-04440-z,B.1.1.7,"For example, the B.1.1.7 lineage (also known as alpha variant), which was first detected in England in September 202042, and thereafter rapidly spread around the world."
2,doi:10.1038/s41598-021-04440-z,P.1,"However, either because the percentage of infected population was not accurately estimated or because the new SARS-CoV-2 P.1 variant was capable of re-infecting, Manaus had a second wave in January 2021 with a higher mortality rate than in the first one49."
0,doi:10.1007/s00395-021-00882-8,B.1.1.7,"Infection with the SARS-CoV-2 variants B.1.1.7, B.1.351, and P.2 resulted in significantly higher levels of viral spike protein."
1,doi:10.1007/s00395-021-00882-8,B.1.351,"Infection with the SARS-CoV-2 variants B.1.1.7, B.1.351, and P.2 resulted in significantly higher levels of viral spike protein."
2,doi:10.1007/s00395-021-00882-8,P.2,"Infection with the SARS-CoV-2 variants B.1.1.7, B.1.351, and P.2 resulted in significantly higher levels of viral spike protein."
0,doi:10.1021/acs.jcim.1c01451,B.1.1.529,"The latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron
(B.1.1.529) has ushered panic responses around the world due to its contagious and
vaccine escape mutations."
0,doi:10.1016/s1473-3099(22)00001-9,B.1.1.529,"In May, 2021, the delta (B.1.617.2) SARS-CoV-2 variant became dominant in the UK, superseded by the omicron (B.1.1.529) variant in December, 2021."
1,doi:10.1016/s1473-3099(22)00001-9,B.1.617.2,"In May, 2021, the delta (B.1.617.2) SARS-CoV-2 variant became dominant in the UK, superseded by the omicron (B.1.1.529) variant in December, 2021."
2,doi:10.1016/s1473-3099(22)00001-9,B.1.1.7,"In May, 2021, the delta (B.1.617.2) SARS-CoV-2 variant became dominant in the UK1 and globally.2 This variant presents a higher risk of severe disease compared with previous variants,2, 3 although vaccination is still protective.4 The delta variant led to an increase in the growth rate of COVID-19 cases in the UK, outcompeting other variants.1, 5 This growth was attributed to increased transmissibility, with a study5 suggesting that the delta variant was 43–68% more transmissible5 than the alpha (B.1.1.7) variant, which was first identified in a sample from September, 2020.6
."
0,doi:10.1007/s11030-022-10405-9,B.1.617.2,"In India, during the second wave of the COVID-19 pandemic, the breakthrough infections were mainly caused by the SARS-COV-2 delta variant (B.1.617.2)."
0,doi:10.1038/s41392-022-00912-4,P.1,"Using pseudovirion-based and trans-complementation SARS-CoV-2 tools, we determine that the Nb1–Nb2 broadly neutralizes multiple SARS-CoV-2 variants at sub-nanomolar levels, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37), Kappa (B.1.617.1), and Mu (B.1.621)."
1,doi:10.1038/s41392-022-00912-4,B.1.1.7,"Using pseudovirion-based and trans-complementation SARS-CoV-2 tools, we determine that the Nb1–Nb2 broadly neutralizes multiple SARS-CoV-2 variants at sub-nanomolar levels, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37), Kappa (B.1.617.1), and Mu (B.1.621)."
2,doi:10.1038/s41392-022-00912-4,C.37,"Using pseudovirion-based and trans-complementation SARS-CoV-2 tools, we determine that the Nb1–Nb2 broadly neutralizes multiple SARS-CoV-2 variants at sub-nanomolar levels, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37), Kappa (B.1.617.1), and Mu (B.1.621)."
3,doi:10.1038/s41392-022-00912-4,B.1.617.2,"Using pseudovirion-based and trans-complementation SARS-CoV-2 tools, we determine that the Nb1–Nb2 broadly neutralizes multiple SARS-CoV-2 variants at sub-nanomolar levels, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37), Kappa (B.1.617.1), and Mu (B.1.621)."
4,doi:10.1038/s41392-022-00912-4,B.1.617.1,"Using pseudovirion-based and trans-complementation SARS-CoV-2 tools, we determine that the Nb1–Nb2 broadly neutralizes multiple SARS-CoV-2 variants at sub-nanomolar levels, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37), Kappa (B.1.617.1), and Mu (B.1.621)."
5,doi:10.1038/s41392-022-00912-4,B.1.351,"Using pseudovirion-based and trans-complementation SARS-CoV-2 tools, we determine that the Nb1–Nb2 broadly neutralizes multiple SARS-CoV-2 variants at sub-nanomolar levels, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37), Kappa (B.1.617.1), and Mu (B.1.621)."
6,doi:10.1038/s41392-022-00912-4,B.1.621,"Using pseudovirion-based and trans-complementation SARS-CoV-2 tools, we determine that the Nb1–Nb2 broadly neutralizes multiple SARS-CoV-2 variants at sub-nanomolar levels, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37), Kappa (B.1.617.1), and Mu (B.1.621)."
7,doi:10.1038/s41392-022-00912-4,B.1.1.529,"For the new Omicron variant (B.1.1.529) that harbors unprecedented multiple RBD mutations, Nb1–Nb2-Fc keeps a firm affinity (KD < 1.0 × 10−12 M) and strong neutralizing activity (IC50 = 1.46 nM for authentic Omicron virus)."
8,doi:10.1038/s41392-022-00912-4,B.1.617,"To isolate Nbs with potential neutralization breadth, recombinant RBD antigens from strains P.1 (isolated from Brazil) and B.1.617 (isolated from India) were used to screen a fully synthetic and highly diversified Nb phage display library.30 After four rounds of reciprocal biopanning and phage ELISA, a panel of Nb binders was obtained."
9,doi:10.1038/s41392-022-00912-4,B.1.341,"To evaluate the neutralization breadth of these discovered Nbs, Spike-pseudotyped particle infection assay from four SARS-CoV-2 variants (B.1.1.7, B.1.341, P.1, and B.1.617) was performed."
0,doi:10.1016/j.jaut.2021.102779,B.1.1.529,A new Variant of Concern (VOC) named the Omicron variant (B.1.1.529) was reported recently.
1,doi:10.1016/j.jaut.2021.102779,P.1,Phylogenetic analysis showed that the Omicron is closely related to the Gamma (P.1) variant.
0,doi:10.3390/jcm11010030,B.1.1.529,"The world identified the rapidly increasing incidence of the causative variant of SARS-CoV-2 Pangolin B.1.1.529 in the Gauteng province, South Africa."
0,doi:10.3346/jkms.2022.37.e70,B.1.1.529,Concerns about the effectiveness of current vaccines against the rapidly spreading severe acute respiratory syndrome-coronavirus-2 omicron (B.1.1.529) variant are increasing.
0,doi:10.15585/mmwr.mm7036a3,B.1.617.2,"However, this study was conducted before the B.1.617.2 (Delta) variant became the dominant strain of SARS-CoV-2 in the United States, which could have affected these findings given that the Delta variant has been found to be associated with increased transmissibility compared to previous variants.."
0,doi:10.1101/2021.02.23.21252268,P.1,"The emergence and rapid rise in prevalence of three independent SARS-CoV-2 “501Y lineages”, B.1.1.7, B.1.351 and P.1, in the last three months of 2020 prompted renewed concerns about the evolutionary capacity of SARS-CoV-2 to adapt to both rising population immunity, and public health interventions such as vaccines and social distancing."
1,doi:10.1101/2021.02.23.21252268,B.1.1.7,"The emergence and rapid rise in prevalence of three independent SARS-CoV-2 “501Y lineages”, B.1.1.7, B.1.351 and P.1, in the last three months of 2020 prompted renewed concerns about the evolutionary capacity of SARS-CoV-2 to adapt to both rising population immunity, and public health interventions such as vaccines and social distancing."
2,doi:10.1101/2021.02.23.21252268,B.1.351,"The emergence and rapid rise in prevalence of three independent SARS-CoV-2 “501Y lineages”, B.1.1.7, B.1.351 and P.1, in the last three months of 2020 prompted renewed concerns about the evolutionary capacity of SARS-CoV-2 to adapt to both rising population immunity, and public health interventions such as vaccines and social distancing."
3,doi:10.1101/2021.02.23.21252268,B.1.1.318,"Independently evolved instances of this deletion have been repeatedly found prior to the emergence of the 501Y lineages and identical independently evolved deletions are also found together with other 501Y lineage signature mutations in the SARS-CoV-2 lineages, B.1.620 (Dudas et al., 2021), B.1.1.318, B.1.525 (https://github.com/cov-lineages/pango-designation/issues/4) and B.1.526 (Annavajhala et al., 2021)."
4,doi:10.1101/2021.02.23.21252268,B.1.525,"Independently evolved instances of this deletion have been repeatedly found prior to the emergence of the 501Y lineages and identical independently evolved deletions are also found together with other 501Y lineage signature mutations in the SARS-CoV-2 lineages, B.1.620 (Dudas et al., 2021), B.1.1.318, B.1.525 (https://github.com/cov-lineages/pango-designation/issues/4) and B.1.526 (Annavajhala et al., 2021)."
5,doi:10.1101/2021.02.23.21252268,B.1.620,"Independently evolved instances of this deletion have been repeatedly found prior to the emergence of the 501Y lineages and identical independently evolved deletions are also found together with other 501Y lineage signature mutations in the SARS-CoV-2 lineages, B.1.620 (Dudas et al., 2021), B.1.1.318, B.1.525 (https://github.com/cov-lineages/pango-designation/issues/4) and B.1.526 (Annavajhala et al., 2021)."
6,doi:10.1101/2021.02.23.21252268,B.1.526,"Independently evolved instances of this deletion have been repeatedly found prior to the emergence of the 501Y lineages and identical independently evolved deletions are also found together with other 501Y lineage signature mutations in the SARS-CoV-2 lineages, B.1.620 (Dudas et al., 2021), B.1.1.318, B.1.525 (https://github.com/cov-lineages/pango-designation/issues/4) and B.1.526 (Annavajhala et al., 2021)."
7,doi:10.1101/2021.02.23.21252268,P.3,"Additionally, whereas a convergent A701V mutation is also found in the B.1.526 and S/E484K carrying lineage that was first identified in New York (Annavajhala et al., 2021), P681H is found in the S/E484K and S/N501Y carrying P.3 lineage first identified in the Philippines (Tablizo et al., 2021), and both S/H655Y and S/P681H are found in the highly mutated S/E484K carrying A.VOI.V2 lineage first identified in Tanzanian travellers (de Oliveira et al., 2021)..

Any of H655Y, P681H, A701V or T716I might directly impact the efficiency of viral entry into host cells (Garry et al., 2021)."
8,doi:10.1101/2021.02.23.21252268,B.1.621,"The lineages containing sequences with the most matches were B.1.526 and B.1.621 (both with modal matches = 5 and maximum = 7), suggesting that they too are possibly scaling the same fitness peak as the 501Y lineage viruses..

Other prominent VOC, VOI and VUI lineages, however, had very few matches."
9,doi:10.1101/2021.02.23.21252268,B.1.617.2,"For example the best matched sequences within the B.1.617.2, P.2 and R.1 lineages each had only three matches to the meta-signature (with modal matches in each being one, two, and one, respectively), implying that viruses in these lineages are likely scaling a different fitness peak to the one that the 501Y lineage viruses are on."
10,doi:10.1101/2021.02.23.21252268,P.2,"For example the best matched sequences within the B.1.617.2, P.2 and R.1 lineages each had only three matches to the meta-signature (with modal matches in each being one, two, and one, respectively), implying that viruses in these lineages are likely scaling a different fitness peak to the one that the 501Y lineage viruses are on."
11,doi:10.1101/2021.02.23.21252268,R.1,"For example the best matched sequences within the B.1.617.2, P.2 and R.1 lineages each had only three matches to the meta-signature (with modal matches in each being one, two, and one, respectively), implying that viruses in these lineages are likely scaling a different fitness peak to the one that the 501Y lineage viruses are on."
12,doi:10.1101/2021.02.23.21252268,B.1.617.1,"Curiously, although the modal number of matches to the meta-signature of viruses in B.1.617.1, the sister lineage of B.1.617.2, is only one, this lineage contains some sequences that match the meta-signature at six sites, suggesting that at least some sub-lineages within B.617 are possibly also climbing the same fitness peak as the 501Y lineage viruses.."
0,doi:10.1101/2021.02.26.21252554,P.1,"Through genome sequencing of viruses sampled in Manaus between November 2020 and January 2021, we identified the emergence and circulation of a novel SARS-CoV-2 variant of concern, lineage P.1, that acquired 17 mutations, including a trio in the spike protein (K417T, E484K and N501Y) associated with increased binding to the human ACE2 receptor."
1,doi:10.1101/2021.02.26.21252554,B.1.1.7,"In late 2020, two SARS-CoV-2 lineages of concern were discovered through genomic surveillance, both characterised by sets of significant mutations: lineage B.1.351, first reported in South Africa (12) and lineage B.1.1.7, detected in the United Kingdom (13)."
2,doi:10.1101/2021.02.26.21252554,B.1.351,"In late 2020, two SARS-CoV-2 lineages of concern were discovered through genomic surveillance, both characterised by sets of significant mutations: lineage B.1.351, first reported in South Africa (12) and lineage B.1.1.7, detected in the United Kingdom (13)."
3,doi:10.1101/2021.02.26.21252554,B.1.1.28,"Phylogenetic analysis indicated that P.1, and another lineage, P.2 (17), were descendants of lineage B.1.1.28 that was first detected in Brazil in early March 2020 (Fig 1B)."
4,doi:10.1101/2021.02.26.21252554,P.2,"Phylogenetic analysis indicated that P.1, and another lineage, P.2 (17), were descendants of lineage B.1.1.28 that was first detected in Brazil in early March 2020 (Fig 1B)."
0,doi:10.1093/jtm/taab154,B.1,"Sera of COVID-19 naive vaccinees, COVID-19 recovered cases with vaccination and breakthrough cases demonstrated 1.3, 2.5 and 1.9-fold reduction in neutralization titers against Delta and 1.5, 3.5, 2.8-fold against Delta AY.1 compared to B.1 respectively."
1,doi:10.1093/jtm/taab154,B.1.617.3,"However, high neutralization titers would still effectively protect against Delta, Delta AY.1 and B.1.617.3 variants.."
0,doi:10.1007/s10989-021-10339-0,P.1,"An in-silico approach was employed to design a therapeutic peptide inhibitor against the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 and its variants (B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 and B.1.617.3)."
1,doi:10.1007/s10989-021-10339-0,B.1.1.7,"An in-silico approach was employed to design a therapeutic peptide inhibitor against the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 and its variants (B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 and B.1.617.3)."
2,doi:10.1007/s10989-021-10339-0,B.1.617.3,"An in-silico approach was employed to design a therapeutic peptide inhibitor against the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 and its variants (B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 and B.1.617.3)."
3,doi:10.1007/s10989-021-10339-0,B.1.617.1,"An in-silico approach was employed to design a therapeutic peptide inhibitor against the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 and its variants (B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 and B.1.617.3)."
4,doi:10.1007/s10989-021-10339-0,B.1.617.2,"An in-silico approach was employed to design a therapeutic peptide inhibitor against the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 and its variants (B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 and B.1.617.3)."
5,doi:10.1007/s10989-021-10339-0,B.1.351,"An in-silico approach was employed to design a therapeutic peptide inhibitor against the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 and its variants (B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 and B.1.617.3)."
6,doi:10.1007/s10989-021-10339-0,B.1.617,"At the same time, E484K and K417N are found in B.1.351 and P.1, and L452R and E484Q found in B.1.617 impart a higher resistance to neutralizing antibodies (Wang et al."
0,doi:10.1056/nejmc2107799,B.1.617.2,The B.1.617.1 (or kappa) and B.1.617.2 (or delta) variants were first identified in India and have rapidly spread to several countries throughout the world.
1,doi:10.1056/nejmc2107799,B.1.617.1,The B.1.617.1 (or kappa) and B.1.617.2 (or delta) variants were first identified in India and have rapidly spread to several countries throughout the world.
0,doi:10.1007/s00430-022-00730-z,B.1.1.529,The current surge in infection rates around the globe is driven by the variant of concern (VoC) omicron (B.1.1.529).
1,doi:10.1007/s00430-022-00730-z,B.1.617.2,"We examined a total of 115 SARS-CoV-2 PCR-negative and 166 SARS-CoV-2 PCR-positive respiratory swab samples (101 omicron, 65 delta (B.1.617.2)) collected from October 2021 until January 2022 as well as cell culture-expanded clinical isolates of both VoCs."
